

DEPARTMENT OF HEALTH, STATE BOARD OF HEALTH

SUBJECT: Controlled Substances List

DESCRIPTION: The proposed listed amendments update the List of Controlled Substances to include these drugs.

1. Schedule I, (b), (67), now (47) is an item that has been marked for clean-up.
2. Fentanyl Related Substances language has been added, marked for clean- up, and will have substances following this updated language. Schedule I, (b), (78), now (52), (i) through (vi). The language indicates the following:

Fentanyl-related substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. Fentanyl-related substance means any substance not otherwise listed, and for which no exemption or approval is in effect under section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that is structurally related to fentanyl by one or more of the following modifications:

- i. Replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle;
 - ii. Substitution in or on the phenethyl group with alkyl, alkenyl, alkoxy, hydroxyl, halo, haloalkyl, amino or nitro groups;
 - iii. Substitution in or on the piperidine ring with alkyl, alkenyl, alkoxy, ester, ether, hydroxyl, halo, haloalkyl, amino or nitro groups;
 - iv. Replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle; or
 - v. Replacement of the N-propionyl group by another acyl group;
 - vi. *Fentanyl-related substances shall include but are not limited to:*
3. Schedule I, (b) (1), (7), (8), (11), (12), (34), (35), (42), (53), (56 through 65), (72 through 77) and (79 through 96) are current controlled substances. In addition, Schedule I, (b), (8) is marked for clean-up. These substances are moved to Fentanyl-related substances designation within Schedule I. Schedule I, (b), (52), (i) through (vi), (A) through (QQ). Relocation of these substances will result in subsequent numbering changes within Schedule I, (b).
 4. Brorphine. The DEA has scheduled this opioid analgesic substance into Schedule I because it has no recognized medical use. This drug would be included in Schedule I to follow DEA. Schedule I, (b), (54).
 5. Upon discussion with other state agencies with relevant knowledge of the substances, a request was submitted for the Benzimidazole-substances designation for substances with the following language be included into Schedule I without a recognized medical use.

It was also requested the following benzimidazole substances also listed after

implemented language which include: 4'-Hydroxy Nitazene, 5-Aminoisotonitazene, Butonitazene, Etodesnitazene [other name(s): Etazene], Flunitazene, Isotodesnitazene, Metodesnitazene, N-Desethyl Etonitazene, N-Desethyl Isotonitazene, N-Piperidinyl Etonitazene [other name(s): Etonitazepipne], N-Pyrrolidino Etonitazene, [other name(s): Etonitazepyne], N-Pyrrolidino Protonitazene and Protonitazene.

Of note, Clonitazene, Etonitazene and Isotonitazene are Schedule I substances and will be relocated from their current position and placed in the Benzimidazole-opioid substances designation within Schedule I with subsequent numbering changes.

Metonitazene. The DEA has placed this opioid analgesic substance into Schedule I because it has no recognized medical use. This drug would be in the Benzimidazole-opioid substances designation within Schedule I.

The language and the following benzimidazole-opioid substances will be included into Schedule I. Schedule I, (b), (55), (i) through (vi), (A) through (Q). The language and added substances are listed as the following:

Benzimidazole-opioid substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. Benzimidazole-opioid substances means any substance not otherwise listed or excepted, and for which no exemption or approval is in effect under section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that structurally has benzimidazole ring with an ethylamine at its 1-position and benzyl group at its 2-position:

- i. With or without substitution on the benzimidazole;*
- ii. With or without substitution at the ethylamine;*
- iii. With or without inclusion of the ethylamine in a cyclic structure;*
- iv. With or without substitution on the benzyl ring; or*
- v. With or without replacement of the benzyl ring with an aromatic ring;*
- vi. Benzimidazole-opioid substances shall include but are not limited to:*
 - A. 4'-Hydroxy Nitazene;*
 - B. 5-Aminoisotonitazene;*
 - C. Butonitazene;*
 - D. Clonitazene;*
 - E. Etodesnitazene, [other name(s): Etazene];*
 - F. Etonitazene;*
 - G. Flunitazene;*
 - H. Isotonitazene;*
 - I. Isotodesnitazene*
 - J. Metodesnitazene;*
 - K. Metonitazene;*
 - L. N-Desethyl Etonitazene;*
 - M. N-Desethyl Isotonitazene;*
 - N. N-Piperidinyl Etonitazene, [other name(s): Etonitazepipne];*
 - O. N-Pyrrolidino Etonitazene, [other name(s): Etonitazepyne];*

*P. N-Pyrrolidino Protonitazene; and
Q. Protonitazene.*

6. Upon discussion with other state agencies with relevant knowledge of the substances, a request was submitted for this substance designation for benzodiazepine substances with the following language to be included into Schedule I without a recognized medical use. In addition, Clonazolam, Flualprazolam, Flubromazepam, Flubromazolam, and Phenazepam are current Schedule I substances and are relocated from their current position in Schedule I and placed in the benzodiazepine-substance designation within Schedule I with subsequent numbering changes.

Bromazolam. It was also requested that this depressant substance with no recognized medical use be included into Schedule I and placed in the benzodiazepine substances designation.

Lastly, Phenazolam [other names(s): Clobromazolam]. It was further requested that this depressant substance with no recognized medical use be included into Schedule I and placed in the benzodiazepine substances designation.

The language and the following benzodiazepine substances is included into Schedule I. Schedule I, (e), (4), (i) through (vii). The language and added substances are noted as the following:

Benzodiazepine substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. Benzodiazepine substances includes any substance not otherwise listed or excepted, and for which no exemption or approval is in effect under section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that structurally has a fused 1,4-diazepine and benzene ring structure with a phenyl connected to the diazepine ring, with any substitution(s) or replacement(s) on the 1,4-diazepine or benzene ring, any substitution(s) on the phenyl ring, or any combination thereof. Benzodiazepine substances shall include but are not limited to:

- i. Bromazolam;*
- ii. Clonazolam;*
- iii. Flualprazolam;*
- iv. Flubromazepam;*
- v. Flubromazolam;*
- vi. Phenazepam; and*
- vii. Phenazolam [other name(s): Clobromazolam].*

7. Upon discussion with other state agencies with relevant knowledge of the substances, a request was submitted for the substance designation for Thienodiazepine substances with the following language included into Schedule I without a recognized medical use.

In addition, Etizolam is relocated from its current position in Schedule I and placed in the Thienodiazepine substances designation within Schedule I with subsequent numbering changes.

The language and the following Thienodiazepine substance are included into Schedule I. Schedule I, (e), (5), (i). The language and added substances are noted as the following:

Thienodiazepine substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. Thienodiazepine substances includes any substance not otherwise listed or excepted, and for which no exemption or approval is in effect under section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that structurally has a fused 1,4-diazepine and thiophene ring structure with a phenyl connected to the 1,4-diazepine ring, with any substitution(s) or replacement(s) on the 1,4-diazepine or thiophene ring, any substitution(s) on the phenyl ring, or any combination thereof. Thienodiazepine substances shall include but are not limited to:

i. Etizolam

8. Methiopropamine. (*N*-methyl-1-(thiophen-2-yl)propan-2-amine). The DEA has scheduled this stimulant substance into Schedule I because it has no recognized medical use. This drug would be included as Schedule I to follow DEA. Schedule I, (f), (1), (xv).
9. Eutylone is a Schedule I controlled substance. To follow DEA, a controlled substance code number has been set forth opposite of this substance. Schedule I, (f), (2), (xx).
10. Fenfluramine is a Schedule IV substance. Schedule IV, (d), (1). To follow DEA this drug is removed from the controlled substance list with subsequent outline changes that will follow within Schedule IV.
11. MDMB-4en-PINACA. Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate. Upon discussion with other state agencies with relevant knowledge of the substances, a request was submitted for this synthetic cannabinoid with no recognized medical use be included into Schedule VI. Schedule VI, (a), (5), (xi), (JJ).
12. CH-PIATA. *N*-cyclohexyl-2-(1-pentylindol-3-yl)acetamide. Upon discussion with other state agencies with relevant knowledge of the substances, a request was submitted for this synthetic cannabinoid with no recognized medical use be included into Schedule VI. Schedule VI, (a), (5), (xi), (KK).

PUBLIC COMMENT: A public hearing was held on this rule on January 23, 2024. The public comment period expired on January 29, 2024. The agency provided the following synopsis of the public comment summary:

The Department received approximately fourteen comments, written and verbal, during the public comment period. All of the noted comments received indicated concerns and conveyed information regarding the scheduling of xylazine, specifically concerns recommending an exemption for veterinary use. (Comments received are attached.)

Due to its length, the full public comment summary is attached separately.

The proposed effective date is April 1, 2024.

FINANCIAL IMPACT: The agency indicated that this rule has no financial impact.

LEGAL AUTHORIZATION: The Department of Health administers the Uniform Controlled Substances Act and has authority to add substances to the Controlled Substances List and to delete or reschedule “any substance enumerated in a schedule[.]” Ark. Code Ann. § 5-64-201(a)(1)(A)(i). “The Secretary of the Department of Health shall revise and republish the schedules annually.” Ark. Code Ann. § 5-64-216. If a substance is controlled under federal law, the Department “shall similarly control the substance” unless the Secretary objects to inclusion within thirty days of publication in the Federal Register of a final order designating a substance as a controlled substance. Ark. Code Ann. § 5-64-201(d).



Arkansas Department of Health

4815 West Markham Street • Little Rock, Arkansas 72205-3867 • Telephone (501) 661-2000

Governor Sarah Huckabee Sanders

Renee Mallory, RN, BSN, Secretary of Health

Jennifer Dillaha, MD, Director

SUMMARY OF PROPOSED AMENDMENTS TO RULES PERTAINING TO THE LIST OF CONTROLLED SUBSTANCES FOR THE STATE OF ARKANSAS

The proposed listed amendments update List of Controlled Substances to include these drugs.

1. Schedule I, (b), (67), now (47) is an item that has been marked for clean-up.
2. Fentanyl Related Substances language has been added, marked for clean-up, and will have substances following this updated language. Schedule I, (b), (78), now (52), (i) through (vi). The language indicates the following:

Fentanyl-related substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. Fentanyl-related substance means any substance not otherwise listed, and for which no exemption or approval is in effect under section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that is structurally related to fentanyl by one or more of the following modifications:

- i. Replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle;
- ii. Substitution in or on the phenethyl group with alkyl, alkenyl, alkoxy, hydroxyl, halo, haloalkyl, amino or nitro groups;
- iii. Substitution in or on the piperidine ring with alkyl, alkenyl, alkoxy, ester, ether, hydroxyl, halo, haloalkyl, amino or nitro groups;
- iv. Replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle; *or*
- v. Replacement of the N-propionyl group by another acyl group;
- vi. *Fentanyl-related substances shall include but are not limited to:*

3. Schedule I, (b) (1), (7), (8), (11), (12), (34), (35), (42), (53), (56 through 65), (72 through 77) and (79 through 96) are current controlled substances. In addition, Schedule I, (b), (8) is marked for clean-up. These substances are moved to Fentanyl-related substances designation within Schedule I. Schedule I, (b), (52), (i) through (vi), (A) through (QQ). Relocation of these substances will result in subsequent numbering changes within Schedule I, (b).
4. Brorphine. The DEA has scheduled this opioid analgesic substance into Schedule I because it has no recognized medical use. This drug would be included in Schedule I to follow DEA. Schedule I, (b), (54).
5. Upon discussion with other state agencies with relevant knowledge of the substances, a request was submitted for the Benzimidazole-substances designation for substances with the following language be included into Schedule I without a recognized medical use.

It was also requested the following benzimidazole substances also listed after implemented language which include: 4'-Hydroxy Nitazene, 5-Aminoisotonitazene, Butonitazene, Etodesnitazene [other name(s): Etazene], Flunitazene, Isotodesnitazene, Metodesnitazene, N-Desethyl Etonitazene, N-Desethyl Isotonitazene, N-Piperidinyl Etonitazene [other name(s): Etonitazepipne], N-Pyrrolidino Etonitazene, [other name(s): Etonitazepyne], N-Pyrrolidino Protonitazene and Protonitazene.

Of note, Clonitazene, Etonitazene and Isotonitazene are Schedule I substances and will be relocated from their current position and placed in the Benzimidazole-opioid substances designation within Schedule I with subsequent numbering changes.

Metonitazene. The DEA has placed this opioid analgesic substance into Schedule I because it has no recognized medical use. This drug would be in the Benzimidazole-opioid substances designation within Schedule I. The language and the following benzimidazole-opioid substances will be included into Schedule I. Schedule I, (b), (55), (i) through (vi), (A) through (Q). The language and added substances are listed as the following:

Benzimidazole-opioid substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. Benzimidazole-opioid substances means any substance not otherwise listed or excepted, and for which no exemption or approval is in effect under section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that structurally has benzimidazole ring with an ethylamine at its 1-position and benzyl group at its 2-position:

- i. With or without substitution on the benzimidazole;*
- ii. With or without substitution at the ethylamine;*
- iii. With or without inclusion of the ethylamine in a cyclic structure;*
- iv. With or without substitution on the benzyl ring; or*
- v. With or without replacement of the benzyl ring with an aromatic ring;*
- vi. Benzimidazole-opioid substances shall include but are not limited to:*
 - A. 4'-Hydroxy Nitazene;*
 - B. 5-Aminoisotonitazene;*
 - C. Butonitazene;*
 - D. Clonitazene;*
 - E. Etodesnitazene, [other name(s): Etazene];*
 - F. Etonitazene;*
 - G. Flunitazene;*
 - H. Isotonitazene;*
 - I. Isotodesnitazene*
 - J. Metodesnitazene;*
 - K. Metonitazene;*
 - L. N-Desethyl Etonitazene;*
 - M. N-Desethyl Isotonitazene;*
 - N. N-Piperidinyl Etonitazene, [other name(s): Etonitazepipne];*
 - O. N-Pyrrolidino Etonitazene, [other name(s): Etonitazepyne];*
 - P. N-Pyrrolidino Protonitazene; and*
 - Q. Protonitazene.*

6. Upon discussion with other state agencies with relevant knowledge of the substances, a request was submitted for this substance designation for

benzodiazepine substances with the following language to be included into Schedule I without a recognized medical use. In addition, Clonazolam, Flualprazolam, Flubromazepam Flubromazolam, and Phenazepam are current Schedule 1 substances and are relocated from their current position in Schedule I and placed in the benzodiazepine-substance designation within Schedule I with subsequent numbering changes.

Bromazolam. It was also requested that this depressant substance with no recognized medical use be included into Schedule I and placed in the benzodiazepine substances designation.

Lastly, Phenazolam [other names(s): Clobromazolam]. It was further requested that this depressant substance with no recognized medical use be included into Schedule I and placed in the benzodiazepine substances designation.

The language and the following benzodiazepine substances is included into Schedule I. Schedule I, (e), (4), (i) through (vii). The language and added substances are noted as the following:

Benzodiazepine substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. Benzodiazepine substances includes any substance not otherwise listed or excepted, and for which no exemption or approval is in effect under section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that structurally has a fused 1,4-diazepine and benzene ring structure with a phenyl connected to the diazepine ring, with any substitution(s) or replacement(s) on the 1,4-diazepine or benzene ring, any substitution(s) on the phenyl ring, or any combination thereof. Benzodiazepine substances shall include but are not limited to:

- i. Bromazolam;*
- ii. Clonazolam;*
- iii. Flualprazolam;*
- iv. Flubromazepam;*
- v. Flubromazolam;*

- vi. *Phenazepam; and*
- vii. *Phenazolam [other name(s): Clobromazolam].*

7. Upon discussion with other state agencies with relevant knowledge of the substances, a request was submitted for the substance designation for Thienodiazepine substances with the following language included into Schedule I without a recognized medical use.

In addition, Etizolam is relocated from its current position in Schedule I and placed in the Thienodiazepine substances designation within Schedule I with subsequent numbering changes.

The language and the following Thienodiazepine substance are included into Schedule I. Schedule I, (e), (5), (i). The language and added substances are noted as the following:

Thienodiazepine substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. Thienodiazepine substances includes any substance not otherwise listed or excepted, and for which no exemption or approval is in effect under section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that structurally has a fused 1,4-diazepine and thiophene ring structure with a phenyl connected to the 1,4-diazepine ring, with any substitution(s) or replacement(s) on the 1,4-diazepine or thiophene ring, any substitution(s) on the phenyl ring, or any combination thereof. Thienodiazepine substances shall include but are not limited to:

- i. *Etizolam*

8. Methiopropamine. (*N*-methyl-1-(thiophen-2-yl)propan-2-amine). The DEA has scheduled this stimulant substance into Schedule I because it has no recognized medical use. This drug would be included as Schedule I to follow DEA. Schedule I, (f), (1), (xv).
9. Eutylone is a Schedule I controlled substance. To follow DEA, a controlled substance code number has been set forth opposite of this substance. Schedule I, (f), (2), (xx).

10. Fenfluramine is a Schedule IV substance. Schedule IV, (d), (1). To follow DEA this drug is removed from the controlled substance list with subsequent outline changes that will follow within Schedule IV.
11. MDMB-4en-PINACA. Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate. Upon discussion with other state agencies with relevant knowledge of the substances, a request was submitted for this synthetic cannabinoid with no recognized medical use be included into Schedule VI. Schedule VI, (a), (5), (xi), (JJ).
12. CH-PIATA. N-cyclohexyl-2-(1-pentylindol-3-yl)acetamide. Upon discussion with other state agencies with relevant knowledge of the substances, a request was submitted for this synthetic cannabinoid with no recognized medical use be included into Schedule VI. Schedule VI, (a), (5), (xi), (KK).

**QUESTIONNAIRE FOR FILING PROPOSED RULES WITH
THE ARKANSAS LEGISLATIVE COUNCIL**

DEPARTMENT _____
 BOARD/COMMISSION _____
 BOARD/COMMISSION DIRECTOR _____
 CONTACT PERSON _____
 ADDRESS _____
 PHONE NO. _____ EMAIL _____
 NAME OF PRESENTER(S) AT SUBCOMMITTEE MEETING _____

 PRESENTER EMAIL(S) _____

INSTRUCTIONS

In order to file a proposed rule for legislative review and approval, please submit this Legislative Questionnaire and Financial Impact Statement, and attach (1) a summary of the rule, describing what the rule does, the rule changes being proposed, and the reason for those changes; (2) both a markup and clean copy of the rule; and (3) all documents required by the Questionnaire.

If the rule is being filed for permanent promulgation, please email these items to the attention of Rebecca Miller-Rice, miller-ricer@blr.arkansas.gov, for submission to the Administrative Rules Subcommittee.

If the rule is being filed for emergency promulgation, please email these items to the attention of Director Marty Garrity, garritym@blr.arkansas.gov, for submission to the Executive Subcommittee.

Please answer each question completely using layman terms.

1. What is the official title of this rule?

2. What is the subject of the proposed rule? _____
3. Is this rule being filed under the emergency provisions of the Arkansas Administrative Procedure Act? Yes No

If yes, please attach the statement required by Ark. Code Ann. § 25-15-204(c)(1).

If yes, will this emergency rule be promulgated under the permanent provisions of the Arkansas Administrative Procedure Act? Yes No

4. Is this rule being filed for permanent promulgation? Yes No

If yes, was this rule previously reviewed and approved under the emergency provisions of the Arkansas Administrative Procedure Act? Yes No

If yes, what was the effective date of the emergency rule? _____

On what date does the emergency rule expire? _____

5. Is this rule required to comply with a *federal* statute, rule, or regulation? Yes No

If yes, please provide the federal statute, rule, and/or regulation citation.

6. Is this rule required to comply with a *state* statute or rule? Yes No

If yes, please provide the state statute and/or rule citation.

7. Are two (2) rules being repealed in accord with Executive Order 23-02? Yes No

If yes, please list the rules being repealed.

If no, please explain.

8. Is this a new rule? Yes No

Does this repeal an existing rule? Yes No

If yes, the proposed repeal should be designated by strikethrough. If it is being replaced with a new rule, please attach both the proposed rule to be repealed and the replacement rule.

Is this an amendment to an existing rule? Yes No

If yes, all changes should be indicated by strikethrough and underline. In addition, please be sure to label the markup copy clearly as the markup.

9. What is the state law that grants the agency its rulemaking authority for the proposed rule, outside of the Arkansas Administrative Procedure Act? Please provide the specific Arkansas Code citation(s), including subsection(s).

10. Is the proposed rule the result of any recent legislation by the Arkansas General Assembly?
Yes No

If yes, please provide the year of the act(s) and act number(s).

11. What is the reason for this proposed rule? Why is it necessary?

12. Please provide the web address by which the proposed rule can be accessed by the public as provided in Ark. Code Ann. § 25-19-108(b)(1).

13. Will a public hearing be held on this proposed rule? Yes No

If yes, please complete the following:

Date: _____

Time: _____

Place: _____

Please be sure to advise Bureau Staff if this information changes for any reason.

14. On what date does the public comment period expire for the permanent promulgation of the rule? Please provide the specific date. _____

15. What is the proposed effective date for this rule? _____

16. Please attach (1) a copy of the notice required under Ark. Code Ann. § 25-15-204(a)(1) and (2) proof of the publication of that notice.

17. Please attach proof of filing the rule with the Secretary of State, as required by Ark. Code Ann. § 25-15-204(e)(1)(A).

18. Please give the names of persons, groups, or organizations that you anticipate will comment on these rules. Please also provide their position (for or against), if known.

19. Is the rule expected to be controversial? Yes No

If yes, please explain.

FINANCIAL IMPACT STATEMENT

PLEASE ANSWER ALL QUESTIONS COMPLETELY.

DEPARTMENT _____
BOARD/COMMISSION _____
PERSON COMPLETING THIS STATEMENT _____
TELEPHONE NO. _____ **EMAIL** _____

To comply with Ark. Code Ann. § 25-15-204(e), please complete the Financial Impact Statement and email it with the questionnaire, summary, markup and clean copy of the rule, and other documents. Please attach additional pages, if necessary.

TITLE OF THIS RULE _____

1. Does this proposed, amended, or repealed rule have a financial impact?
Yes No

2. Is the rule based on the best reasonably obtainable scientific, technical, economic, or other evidence and information available concerning the need for, consequences of, and alternatives to the rule?
Yes No

3. In consideration of the alternatives to this rule, was this rule determined by the agency to be the least costly rule considered? Yes No

If no, please explain:

(a) how the additional benefits of the more costly rule justify its additional cost;

(b) the reason for adoption of the more costly rule;

(c) whether the reason for adoption of the more costly rule is based on the interests of public health, safety, or welfare, and if so, how; and

(d) whether the reason for adoption of the more costly rule is within the scope of the agency’s statutory authority, and if so, how.

4. If the purpose of this rule is to implement a *federal* rule or regulation, please state the following:
 - (a) What is the cost to implement the federal rule or regulation?

Current Fiscal Year

General Revenue _____
Federal Funds _____
Cash Funds _____
Special Revenue _____
Other (Identify) _____

Total _____

Next Fiscal Year

General Revenue _____
Federal Funds _____
Cash Funds _____
Special Revenue _____
Other (Identify) _____

Total _____

(b) What is the additional cost of the state rule?

Current Fiscal Year

General Revenue _____
Federal Funds _____
Cash Funds _____
Special Revenue _____
Other (Identify) _____

Total _____

Next Fiscal Year

General Revenue _____
Federal Funds _____
Cash Funds _____
Special Revenue _____
Other (Identify) _____

Total _____

5. What is the total estimated cost by fiscal year to any private individual, private entity, or private business subject to the proposed, amended, or repealed rule? Please identify those subject to the rule, and explain how they are affected.

Current Fiscal Year

\$ _____

Next Fiscal Year

\$ _____

6. What is the total estimated cost by fiscal year to a state, county, or municipal government to implement this rule? Is this the cost of the program or grant? Please explain how the government is affected.

Current Fiscal Year

\$ _____

Next Fiscal Year

\$ _____

7. With respect to the agency's answers to Questions #5 and #6 above, is there a new or increased cost or obligation of at least one hundred thousand dollars (\$100,000) per year to a private individual, private entity, private business, state government, county government, municipal government, or to two (2) or more of those entities combined?

Yes No

If yes, the agency is required by Ark. Code Ann. § 25-15-204(e)(4) to file written findings at the time of filing the financial impact statement. The written findings shall be filed simultaneously with the financial impact statement and shall include, without limitation, the following:

- (1) a statement of the rule's basis and purpose;
- (2) the problem the agency seeks to address with the proposed rule, including a statement of whether a rule is required by statute;
- (3) a description of the factual evidence that:
 - (a) justifies the agency's need for the proposed rule; and
 - (b) describes how the benefits of the rule meet the relevant statutory objectives and justify the rule's costs;
- (4) a list of less costly alternatives to the proposed rule and the reasons why the alternatives do not adequately address the problem to be solved by the proposed rule;
- (5) a list of alternatives to the proposed rule that were suggested as a result of public comment and the reasons why the alternatives do not adequately address the problem to be solved by the proposed rule;
- (6) a statement of whether existing rules have created or contributed to the problem the agency seeks to address with the proposed rule and, if existing rules have created or contributed to the problem, an explanation of why amendment or repeal of the rule creating or contributing to the problem is not a sufficient response; and
- (7) an agency plan for review of the rule no less than every ten (10) years to determine whether, based upon the evidence, there remains a need for the rule including, without limitation, whether:
 - (a) the rule is achieving the statutory objectives;
 - (b) the benefits of the rule continue to justify its costs; and
 - (c) the rule can be amended or repealed to reduce costs while continuing to achieve the statutory objectives.

REVISED NOTICE OF PUBLIC HEARING

The Arkansas Department of Health is extending the period to accept public comments on the Rules Pertaining to the List of Controlled Substances in Arkansas from December 22, 2023 to January 29, 2024.

Copies of the proposed Rules are available at www.healthy.arkansas.gov and at Pharmacy Services, Room #357, 3rd Floor South, at the Arkansas Department of Health, 4815 W. Markham St. Little Rock, AR 72205.

The Arkansas Department of Health will hold a public hearing at 9:30 a.m. on January 23, 2024, at the Arkansas Department of Health, Room 2508, located at 4815 West Markham, Little Rock, Arkansas, 72205 to allow interested persons to comment on the proposed amendments.

The public may submit written comments no later than 4:30 p.m. on January 29, 2024. Comments may be sent by email to shane.david@arkansas.gov or by mail to Shane David, Pharm.D., Pharmacy Services Section, Arkansas Department of Health, 4815 West Markham Street, Slot #25, Little Rock, Arkansas, 72205.

List
Of
Controlled
Substances



For the
State
Of
Arkansas

Pursuant to the provisions of Arkansas Code Annotated § 5-64-201 and § 5-64-216 of the laws of the State of Arkansas, the Secretary of the Arkansas Department of Health or duly authorized agent, as specified by law, is giving public notice of the publication of the List of Controlled Substances for the State of Arkansas.

Due consideration has been given applicable federal regulations, current scientific knowledge regarding the listed substances, the evidence of actual or relative potential for abuse, the history and current patterns of abuse, the risk to the public health, and potential to produce psychic or psychological dependence liability.

Based on these considerations the attached listing of the Schedule of Controlled Substances and the corresponding drugs that are included in each schedule is hereby promulgated by the Secretary of the Arkansas Department of Health as the List of Controlled Substances for the State of Arkansas.

Each controlled substance or basic class thereof has been assigned an "Administration Controlled Substance Code Number" for purposes of identification. These numbers are for internal management and are used as a means to identify substances with complex and cumbersome chemical names.

Next to the code number is the date the substance was placed in schedule by the Secretary of the Arkansas Department of Health. A "*" denotes the substance was scheduled prior to April, 1979.

I, Shane David, Pharm.D., Section Chief of Pharmacy Services for the Arkansas Department of Health, do hereby certify that the documents attached hereto are true and correct copies of the current List of Controlled Substances adopted by the Arkansas State Board of Health in accordance with Arkansas state law.

Shane David, Pharm.D., Branch Chief
Pharmacy Services Section

STATE OF ARKANSAS)
)
COUNTY OF SALINE)

I, Marci Middleton, do hereby certify that Shane David, Pharm.D., well known to me, appeared before me and signed the above referenced document.

Sworn and subscribed to before me this day of, _____.

Notary Public

My commission expires

ARKANSAS DEPARTMENT OF HEALTH

LIST OF CONTROLLED SUBSTANCES

SECTION I AUTHORITY

The following scheduling of these controlled substances has been hereby promulgated pursuant to Arkansas Code Annotated §5-64-201 and §5-64-216.

SECTION II PURPOSE

Due consideration has been given applicable Federal regulations, current scientific knowledge regarding the listed substances, the evidence of actual or relative potential for abuse, the history and current patterns of abuse, the risk to the public health, and potential to produce psychic or psychological dependence liability.

SECTION III GENERAL REQUIREMENTS

(Attached copy of the listing of scheduling of controlled substances)

SECTION IV REPEAL

All lists of schedules of controlled substances in conflict herewith are hereby repealed.

CERTIFICATION

This will certify the following list of scheduling of controlled substances was adopted by the Arkansas State Board of Health at a session of the Board held in Little Rock, Arkansas on the _____ day of _____, _____, and after a Public Hearing on the _____ day of _____, _____, held in Little Rock, Arkansas, at the State Department of Health Building.

Secretary of Health, Arkansas Department of Health

ARTICLE II

SCHEDULE I

(a) Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.

(b) **Opiates: (Narcotic Drugs)** Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, salts is possible within the specific chemical designation (for purposes of 3-methylthiofentanyl only, the term isomer includes the optical and geometric isomers):

(1) Acetyl-alpha-methylfentanyl [other name(s): (N-[1-[1-methyl-2-phenethyl]-4-piperidinyl]-N-phenylacetamide)]	9815 (2-1986)
(2)(1) Acetylmethadol -----	9601*
(3)(2) Allylprodine -----	9602*
(4)(3) Alphacetylmethadol (except Levo-alphacetylmethadol (LAAM)) -----	9603*
(5)(4) Alphameprodine -----	9604*
(6)(5) Alphamethadol -----	9605*
(7) Alpha-methylfentanyl [other name(s): (N-[1-(alpha-methyl-beta-phenyl)-ethyl-4-piperidyl]propranilide; 1-(1-methyl-2-phenylethyl)-4(N-propanilido)piperidine)]	9814 (6-1982)
(8) Alpha-methylthiofentanyl(N-[1-methyl-2-(2thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide)	9832 (2-1986)
(9)(6) Benzethidine -----	9606*
(10)(7) Betacetylmethadol -----	9607*
(11) Beta-hydroxyfentanyl [other name(s): (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide)]	9830 (2-1986)
(12) Beta-hydroxy-3-methylfentanyl [other name(s): N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide]	9831 (2-1986)
(13)(8) Betameprodine -----	9608*
(14)(9) Betamethadol -----	9609*
(15)(10) Betaprodine -----	9611*
(16) Clonitazene -----	9612*
(17)(11) Dextromoramide -----	9613*
(18)(12) Diampromide -----	9615*
(19)(13) Diethylthiambutene -----	9616*

(20) (14) Difenoxin -----	9168*
(21) (15) Dimenoxadol -----	9617*
(22) (16) Dimepheptanol -----	9618*
(23) (17) Dimethylthiambutene -----	9619*
(24) (18) Dioxaphetyl butyrate -----	9621*
(25) (19) Dipipanone -----	9622*
(26) (20) Ethylmethylthiambutene -----	9623*
(27) Etonitazene -----	9624*
(28) (21) Etoxidine -----	9625*
(29) (22) Furethidine -----	9626*
(30) (23) Hydroxypethidine -----	9627*
(31) (24) Ketobemidone -----	9628*
(32) (25) Levomoramide -----	9629*
(33) (26) Levophenacilmorphan -----	9631*
(34) 3-Methylfentanyl [other name(s): (N-[3-Methyl-1-(2-phenylethyl)-4-piperidyl]-N-Phenylpropanamide)] -----	9813-(10-1985)
(35) 3-methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidyl]-N-phenylpropanamide) -----	9833-(2-1986)
(36) (27) Morpheridine -----	9632*
(37) (28) MPPP [other name(s): (1-methyl-4-phenyl-4-propionoxypiperidine)]-----	9661-(10-1985)
(38) (29) Noracymethadol -----	9633*
(39) (30) Norlevorphanol -----	9634*
(40) (31) Normethadone -----	9635*
(41) (32) Norpipanone -----	9636*
(42) Para-fluorofentanyl [other name(s): (N-[4-fluorophenyl]-N-[1-(2-phenethyl)-4-piperindinyl]propanamide)] -----	9812-(11-1986)
(43) (33) PEPAP [other name(s): 1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine] -----	9663-(10-1985)
(44) (34) Phenadoxone -----	9637*
(45) (35) Phenampromide -----	9638*
(46) (36) Phenomorphan -----	9647*
(47) (37) Phenoperidine -----	9641*
(48) (38) Piritramide -----	9642*
(49) (39) Proheptazine -----	9643*

(50) (40) Properidine -----	9644*
(51) (41) Propiram -----	9649*
(52) (42) Racemoramide -----	9645*
(53) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide) -----	9835 (2-1986)
(54) (43) Tilidine -----	9750-(9-1981)
(55) (44) Trimeperidine -----	9646*
(56) Acetyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide] -----	9821 (4-2017)
(57) Butyryl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide] -----	9822 (4-2017)
(58) Beta-hydroxythiofentanyl [other name(s): N-{1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl}-N-phenylpropionamide] -----	9836 (4-2017)
(59) Acetyl fentanyl 4-methylphenethyl analog [other name(s): N-{1-[2-(4-methylphenyl)ethyl]-4-piperidinyl}-N-phenylacetamide] -----	(4-2017)
(60) Valeryl fentanyl [other name(s): N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-pentanamide] -----	9840 (4-2017)
(61) Furanyl fentanyl [other name(s): N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylfuran-2-carboxamide] -----	9834 (4-2017)
(62) Isobutyryl fentanyl [other name(s): 2-methyl-N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide] -----	9827 (4-2017)
(63) Oefentanil [other name(s): N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide] -----	9838 (4-2017)
(64) 4-methoxy butyryl fentanyl [other name(s): N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide] -----	(4-2017)
(65) Para-fluorobutyryl fentanyl [other name(s): N-(4-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide] -----	9823 (4-2017)
(66) (45) Acetyl norfentanyl [other name(s): N-phenyl-N-4-piperidinyl-acetamide] -----	(4-2017)
(67) (46) AH-7921 [other name(s): 3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide] -----	9551-(4-2017)
(68) (47) W-18 [other name(s): 1-(4-nitrophenylethyl)piperidylidene-2-(4-chlorophenyl)sulfonamide] -----	(4-2017)
(69) (48) W-15 [other name(s): 1-phenylethylpiperidylidene-2-(4-chlorophenyl)sulfonamide] -----	(4-2017)
(70) (49) MT-45 [other name(s): 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine] -----	9560-(4-2017)
(71) (50) U-47700 [other name(s): trans-3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide] -----	9547-(4-2017)

- (72) ~~Acryl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide]~~ ----- 9811 (6-2020)
- (73) ~~4-Fluoroisobutyryl fentanyl [other name(s): N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide]~~ ----- 9824 (6-2020)
- (74) ~~Tetrahydrofuranyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide]~~ ----- 9843 (6-2020)
- (75) ~~Cyclopropyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide]~~ ----- 9845 (4-2021)
- (76) ~~Methoxyacetyl fentanyl [other name(s): 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide]~~ ----- 9825 (4-2021)
- (77) ~~Ortho-fluorofentanyl [other name(s): N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide]~~ ----- 9816 (4-2021)
- (78)(51) Fentanyl-related substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. Fentanyl-related substance means any substance not otherwise listed, and for which no exemption or approval is in effect under section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that is structurally related to fentanyl by one or more of the following modifications: ----- (4-2021)
- (i) Replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle;
 - (ii) Substitution in or on the phenethyl group with alkyl, alkenyl, alkoxy, hydroxyl, halo, haloalkyl, amino or nitro groups;
 - (iii) Substitution in or on the piperidine ring with alkyl, alkenyl, alkoxy, ester, ether, hydroxyl, halo, haloalkyl, amino or nitro groups;
 - (iv) Replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle; ~~and/or~~
 - (v) Replacement of the N-propionyl group by another acyl group.
 - (vi) Fentanyl-related substances shall include, but are not limited to:
 - (A) Acetyl-alpha-methylfentanyl [other name(s): (N-[1-[1-methyl-2-phenethyl]-4-piperidinyl]-N-phenylacetamide)] ----- 9815-(2-1986)
 - (B) Alpha-methylfentanyl [other name(s): (N-[1-(alpha-methyl-beta-phenylethyl)-4-piperidyl] propronanilide; 1-(1-methyl-2-phenylethyl)-4(N-propanilido)piperidine)] ----- 9814-(6-1982)
 - (C) Alpha-methylthiofentanyl(N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide) ----- 9832-(2-1986)
 - (D) Beta-hydroxyfentanyl [other name(s): (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide)] ----- 9830-(2-1986)
 - (E) Beta-hydroxy-3-methylfentanyl [other name(s): N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropamide] ----- 9831-(2-1986)

- (F) 3-Methylfentanyl [other name(s): (N-[3-Methyl-1-(2-phenylethyl)-4-piperidyl]-N-Phenylpropanamide)] ----- 9813-(10-1985)
- (G) 3-methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide) ----- 9833-(2-1986)
- (H) Para-fluorofentanyl [other name(s): (N-[4-fluorophenyl]-N-[1-(2-phenethyl)-4-piperindinyl]propanamide] ----- 9812-(11-1986)
- (I) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide ----- 9835-(2-1986)
- (J) Acetyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide] ----- 9821-(4-2017)
- (K) Butyryl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide]----- 9822-(4-2017)
- (L) Beta-hydroxythiofentanyl [other name(s): N-{1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl}-N-phenylpropionamide]----- 9836-(4-2017)
- (M) Acetyl fentanyl 4-methylphenethyl analog [other name(s): N-{1-[2-(4-methylphenyl)ethyl]-4-piperidinyl}-N-phenyl-acetamide] ----- (4-2017)
- (N) Valeryl fentanyl [other name(s): N-phenyl-N[1-(2-phenylethyl)-4-piperidinyl]-pentanamide]----- 9840-(4-2017)
- (O) Furanyl fentanyl [other name(s): N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylfuran-2-carboxamide]----- 9834-(4-2017)
- (P) Isobutyryl fentanyl [other name(s): 2-methyl-N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide]----- 9827-(4-2017)
- (Q) Ocfentanil [other name(s): N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide] ----- 9838-(4-2017)
- (R) 4-methoxy butyryl fentanyl [other name(s): N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide] ----- (4-2017)
- (S) Para-fluorobutyryl fentanyl [other name(s): N-(4-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide] ----- 9823-(4-2017)
- (T) Acryl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide] ----- 9811-(6-2020)
- (U) 4-Fluoroisobutyryl fentanyl [other name(s): N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide]----- 9824-(6-2020)
- (V) Tetrahydrofuranyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide] ----- 9843-(6-2020)
- (W) Cyclopropyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide] ----- 9845-(4-2021)
- (X) Methoxyacetyl fentanyl [other name(s): 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide] ----- 9825-(4-2021)

- (A)(Y) Ortho-fluorofentanyl [other name(s): N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide] ----- 9816-(4-2021)
- (B)(Z) Crotonyl fentanyl [other name(s): (E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide] ----- 9844-(5-2022)
- (C)(AA) Cyclopentyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide] ----- 9847-(5-2022)
- (D)(BB) Para-chloroisobutyryl fentanyl [other name(s): N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide] ----- 9826-(5-2022)
- (E)(CC) Para-methoxybutyryl fentanyl [other name(s): N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide] ----- 9837-(5-2022)
- (F)(DD) Beta-methyl fentanyl [other name(s): N-phenyl-N-(1-(2-phenylpropyl) piperidin-4-yl)propionamide] ----- 9856-(5-2022)
- (G)(EE) Beta'-phenyl fentanyl [other name: N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide] ----- 9842-(5-2022)
- (H)(FF) 2'-Fluoro ortho-fluorofentanyl [other name(s): N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide] ----- 9855-(5-2022)
- (I)(GG) 4'-Methyl acetyl fentanyl [other name(s): N-(1-(4-methylphenethyl) piperidin-4-yl)-N-phenylacetamide] ----- 9819-(5-2022)
- (J)(HH) Ortho-fluorobutyryl fentanyl [other name(s): N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide] ----- 9846-(5-2022)
- (K)(II) Ortho-methyl acetylfentanyl [other name(s): N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide] ----- 9848-(5-2022)
- (L)(JJ) Ortho-methyl methoxyacetyl fentanyl [other name(s): 2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide] ----- 9820-(5-2022)
- (M)(KK) Para-methylfentanyl [other name(s): N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide] ----- 9817-(5-2022)
- (N)(LL) Phenyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide] ----- 9841-(5-2022)
- (O)(MM) Thiofuranyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide] ----- 9839-(5-2022)
- (P)(NN) Fentanyl carbamate [other name(s): ethyl(1-phenethylpiperidin-4-yl)(phenyl)carbamate] ----- 9851-(5-2022)
- (Q)(OO) Ortho-fluoroacryl fentanyl [other name(s): N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)acrylamide] ----- 9852-(5-2022)
- (R)(PP) Ortho-fluoroisobutyryl fentanyl [other name(s): N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide] ----- 9853-(5-2022)
- (S)(QQ) Para-fluoro furanyl fentanyl [other name(s): N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide] ----- 9854-(5-2022)

~~(79) Isotonitazene~~-----9614

~~(80)~~(52) Zipeprol----- 9873

~~(81)~~(53) Brorphine ----- 9098

(54) Benzimidazole-opioid substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. Benzimidazole-opioid substances includes any substance, not otherwise listed or excepted, and for which no exemption or approval is in effect under Section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that structurally has benzimidazole ring with an ethylamine at its 1-position and benzyl group at its 2-position:

(i) With or without substitution on the benzimidazole;

(ii) With or without substitution at the ethylamine;

(iii) With or without inclusion of the ethylamine in a cyclic structure;

(iv) With or without substitution on the benzyl ring; or

(v) With or without replacement of the benzyl ring with an aromatic ring.

(vi) Benzimidazole-opioid substances shall include but are not limited to:

(A) 4'-Hydroxy Nitazene;

(B) 5-Aminoisotonitazene;

(C) Butonitazene;

(D) Clonitazene ; ----- 9612 *

(E) Etodesnitazene, [other name(s): Etazene];

(F) Etonitazene ; ----- 9624*

(G) Flunitazene;

(H) Isotonitazene; ----- 9614

(I) Isotodesnitazene ;

(J) Metodesnitazene;

(K) Metonitazene; ----- 9757

(L) N-Desethyl Etonitazene ;

(M) N-Desethyl Isotonitazene ;

(N) N-Piperidiny Etonitazene [other name(s): Etonitazepipne];

(O) N-Pyrrolidino Etonitazene [other name(s): Etonitazepyne];

(P) N-Pyrrolidino Protonitazene; and

(Q) Protonitazene.

(c) **Opium derivatives: (Narcotic Drugs)** Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers whenever

the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Acetorphine -----	9319*
(2) Acetyldihydrocodeine -----	9051*
(3) Benzylmorphine -----	9052*
(4) Codeine methylbromide -----	9070*
(5) Codeine-N-Oxide -----	9053*
(6) Cyprenorphine -----	9054*
(7) Desomorphine -----	9055*
(8) Dihydromorphine -----	9145*
(9) Drotebanol -----	9335*
(10) Etorphine (except hydrochloride salt) -----	9056*
(11) Heroin -----	9200*
(12) Hydromorphanol -----	9301*
(13) Methyldesorphine -----	9302*
(14) Methyldihydromorphine -----	9304*
(15) Morphine methylbromide -----	9305*
(16) Morphine methylsulfonate -----	9306*
(17) Morphine-N-Oxide -----	9307*
(18) Myrophine -----	9308*
(19) Nicocodeine -----	9309*
(20) Nicomorphine -----	9312*
(21) Normorphine -----	9313*
(22) Pholcodine -----	9314*
(23) Thebacon -----	9315*
(24) Mitragynine -----	(11-2015)
(25) 7-Hydroxymitragynine-----	(11-2015)

- (d) **Hallucinogenic substances:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of the following hallucinogenic substance, or which contains any of its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation (for purposes of this paragraph only, the term "isomer" includes the optical, position and geometric isomers):

- (1) alpha-ethyltryptamine ----- 7249-(12-1993)
Some trade or other names: etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl)indole; alpha-ET; and AET.
- (2) 4-bromo-2,5-dimethoxy-amphetamine ----- 7391*
Some trade or other names: 4-bromo-2,5-dimethoxy-alpha-methylphenethylamine; 4-bromo-2,5-DMA.
- (3) 4-bromo-2,5-dimethoxyphenethylamine ----- 7392-(8-1995)
Some trade or other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1 aminoethane; alpha-desmethyl DOB; 2C-B, Nexus.
- (4) 2,5-dimethoxyamphetamine ----- 7396*
Some trade or other names: 2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA.
- (5) 2,5-dimethoxy-4-ethylamphetamine ----- 7399-(3-1988)
Some trade or other names: DOET.
- (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine ----- 7348-(1-2005)
Some trade or other names: 2C-T-7.
- (7) 4-methoxyamphetamine ----- 7411*
Some trade or other names: 4-methoxy-alpha- methylphenethylamine; paramethoxyamphetamine; PMA.
- (8) 5-methoxy-3,4-methylenedioxy-amphetamine ----- 7401*
- (9) 4-methyl-2,5-dimethoxyamphetamine ----- 7395*
Some trade and other names: 4-methyl-2,5-dimethoxy-alphamethylphenethylamine; "DOM"; and "STP".
- (10) 3,4-methylenedioxy amphetamine ----- 7400*
- (11) 3,4-methylenedioxymethamphetamine ----- 7405-(10-1985)
Some trade or other names: MDMA)
- (12) 3,4-methylenedioxy-N-ethylamphetamine ----- 7404-(6-1990)
Some trade or other names: N- ethy-alpha-methyl-3,4 (methylenedioxy) phenethylamine, N-ethyl MDA; MDE; MDEA.
- (13) N-hydroxy-3,4-methylenedioxyamphetamine ----- 7402-(6-1990)
Some trade or other names: N-hydroxy-alpha-methyl-3,4(methylenedioxy) phenethylamine; N-hydroxy MDA
- (14) 3,4,5-trimethoxy amphetamine ----- 7390*
- (15) 5-methoxy-n,n-dimethyltryptamine 5-MeO-DMT ----- 7431*(1-2011)
- (16) alpha-methyltryptamine ----- 7432-(7-2005)

- Some trade or other names: AMT
- (17) Bufotenine ----- 7433*
 Some trade and other names: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole;
 3-(2-dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-
 dimethyltryptamine; mappine.
- (18) Diethyltryptamine ----- 7434*
 Some trade or other names: N,N-Diethyltryptamine;DET.
- (19) Dimethyltryptamine ----- 7435*
 Some trade or other names: DMT
- (20) 5-methoxy-N,N-diisopropyltryptamine ----- 7439-(7-2005)
 Some trade or other names: 5-MeO-DIPT.
- (21) Ibogaine ----- 7260*
 Some trade and other names: 7-Ethyl-6,6 beta; 7,8,9,10,12,13-octahydro-2-
 methoxy-6,9-methano-5H-pyrido [1',2': 1,2] azepino [5,4-b] indole;
 Tabernanthe iboga.
- (22) Lysergic acid diethylamide ----- 7315*
- (23) Mescaline ----- 7381*
- (24) Parahexyl ----- 7374-(7-1983)
 Some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-
 trimethyl-6H-dibenzo [b,d] pyran; Synhexyl.
- (25) Peyote ----- 7415*
 Meaning all parts of the plant presently classified botanically as *Lophophora
 williamsii* Lemaire, whether growing or not; the seeds thereof; any extract
 from any part of such plant; and every compound, manufacture, salts,
 derivative, mixture or preparation of such plant, its seeds or extracts.
 (Interprets 21 USC 812 (c), Schedule I (c) (12)).
- (26) N-ethyl-3-piperidyl benzilate ----- 7482*
- (27) N-methyl-3-piperidyl benzilate ----- 7484*
- (28) Psilocybin ----- 7437*
- (29) Psilocyn ----- 7438*
- (30) Ethylamine Analog of phencyclidine ----- 7455*
 Some trade or other names: N-ethyl-1-phenylcyclohexylamine,
 (phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine;
 cyclohexamine; PCE.
- (31) Pyrrolidine Analog of phencyclidine ----- 7458*
 Some trade or other names: 1-(1-phenylcyclohexyl)-pyrrolidine; PCPy; PHP

- (32) Thiophene Analog of phencyclidine ----- 7470*
Some trade or other names: 1-[1-(2-thienyl) cyclohexyl] Piperidine; 2-Thienyl analog of phencyclidine; TPCP; TCP.
- (33) 1-[1-(2-Thienyl)cylcohexyl]pyrrolidine ----- 7473-(9-1989)
Some other trade or other names: TCPy.
- (34) N,N-Diallyl-5-Methoxytryptamine; -----(6-2012)
Some trade or other names: 5-MeO DALT; 5-Methoxy-DALT
- (35) 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine;
25C-NBOMe -----(5-2013)
- (36) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl) methyl]ethanamine;
25I-NBOMe -----(8-2013)
- (37) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine; 2C-E----- 7509-(11-2013)
- (38) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine; 2C-D----- 7508-(11-2013)
- (39) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine; 2C-C----- 7519-(11-2013)
- (40) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine; 2C-I----- 7518-(11-2013)
- (41) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine; 2C-T-2 ----- 7385-(11-2013)
- (42) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine; 2C-T-4 ----- 7532-(11-2013)
- (43) 2-(2,5-Dimethoxyphenyl)ethanamine; 2C-H----- 7517-(11-2013)
- (44) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine; 2C-N----- 7521-(11-2013)
- (45) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine; 2C-P ----- 7524-(11-2013)
- (46) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine; 25B-
NBOMe -----(9-2018)
- (47) 2-[[[2-(4-bromo-2,5-dimethoxyphenyl)ethyl]amino]methyl]-phenol; 25B-
NBOH ----- (11-2018)
- (48) 2-[[[2-(4-iodo-2,5-dimethoxyphenyl)ethyl]amino]methyl]-phenol; 25I-NBOH----- (11-2018)
- (49) 2-(4-ethyl-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl) methyl]ethanamine;
25E-NBOMe -----(7-2019)
- (50) 2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl) methyl]ethanamine; 25H-
NBOMe -----(7-2019)
- (51) 2-[[[2-(4-chloro-2,5-dimethoxyphenyl)ethyl]amino]methyl]- phenol; 25C-
NBOH -----(7-2019)
- (52) 2-[[[2-(2,5-dimethoxyphenyl)ethyl]amino]methyl]-phenol; 25H-NBOH----- (7-2019)
- (53) 1-(4-methoxyphenyl)-N-methylpropan-2-amine ----- 1245-(5-2022)
Some trade or other names: Para-methoxymethamphetamine; PMMA
- (54) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one ----- 7286

Some trade or other names: Methoxetamine; MXE

- (e) **Depressants:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

~~(1) Phenazepam ----- (6-2012)~~

~~(2)(1) gamma-hydroxybutyric acid [other name(s): GHB; gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxydutanoic acid; sodium oxybate; sodium oxybutyrate], and its known precursors and analogs. Precursors include but are not limited to: gamma-butyrolactone ----- 2010-(2-2001)~~

~~(3)(2) Mecloqualone ----- 2572*~~

~~(4)(3) Methaqualone ----- 2565*~~

~~(5) Etizolam ----- (12-2014)~~

~~(6) Clonazolam ----- (4-2021)~~

~~(7) Flualprazolam ----- (4-2021)~~

~~(8) Flubromazepam ----- (4-2021)~~

~~(9) Flubromazolam ----- (4-2021)~~

(4) Benzodiazepine substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. Benzodiazepine substances includes any substance, not otherwise listed or excepted, and for which no exemption or approval is in effect under section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that structurally has a fused 1,4-diazepine and benzene ring structure with a phenyl connected to the diazepine ring, with any substitution(s) or replacement(s) on the 1,4-diazepine or benzene ring, any substitution(s) on the phenyl ring, or any combination thereof. Benzodiazepine substances shall include but are not limited to:

(i) Bromazolam;

(ii) Clonazolam; ----- (4-2021)

(iii) Flualprazolam; ----- (4-2021)

(iv) Flubromazepam; ----- (4-2021)

(v) Flubromazolam; ----- (4-2021)

(vi) Phenazepam; ----- (6-2012)

(vii) Phenazolam [other name(s): Clobromazolam].

(5) Thienodiazepine substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. Thienodiazepine substances includes any substance, not otherwise listed or excepted, and for which no exemption or approval is in

effect under section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that structurally has a fused 1,4-diazepine and thiophene ring structure with a phenyl connected to the 1,4-diazepine ring, with any substitution(s) or replacement(s) on the 1,4-diazepine or thiophene ring, any substitution(s) on the phenyl ring, or any combination thereof. Thienodiazepine substances shall include but are not limited to:

(i) Etizolam ----- (12-2014)

(f) **Stimulants:**

(1) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:

- (i) Cathinone ----- 1235-(3-1988)
- (ii) (±) CIS-4-Methylaminorex [(±)CIS-4,5-dihydro-4- methyl-5-phenyl-2-oxazolamine] ----- 1590-(6-1990)
- (iii) Fenethylline ----- 1503-(9-1981)
- (iv) N-Benzylpiperazine----- 7493-(1-2005)
Some trade or other names: BZP, 1-Benzylpiperazine
- (v) N-ethylamphetamine ----- 1475-(6-1982)
- (vi) N-[1-(1-benzyl-4-piperidyl)-N-phenylpropanamide (benzylfentanyl), its optical isomers, salts and salts of isomers ----- 9818-(2-1986)
- (vii) N-[1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropan-mide (thenylfentanyl), its optical isomers, salts and salts of isomers ----- 9834-(2-1986)
- (viii) N,N-Dimethylamphetamine [other name(s): N,N,Alpha-trimethylbenzeneethanamine; N,N,Alpha-trimethylphenethylamine], its salts, optical isomers, and salts of optical isomers ----- 1480-(2-1989)
- (ix) Methcathinone (some other names: 2-Methylamine-Propiophenone, alpha (methylamino)- Propiophenone, 2 (methylamino)-1-phenylpropan-1-one, alpha-N-Methylaminopropiophenone, monomethylpropion, ephedrone, N-methylcathinone, methycathinone, AL-464, AL-422, AL-463 and UR-1431), its salts, optical isomers and salts of optical isomers ----- 1237-(12-1993)
- (x) Aminorex [other name(s): aminoraphen, 2-amino-5 phenyl-2-oxazoline, or 4,5 dihyrdo-5-phenyl-2-oxazolamine], its salts, optical isomers, and salts of optical isomers ----- 1585-(12-1993)
- (xi) 4,4'-Dimethylaminorex some other names: 4,4'-DMAR, 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine, or 4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine ----- 1595-(5-2022)
- (xii) Amineptine ----- 1219

- (xiii) Mesocarb ----- 1227
- (xiv) Methyl-N-ethylcathinone (MEC)----- (6-2014)
- (xv) [Methiopropamine. \[other name\(s\): N-methyl-1-\(thiophen-2-yl\)propan-2-amine\]](#) ----- 1478

(2) Any material, compound, mixture, or preparation, whether produced directly or indirectly from a substance of vegetable origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis, that contains any quantity of the following substances, or that contains any of the following substances' analogs, salts, isomers, and salts of isomers when the existence of the analogs, salts, isomers, and salts of isomers is possible within the specific chemical designation, with the following chemical structure is included in Schedule I:

- (i) 4-Methylmethcathinone (Mephedrone) ----- 1248-(3-2011)
- (ii) Methylenedioxypropylvalerone (MDPV) ----- (3-2011)
- (iii) 3,4-Methylenedioxy-N-methylcathinone (Methylone) ----- 7540-(3-2011)
- (iv) 4-Methoxymethcathinone ----- (3-2011)
- (v) 3-Fluoromethcathinone ----- (3-2011)
- (vi) 4-Fluoromethcathinone----- (3-2011)
- (vii) 1-(1,3-benzodioxol-5-yl)-2-methylamino)butan-1-one-(Butylone) ----- 7541-(11-2014)
- (viii) Alpha-Pyrrolidinopentiophenone (Alpha-PVP) ----- 7545-(11-2015)
- (ix) 4-methyl-N-ethylcathinone (4-MEC) ----- 1249-(9-2018)
- (x) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP) ----- 7498-(9-2018)
- (xi) 2-(methylamino)-1-phenylpentan-1-one (Pentadrone) ----- 1246-(9-2018)
- (xii) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (Pentylone; bk-MBDP) ----- 7542-(9-2018)
- (xiii) 4-fluoro-N-methylcathinone (4-FMC, Flephedrone) ----- 1238-(9-2018)
- (xiv) 3-fluoro-N-methylcathinone (3-FMC)----- 1233-(9-2018)
- (xv) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (Naphyrone) ----- 1258-(9-2018)
- (xvi) Alpha-pyrrolidinobutiophenone ([Alpha]-PBP) ----- 7546-(9-2018)
- (xvii) A compound, unless listed in another schedule or a legend drug, that is structurally derived from 2-Amino-phenyl-1-propanone by modification or by substitution: ----- (3-2012)
- (A) In the phenyl ring to any extent with alkyl, alkoxy, alkylendioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one (1) or more other univalent substituents;
- (B) At the 3-position with an alkyl substituent; or

(C) At the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.

(xviii)	1-(1,3-benzodioxol-5-yl)-2-(ethylamino)pentan-1-one (N-Ethylpentylone)	7543-(7-2019)
(xix)	1-(1,3-benzodioxol-5-yl)-2-(ethylamino)propan-1-one (Ethylone)	7547-(4-2021)
(xx)	1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-1-butanone (Eutylone)	7549-(4-2021)
(xxi)	2-(ethylamino)-1-phenylhexan-1-one [other name(s): (N-Ethylhexedrone ; Alpha-Ethylaminohexanophenone)]	7246
(xxii)	1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one [other name(s): (Alpha-Pyrrolidinohexanophenone ; Alpha-PHP)]	7544
(xxiii)	2-(ethylamino)-1-(4-methylphenyl)pentan-1-one [other name(s): (4-Methyl-alpha-ethylaminopentiophenone ; 4-MEAP)]	7245
(xxiv)	1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one [other name(s): (4'-Methyl-alpha-pyrrolidinohexiophenone ; MPHP)]	7446
(xxv)	1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one [other name(s): (Alpha-Pyrrolidinoheptaphenone ; PV8)]	7548
(xxvi)	1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one [other name(s): (4'-Chloro-alpha-pyrrolidinovalerophenone ; 4-chloro-alpha-PVP)]	7443

SCHEDULE II

- (a) Schedule II shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the Controlled Substances Code Number set forth opposite it.
- (b) **Narcotic Drugs:** Substances, vegetable origin or chemical synthesis. Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis:
- (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrophan, nalbuphine, naldemedine, nalmefene, naloxegol, naloxone, 6 β -naltrexol, naltrexone and samidorphan, and their respective salts, but including the following:
- | | | |
|-------|----------------------|-------|
| (i) | Raw opium | 9600* |
| (ii) | Opium extracts | 9610* |
| (iii) | Opium fluid extracts | 9620* |
| (iv) | Powdered opium | 9639* |
| (v) | Granulated opium | 9640* |
| (vi) | Tincture of opium | 9630* |

(vii) Codeine -----	9050*
(viii) Dihydroetorphine -----	9334*
(ix) Ethylmorphine -----	9190*
(x) Etorphine hydrochloride -----	9059*
(xi) Hydrocodone -----	9193*
(xii) Hydromorphone -----	9150*
(xiii) Metopon -----	9260*
(xiv) Morphine -----	9300*
(xv) Oripavine -----	9330*(9-2007)
(xvi) Oxycodone -----	9143*
(xvii) Oxymorphone -----	9652*
(xviii) Thebaine -----	9333*
(xix) Tapentadol -----	9780-(5-2009)
(xx) Noroxymorphone -----	9668-(4-2021)

(2) Any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (b) (1) of this section, except that these substances shall not include the isoquinoline alkaloids of opium.*

(3) Opium poppy and poppy straw.*

(4) Coca leaves (9040) and any salt, compound, derivative, or preparation of coca leaves, (including cocaine (9041) and ecgonine (9180) and their salts, isomers, derivatives and salts of isomers and derivatives), and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, except that the substances shall not include: ----- *

(i) Decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine ; ----- *

(ii) [¹²³I]ioflupane; or

(iii) [¹⁸F]FP-CIT.

(5) Concentrate or poppy straw (the crude extract of poppy straw in either liquid, solid or powder form which contains the phenanthrene alkaloids of the opium poppy), ----- 9670.*

(c) **Opiates: (Narcotic Drugs)** Unless specifically excepted or unless in another schedule, any of the following opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designations:

(1) Alfentanil ----- 9737-(2-1987)

(2) Alphaprodine -----	9010*
(3) Anileridine -----	9020*
(4) Bezitramide -----	9800*
(5) Bulk Dextropropoxyphene (non-dosage forms) -----	9273-(9-1981)
(6) Carfentanil -----	9743-(9-1988)
(7) Dihydrocodeine -----	9120*
(8) Diphenoxylate -----	9170*
(9) Fentanyl -----	9801*
(10) Isomethadone -----	9226*
(11) Levo-alphaacetylmethadol (LAAM) -----	9648-(12-1993)
(12) Levomethorphan -----	9210*
(13) Levorphanol -----	9220*
(14) Metazocine -----	9240*
(15) Methadone -----	9250*
(16) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane -----	9254*
(17) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid -----	9802*
(18) Pethidine (Meperidine) -----	9230*
(19) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine -----	9232*
(20) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate -----	9233*
(21) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid -----	9234*
(22) Phenazocine -----	9715*
(23) Piminodine -----	9730*
(24) Racemethorphan -----	9732*
(25) Racemorphan -----	9733*
(26) Remifentanil -----	9739-(11-1996)
(27) Sufentanil -----	9740-(9-1981)
(28) Thiafentanil -----	9729-(4-2021)
(29) Oliceridine -----	9245-(5-2022)
(30) Tianeptine -----	(5-2022)

(d) **Stimulants:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system:

- (1) Amphetamine, its salts, optical isomers, and salts of its optical isomers ----- 1100*
- (2) Methamphetamine, its salts, isomers, and salts of its isomers ----- 1105*
- (3) Lisdexamfetamine ----- 1205*(7-2007)
- (4) Phenmetrazine and its salts ----- 1631*
- (5) Methylphenidate ----- 1724*

(e) **Depressants:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

- (1) Amobarbital ----- 2125*
- (2) Glutethimide ----- 2550-(2-1991)
- (3) Pentobarbital ----- 2270*
- (4) Phencyclidine ----- 7471*
- (5) Secobarbital ----- 2315*

(f) **Hallucinogenic Substances:**

- (1) Nabilone ----- 7379-(11-1987)
 [Other name(s) for nabilone: (+)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one].
- (2) Dronabinol in an oral solution in a drug product approved for marketing by the U.S. Food and Drug Administration; [(-)-delta-9-trans-tetrahydrocannabinol(delta-9-THC)]. ----- 7365-(7-2019)

(g) **Immediate Precursor:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances:

(1) Immediate precursor to Amphetamine and Methamphetamine:

- (i) Phenylacetone ----- 8501-(3-1980)
 Some trade or other names: phenyl-2-propanone; P2P; benzyl methyl Ketone; methyl benzyl Ketone.

(2) Immediate precursor to Phencyclidine (PCP):

- (i) 1-phenylcyclohexylamine ----- 7460*
- (ii) 1-piperidinocyclohexanecarbonitrile (PCC) ----- 8603*

(3) Immediate precursor to Fentanyl:

- (i) 4-anilino-N-phenethylpiperidine (ANPP) ----- 8333*(8-2010)

(ii) N-phenyl-N-(piperidin-4-yl)propionamide (norfentanyl) ----- 8366-(4-2021)

SCHEDULE III

(a) Schedule III shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.

(b) **Stimulants:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

- (1) Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under Section 308.32, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances ----- 1405*
- (2) Benzphetamine ----- 1228*
- (3) Chlorphentermine ----- 1645*
- (4) Clortermine ----- 1647*
- (5) Phendimetrazine ----- 1615*

(c) **Depressants:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:

- (1) Any compound, mixture, or preparation containing:
- (i) Amobarbital ----- 2126*
- (ii) Secobarbital ----- 2316*
- (iii) Pentobarbital ----- 2271*
- (iv) Embutramide ----- 2020*(9-2006)

or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule.

- (2) Any suppository dosage form containing:
- (i) Amobarbital ----- 2126*
- (ii) Secobarbital ----- 2316*
- (iii) Pentobarbital ----- 2271*

or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository.

- (3) Any substance which contains any quantity of a derivative of barbituric acid or any salt thereof ----- 2100*
- (4) Chlorhexadol ----- 2510*
- (5) Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the Federal Food, Drug, and Cosmetic Act----- 2012-(2-2001)
- (6) Ketamine. its salts, isomers, and salts of isomers ----- 7285-(7-1999)
Some other names for Ketamine: (+-)-2-(2-Chlorophenyl)-2-(Methylamino)-Cyclohexanone.
- (7) Lysergic acid ----- 7300*
- (8) Lysergic acid amide ----- 7310*
- (9) Methyprylon ----- 2575*
- (10) Sulfondiethylmethane -----2600*
- (11) Sulfonethylmethane ----- 2605*
- (12) Sulfonmethane ----- 2610*
- (13) Tiletamine and zolazepam or any salt thereof ----- 7295-(3-1988)
Some trade or other name for a tiletamine- zolazepam combination product: Telazol.
Some trade or other names for tiletamine: -2(ethylamino)-2-(2-thienyl)-cyclohexanone.
Some trade or other names for zolazepam: -4(2-fluorophenyl)-6,8-dihydro-1,3,8,-trimethylpyrazolo-[3,4-e] [1,4,-]diazepin-7(1-H)-one. flupyrazapon.
- (14) Perampanel ----- 2261-(11-2013)
- (d) Nalorphine ----- 9400*
- (e) **Narcotic drugs:** Unless specifically excepted or unless listed in another schedule:
- (1) Any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:
- (i) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium ----- 9803*
- (ii) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts ----- 9804*

- (iii) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts ----- 9807*
- (iv) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts ----- 9808*
- (v) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts ----- 9809*
- (vi) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts ----- 9810*
- (2) Any material, compound, mixture, or preparation containing any of the following narcotic drugs or their salts, as set forth below:
- (i) Buprenorphine ----- 9064-(6-1985)
(10-02 Transfer)
- (ii) Reserved
- (f) Anabolic Steroids: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts of isomers is possible within the specific chemical designation: ----- 4000
- (1) Boldenone; ----- (9-1991)
- (2) Boldione; ----- (1-2010)
- (3) Chlorotestosterone (4-chlortestosterone); ----- (9-1991)
- (4) Clostebol; ----- (9-1991)
- (5) Dehydrochlormethyltestosterone; ----- (9-1991)
- (6) Desoxymethyltestosterone ----- (1-2010)
- (7) Dihydrotestosterone (4-dihydrotestosterone); ----- (9-1991)
- (8) Drostanolone; ----- (9-1991)
- (9) Ethylestrenol; ----- (9-1991)
- (10) Fluoxymesterone; ----- (9-1991)
- (11) Formebolone (formebolone); ----- (9-1991)
- (12) Mesterolone; ----- (9-1991)
- (13) Methandienone, also known as Methandrostenolone; ----- (9-1991)
- (14) Methandranone; ----- (9-1991)
- (15) Methandriol; ----- (9-1991)

- (16) Methenolone;----- (9-1991)
- (17) Methyltestosterone; ----- (9-1991)
- (18) Mibolerone; ----- (9-1991)
- (19) Nandrolone; ----- (9-1991)
- (20) 19-Nor-4,9(10)-Androstadienedione ----- (1-2010)
- (21) Norethandrolone; ----- (9-1991)
- (22) Oxandrolone; ----- (9-1991)
- (23) Oxymesterone; ----- (9-1991)
- (24) Oxymetholone; ----- (9-1991)
- (25) Stanolone; ----- (9-1991)
- (26) Stanozolol; ----- (9-1991)
- (27) Testolactone; ----- (9-1991)
- (28) Testosterone; ----- (9-1991)
- (29) Trenbolone ----- (9-1991)
- (30) Prostanazol ----- (8-2012)
- (31) Methasterone ----- (8-2012);
- and
- (32) Any salt, ester, or isomer of a drug or substance described or list in this paragraph, if that salt, ester, or isomer promotes muscle growth. ----- (9-1991)

- (g) Exempt anabolic steroid products: Compounds, mixtures, or preparations that contain an anabolic steroid that have been exempted by the Secretary:

NDC Number

- (1) Andro-Estro 90-4 ----- 0536-1605
- (2) Androgyn L.A ----- 0456-1005
- (3) Component E-H in Process Pellets ----- Ivy Labs Inc.
- (4) Component E-H in Process Granulation ----- Ivy Labs Inc
- (5) Component TE-S in process Granulation ----- Ivy Labs Inc
- (6) Component TE-S in process Pellets ----- Ivy Labs Inc
- (7) depANDROGYN ----- 0456-1020
- (8) Depo-Testadiol ----- 0009-0253
- (9) DEPO-T.E ----- 52765-257
- (10) depTESTROGEN ----- 51698-257
- (11) Duomone ----- 52047-360

(12)	DUO-SPAN II -----	0684-0102
(13)	DURATESTRIN -----	43797-016
(14)	Essian -----	Pharmaceutics
(15)	Essian H.S -----	Pharmaceutics
(16)	Esterified Estrogens & Methyltestosterone, USP (0.625 mg/1.25mg) -----	Interpharm
(17)	Esterified Estrogens & Methyltestosterone, USP (1.25mg/2.5mg) -----	Interpharm
(18)	Esterified Estrogens & Methyltestosterone (0.625mg/1.25mg) Tablet-----	ANDAPharm
(19)	Esterified Estrogens & Methyltestosterone (1.25mg/2.5mg) Tablet-----	ANDAPharm
(20)	Estratest -----	0032-1026
(21)	Estratest HS -----	0032-1023
(22)	Menogen -----	59243-570
(23)	Menogen HS -----	59243-560
(24)	Methyltestosterone & Esterified Estrogens (2.5mg/1.25Mg) -----	Lannett Co
(25)	Methyltestosterone & Esterified Estrogens (Half Strength) (1.25mg/0.625mg) -----	Lannett Co
(26)	PAN ESTRA TEST -----	0525-0175
(27)	Premarin with Methyltestosterone -----	0046-0879
(28)	Premarin with Methyltestosterone -----	0046-0878
(29)	Syntest D.S -----	66576-231
(30)	Stntest H.S-----	66576-230
(31)	Synovex H in process bulk pellets -----	Syntex Animal
(32)	Synovex H in process granulation -----	Syntex Animal
(33)	Synovex Plus in process granulation -----	Fort Dodge
(34)	Synovex Plus in process bulk pellets -----	Fort Dodge
(35)	TEST-ESTRO Cypionates -----	0536-9470
(36)	Testoderm with Adhesive 4mg/d-----	Alza Corp
(37)	Testoderm 4mg/d-----	17314-4608
(38)	Testoderm 6mg/d-----	17314-4609
(39)	Testoderm with Adhesive 6mg/d-----	17314-2836
(40)	Testoderm in process film-----	Alza Corp
(41)	Testoderm with Adhesive in process film -----	Alza Corp
(42)	Testosterone Cypionate/Estradiol Cypionate injection -----	54274-530
(43)	Testosterone Cypionate/Estradiol Cypionate injection -----	0182-3069
(44)	Testosterone Cyp 50 Estradiol Cyp 2 -----	0814-7737

- (45) Testosterone Cypionate/Estradiol Cypionate injection ----- 0364-6611
- (46) Testosterone Cypionate/Estradiol Cypionate injection ----- 0402-0257
- (47) Testosterone Enanthate/Estradiol Valerate injection ----- 0182-3073
- (48) Testosterone Enanthate/Estradiol Valerate injection ----- 0364-6618
- (49) Testosterone Enanthate/Estradiol Valerate injection ----- 0402-0360
- (50) Testosterone Ophthalmic Solution ----- Allergan
- (51) Tilapia Sex Reversal Feed (investigational) ----- Ranger, Inc

(h) Veterinary Anabolic Steroid Implant Products: Anabolic steroid products expressly intended for administration through implants in cattle or other nonhuman species exempted by the Secretary.

NDC/DIN

- (1) Component E-H ----- 021641-002
- (2) Component E-H ----- 01968327
- (3) Component TE-S ----- 021641-004
- (4) Component T-H ----- 0211641-006
- (5) Component T-S ----- 0211641-005
- (6) F-TO ----- 00093351
- (7) Finaplix-H ----- 12799-807-10
- (8) Finaplix-S ----- 12799-807-07
- (9) Heifer-old ----- Boehringer
- (10) Heifer-old ----- Ingelheim
- (11) Heifer-old ----- Ivy Lab.
- (12) Implus-H ----- 0009-0434-01
- (13) Implus-H ----- 06-0434-01
01968327
- (14) Masculinizing Feed for Fish (Investigational) ----- Rangen, Inc.
- (15) Revalor-G ----- 12799-811
- (16) Revalor-H ----- 12799-810
- (17) Revalor-S ----- 12799-809
- (18) Synovex H ----- 0856-3901
- (19) Synovex H ----- Syntex
- (20) Synovex Plus ----- 0856-3904
- (21) Tilapia Sex Reversal Feed (investigational) ----- Zeigler Bros.

If veterinary products that are granted exempted status are subsequently distributed with the intent that they be used in humans, the distribution would be subject to the criminal sanctions of the CSA despite the drugs' exempted status.

(i) **Hallucinogenic substances:**

- (1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration approved drug product ----- 7369-(11-1987)

[Some other names for dronabinol: (6a R-trans)-6a,7,8, 10a-tetrahydro-6, 6, 9-trimethyl-3-pentyl-6H-dibenzo [b,d] pyran-1-ol, or (-)-delta 9-(trans)-tetrahydrocannabinol]

SCHEDULE IV

- (a) Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.

- (b) **Narcotic drugs:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

- (1) Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit----- 9167*

- (2) Dextro propoxyphene (alpha-(+)-4-dimethylamino- 1,2-diphenyl-3-methyl-2-propionoxybutane) ----- 9278-(11-1987)

- (c) **Depressants:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

- (1) Alprazolam ----- 2882-(6-1982)

- (2) Barbital ----- 2145*

- (3) Bromazepam ----- 2748-(1-1985)

- (4) Camazepam ----- 2749-(1-1985)

- (5) Chloral betaine ----- 2460*

- (6) Chloral hydrate ----- 2465*

- (7) Chlordiazepoxide ----- 2744*

- (8) Clobazam ----- 2751-(1-1985)

- (9) Clonazepam ----- 2737*

- (10) Clorazepate ----- 2768*

(11)	Clotiazepam	2752-(1-1985)
(12)	Cloxazolam	2753-(1-1985)
(13)	Delorazepam	2754-(1-1985)
(14)	Diazepam	2765*
(15)	Dichloralphenazone	2467-(10-2002)
(16)	Estazolam	2756-(1-1985)
(17)	Ethchlorvynol	2540*
(18)	Ethinamate	2545*
(19)	Ethyl loflazepate	2758-(1-1985)
(20)	Fludiazepam	2759-(1-1985)
(21)	Flunitrazepam	2763-(1-1985)
(22)	Flurazepam	2767*
(23)	Fospropofol	2138-(11-2009)
(24)	Halazepam	2762-(6-1982)
(25)	Haloxazolam	2771-(1-1985)
(26)	Ketazolam	2772-(1-1985)
(27)	Loprazolam	2773-(1-1985)
(28)	Lorazepam	2885*
(29)	Lormetazepam	2774-(1-1985)
(30)	Mebutamate	2800*
(31)	Medazepam	2836-(1-1985)
(32)	Meprobamate	2820*
(33)	Methohexital	2264*
(34)	Methylphenobarbital (mephobarbital)	2250*
(35)	Midazolam	2884-(1-1985)
(36)	Nimetazepam	2837-(1-1985)
(37)	Nitrazepam	2834-(1-1985)
(38)	Nordiazepam	2838-(1-1985)
(39)	Oxazepam	2835*
(40)	Oxazolam	2839*
(41)	Paraldehyde	2585*
(42)	Petrichloral	2591*
(43)	Phenobarbital	2285*

(44)	Pinazepam -----	2883-(1-1985)
(45)	Prazepam -----	2764*
(46)	Quazepam -----	2881-(11-1986)
(47)	Temazepam -----	2925-(9-1981)
(48)	Tetrazepam -----	2886-(1-1985)
(49)	Triazolam -----	2887-(7-1983)
(50)	Zaleplon -----	2781-(9-1999)
(51)	Zolpidem -----	2783-(12-1993)
(52)	Zopiclone -----	2784-(1-2006)
(53)	Alfaxalone -----	2731-(2-2014)
(54)	Carisoprodol -----	8192-(4-1997)
(55)	Tramadol -----	9752-(8-2007)
(56)	Suvorexant -----	2223-(8-2014)
(57)	Brexanolone -----	2400-(4-2021)
(58)	Lemborexant -----	2245-(4-2021)
(59)	Remimazolam -----	2846-(5-2022)
(60)	Daridorexant -----	2410

~~(d) **Fenfluramine:** Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:~~

~~(1) Fenfluramine ----- 1670*~~

(e)(d) Stimulants: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1)	Cathine ((+)-Norpseudeophedrine-----	1230-(3-1988)
(2)	Diethylpropion -----	1610*
(3)	Fencamfamin -----	1760-(3-1988)
(4)	Fenproporex -----	1575-(3-1988)
(5)	Lorcaserin -----	1625-(6-2013)
(6)	Mazindol -----	1605-(6-1982)
(7)	Mefenorex -----	1580-(3-1988)

(8) Modafinil-----	1680-(1-1999)
(9) Pemoline (including organometallic complexes and chelates thereof) -----	1530*
(10) Phentermine -----	1640*
(11) Pipradrol -----	1750-(9-1981)
(12) Serdexmethylphenidate -----	1729
(13) Sibutramine -----	1675-(2-1998)
(14) Solriamfetol -----	1650-(4-2021)
(15) SPA ((-)-1-dimethylamino-1,2-diphenylethane) -----	1635-(9-1981)

(e) Other substances: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts; isomers whether optical, position, or geometric), and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:

(1) Pentazocine -----	9709-(4-1979)
(2) Butorphanol -----	9720-(4-1997)
(3) Nalbuphine -----	(4-1997)
(4) Eluxadoline -----	9725-(4-2017)

SCHEDULE V

- (a) Schedule V shall consist of the drugs and other substances by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section.
- (b) **Narcotic Drugs:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs and their salts, as set forth below.

Reserved

- (c) **Narcotic drugs containing nonnarcotic active medicinal ingredients.** Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs or salts thereof, which shall include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:

(1) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams. -----	*
(2) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams. -----	*
(3) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams. -----	*

- (4) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit. ----- *
- (5) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams. ----- *
- (6) Not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit. ----- *

(d) **Stimulants:** unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having stimulant effect on the central nervous system, including its salts, isomers and salts of isomers:

- (1) Pyrovalerone ----- 1485-(3-1988)
- (2) Ephedrine: a -{(Methylamino)ethyl}benzene-methanol; ----- (10-1995)
 a -{(methylamino) ethyl}benzyl alcohol; 2-methylamino-1-phenyl-1-propanol;
 1-phenyl-1-hydroxy-2-methylaminopropane; 1-phenyl-2-methylaminopropanol; a - hydroxy-b-methylaminopropylbenzene; a product which occurs in the Chinese herb Ma Huang (*Ephedra vulgaris*, *Ephedra sinica* Stapf., *Ephedra equisetina* Bunge, Gnetaceae) in several other *Ephedra* spp.
- (3) Phenylpropanolamine ----- (7-2005)
- (4) Pseudoephedrine ----- (7-2005)

Pursuant to Ark. Code Ann. § 5-64-212 as amended in 2005, this Schedule V classification shall NOT apply to any ephedrine, phenylpropanolamine, or pseudoephedrine in liquid, liquid capsule, or liquid gel capsule form. However, sales limits mandated by statute shall apply to all products with ephedrine, phenylpropanolamine, or pseudoephedrine as a listed ingredient regardless of the dosage form.

(e) **Depressants:** Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers:

- (1) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid ----- 2782-(1-2006)
- (2) Lacosamide ----- 2746-(5-2009)
- (3) Brivaracetam ----- 2710-(4-2017)
- (4) Lasmiditan ----- 2790-(4-2021)
- (5) Cenobamate ----- 2720-(4-2021)
- (6) Ganaxolone ----- 2401

(f) **Other substances:**

(1) [None.](#)

SCHEDULE VI ****

(a) In addition to any substance placed in Schedule VI by the Secretary of the Department of Health under § 5-64-214, any material, compound, mixture, or preparation, whether produced directly or indirectly from a substance of vegetable origin or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, that contains any quantity of the following substances, or that contains any of their salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation, is included in Schedule VI:

- (1) Marijuana ----- **
- (2) Tetrahydrocannabinols, unless the tetrahydrocannabinol is: ----- **
- (i) Contained in hemp-derived cannabidiol; ----- (6-2020)
- (ii) Not more than three-tenths of one percent (0.3%) of delta-9 tetrahydrocannabinol in the hemp-derived cannabidiol on a dry weight basis as verified by a nationally accredited laboratory for quality, purity and accuracy standards; and ----- (6-2020) ***
- (iii) Not approved by the United States Food and Drug Administration for marketing as a medication; ----- (6-2020)
- (3) A synthetic equivalent of:
- (i) The substance contained in the Cannabis plant; or ----- **
- (ii) The substance contained in the resinous extractives of the genus Cannabis; ----- **
- (4) Salvia divinorum or Salvinorin A, which includes all parts of the plant presently classified botanically as Salvia divinorum, whether growing or not, the seeds of the plant, any extract from any part of the plant, and every compound, manufacture, derivative, mixture, or preparation of the plant, its seeds, or its extracts, including salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation; ----- **
- (5) Synthetic substances, derivatives, or their isomers in the chemical structural classes described below in subdivisions (a)(5)(i)-(a)(5)(x) of this section and also specific unclassified substances in subdivision (a)(5)(xi) of this section. Compounds of the structures described in this subdivision (a)(5), regardless of numerical designation of atomic positions, are included in this subdivision (a)(5). The synthetic substances, derivatives, or their isomers included in this subdivision (a)(5) are:
- (i) Tetrahydrocannabinols:
- (A) Tetrahydrocannabinols, including without limitation the following: ----- **
- a) Delta-1 cis or trans tetrahydrocannabinol [other name(s): Delta-9 cis or trans tetrahydrocannabinol], and its optical isomers; ----- **

- b) Delta-6 cis or trans tetrahydrocannabinol [other name(s): Delta-8 cis or trans tetrahydrocannabinol], and its optical isomers; ----- **
- c) Delta- 3,4 cis or trans tetrahydrocannabinol [other name(s): Delta-6a,10a cis or trans tetrahydrocannabinol], and its optical isomers ; ----- **
- d) Delta-10 cis or trans tetrahydrocannabinol, and its optical isomers ;----- ***
- e) Delta-8 tetrahydrocannabinol acetate ester; ----- ***
- f) Delta-9 tetrahydrocannabinol acetate ester; ----- ***
- g) Delta-6a,10a, tetrahydrocannabinol acetate ester; ----- ***
- h) Delta-10 tetrahydrocannabinol acetate ester; and, ----- ***
- i) A product derived from industrial hemp that was produced as a result of a synthetic chemical process that converted the industrial hemp or a substance contained in industrial hemp into Delta-8, Delta-9, Delta 6a,10a, or Delta-10 tetrahydrocannabinol including their respective acetate esters. ----- ***
- (B) Dronabinol in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the United States Food and Drug Administration is not a tetrahydrocannabinol under this subdivision (a)(5)(i); ----- **
- (ii) Naphthoylindoles, or any compound structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation the following: ----- **
- (A) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole; ----- **
- (B) JWH-015, or 1-Propyl-2-methyl-3-(1-naphthoyl)indole; ----- **
- (C) JWH-018, or 1-Propyl-3-(1-naphthoyl)indole; -----
- (D) JWH-019, or 1-Hexyl-3-(1-naphthoyl)indole; ----- **
- (E) JWH-073, or 1-Butyl-3-(1-naphthoyl)indole; ----- **
- (F) JWH-081, or 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole; ----- **
- (G) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole; ----- **
- (H) JWH-122, or 1-Pentyl-3-(4-methyl-1-naphthoyl)indole; ----- **
- (I) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole; ----- **
- (J) JWH-200, or 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl) indole; ----- **
- (K) JWH-210, or 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole; ----- **
- (L) JWH-398, or 1-Pentyl-3-(4-chloro-1-naphthoyl)indole; ----- **

- (M) AM-2201, or 1-(5-fluoropentyl)-3-(1-naphthoyl)indole; ----- **
- (N) MAM2201, or (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone; ----- **
- (O) EAM2201, or (1-(5-fluoropentyl)-1H-indol-3-yl)(4-ethyl-1-naphthalenyl)-methanone; and ----- **
- (P) THJ-2201, or [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone; ----- 7024-(7-2019)
- (iii) Naphthylmethylindoles, or any compound structurally derived from an H-indol-3-yl-(1-naphthyl) methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation the following: ----- **
- (A) JWH-175, or 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane; and ----- **
- (B) JWH-184, or 1-Pentyl-1H-3-yl-(4-methyl-1-naphthyl)methane; ----- **
- (iv) Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; ----- **
- (v) Naphthylmethylindenes, or any compound structurally derived from 1-(1-naphthylmethyl)indene with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-176, or E-1-[1-(1-Naphthalenylmethylene)-1H-inden-3-yl]pentane; ----- **
- (vi) Phenylacetylindoles, or any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including without limitation the following: ----- **
- (A) JWH-201, or 2-(4-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone; ----- **
- (B) JWH-203, or 1-Pentyl-3-(2-chlorophenylacetyl)indole; ----- **
- (C) JWH-250, or 1-Pentyl-3-(2-methoxyphenylacetyl)indole; ----- **

- (D) JWH-251, or 1-Pentyl-3-(2-methylphenylacetyl)indole; and ----- **
- (E) RCS-8, or 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole; ----- **
- (vii) Cyclohexylphenols, or any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent, including without limitation the following: ----- **
- (A) CP 47,497 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol; ----- **
- (B) Cannabicyclohexanol or CP 47,497 C8 homologue, or 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol; and ----- **
- (C) CP 55,940, or 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol; ----- **
- (viii) Benzoylindoles, or any compound structurally derived from a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including without limitation the following: ----- **
- (A) AM-694, or 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole; ----- **
- (B) RCS-4, or 1-Pentyl-3-(4-methoxybenzoyl)indole; ----- **
- (C) WIN-48,098 or Pravadoline, or (4-Methoxyphenyl)-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone; ----- **
- (D) AM-2233, or 1-[(N-methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole; and ----- **
- (E) RCS-4 (C4 homologue) or (4-methoxyphenyl)(1-butyl-1H-indol-3-yl)-methanone; ----- **
- (ix) Adamantoylindoles, or Adamantoylindazoles, including Adamantyl Carboxamide Indoles and Adamantyl Carboxamide Indazoles, or any compound structurally derived from 3-(1-adamantoyl) indole, 3-(1-adamantoyl) indazole, or 3-(2-adamantoyl)indole by substitution at a nitrogen atom of the indole or indazole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole or indazole ring to any extent and whether or not substituted in the adamantyl ring to any extent, including without limitation the following: ----- **
- (A) AM-1248, or 1-adamantyl-[1-[(1-methylpiperidin-2-yl)methyl]indol-3-yl]methanone; ----- **

- (B) AB-001, or 1-adamantyl-(1-pentylindol-3-yl)methanone; ----- **
- (C) JWH-018 adamantyl carboxamide, or 1-pentyl-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1H-indole-3-carboxamide [other name(s): 2NE1, moved in Schedule VI in 2020] ----- **
- (D) AKB-48, or N-(1-adamantyl)-pentyl-1H-indazole-3-carboxamide; ----- **
- (E) 5F-AKB-48, or N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide ----- 7049**
- (F) STS-135, or N-(1-adamantyl)-1-(5-fluoropentyl)indole-3-carboxamide; ----- **
- (x) Tetramethylcyclopropylcarbonylindoles or any compound structurally derived from 3-(2,2,3,3-tetramethylcyclopropylcarbonyl) indole by substitution at the nitrogen atom of the indole ring with alkyl,haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent, including without limitation the following: ----- **
- (A) UR-144, or (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone; ----- **
- (B) XLR-11, or [1-(5-fluoropentyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone; ----- **
- (C) A-796,260, or [1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone; ----- **
- (D) 5-Chloro-UR-144, or [1-(5-chloropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone; ----- **
- (E) 5-Bromo-UR-144, or [1-(5-bromopentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone; and ----- **
- (F) A-834,735, or 1-(tetrahydropyran-4-ylmethyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone; ----- **
- (xi) Unclassified Synthetic Cannabinoids, including without limitation the following: ----- **
- (A) CP 50556-1 hydrochloride, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] Acetate; ----- **
- (B) HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; ----- **
- (C) HU-211, or Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; ----- **
- (D) Dimethylheptylpyran or DMHP; ----- **

- (E) WIN55,212-2, or 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl-1-naphthalenylmethanone; ----- **
- (F) URB597, or [3-(3-carbamoylphenyl)phenyl] N-Cyclohexylcarbamate; ----- **
- (G) URB754, or 6-methyl-2-[(4-methylphenyl)amino]-1-benzoxazin-4-one; ----- **
- (H) CB-13, or 1-naphthalenyl[4-(pentyloxy)-1 naphthalenyl]-methanone; ----- **
- a) URB602, or cyclohexyl N-(3-phenylphenyl)carbamate; ----- **
- (I) PB-22, or quinolin-8-yl 1-(5-pentyl)-1H-indole-3-carboxylate; ----- **
- (J) 5F-PB-22, or quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate; ----- **
- (K) BB-22, or quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate; ----- **
- (L) NNEI (MN-24), or N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide;
 **
- (M) 5F-NNEI, or 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-carboxamide; ----- **
- (N) 5-Fluoro-AMB, or n-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine methyl ester ----- 7033-(9-2018)
- (O) MMB-CHMICA, or methyl-(1-cyclohexylmethyl)-1H-indole-3-carbonyl)-L-valinate ----- 7044-(9-2018)
- (P) 5-Fluoro-ADB, or methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate; ----- 7034-(11-2018)
- (Q) 5-Fluoro-MDMB-PICA, or methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate ----- 7041-(11-2018)
- (R) MDMB-CHMICA, or methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate; ----- 7042-(11-2018)
- (S) FUB-AMB, or methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate; ----- 7021-(11-2018)
- (T) MDMB-FUBINACA, or methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate; ----- 7020-(11-2018)
- (U) AB-PINACA, or N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide; ----- 7023-(7-2019)
- (V) AB-CHMINACA, or N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide; ----- 7031-(7-2019)
- (W) MAB-CHMINACA, or N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide; ----- (11-2014)
- (X) AB-FUBINACA, or N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide; ----- (9-2018)

(Y) ADB-PINACA, or N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide;-----	(9-2018)
(Z) 5F-CUMYL-PINACA, or 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide -----	7083-(6-2020)
(AA) ADB-FUBINACA, or N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide -----	7010-(4-2021)
(BB) 4-Fluoro-MDMB-BUTINACA, or methyl(S)-2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate; -----	7043-(4-2021)
(CC) 5F-AB-PINACA, or N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide-----	7025-(5-2022)
(DD) 4-CN-CUMYL-BUTINACA, or 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide -----	7089 -(5-2022)
(EE) 5F-CUMYL-P7AICA, or 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide -----	7085-(5-2022)
(FF) NM2201, or Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate-----	7221-(5-2022)
(GG) 5F-EDMB-PINACA, or Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate -----	7036
(HH) FUB-144, or (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl) methanone; -----	7014
(II) FUB-AKB48, or N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide; -----	7047
<u>(JJ)MDMB-4en-PINACA, or Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate;</u>	
<u>(KK) CH-PIATA, or N-cyclohexyl-2-(1-pentylindol-3-yl)acetamide.</u>	

(6) A synthetic substance, derivative, or its isomers with:

- (i) Similar chemical structure to any substance described in subdivisions (a)(1)-(a)(5) of this section; or ----- **
- (ii) Similar pharmacological effects to any substance described in subdivisions (a)(1)-(a)(5) of this section. ----- **

(b) However, except as provided under subsection (c) of this section, the Secretary shall not delete a controlled substance listed in this section from Schedule VI.

(c) A prescription drug approved by the United States Food and Drug Administration under 21 U.S.C. § 355 is excluded from Schedule VI unless the secretary objects under § 5-64-201.

*-Scheduled before April, 1979.

** -Schedule VI is revised to conform to Act 329 of 2013.

*** - Schedule VI is revised further to conform to Act 629 of 2023. Each substance added to the Controlled Substances List pursuant to Act 629 of 2023 shall have the following effective dates:

(a) For persons who are under twenty-one (21) years of age, the effective date shall be the effective date of Act 629 of 2023; and,

(b) For persons who are twenty-one (21) years of age or older, the effective date shall be August 1, 2023.

**** Pursuant to ongoing litigation, and a preliminary injunction against enforcing Act 629 of 2023, the changes made to the List of Controlled Substances pursuant to Act 629 of 2023 are not enforceable until a final order issued in the matter, Bio Gen, LLC, et al. v. Sarah Huckabee Sanders, et al., Case No. 4:23-CV-00718-BRW, Central Division, Eastern District of Arkansas, United States District Court.

DRAFT

List
Of
Controlled
Substances



For the
State
Of
Arkansas

Pursuant to the provisions of Arkansas Code Annotated § 5-64-201 and § 5-64-216 of the laws of the State of Arkansas, the Secretary of the Arkansas Department of Health or duly authorized agent, as specified by law, is giving public notice of the publication of the List of Controlled Substances for the State of Arkansas.

Due consideration has been given applicable federal regulations, current scientific knowledge regarding the listed substances, the evidence of actual or relative potential for abuse, the history and current patterns of abuse, the risk to the public health, and potential to produce psychic or psychological dependence liability.

Based on these considerations the attached listing of the Schedule of Controlled Substances and the corresponding drugs that are included in each schedule is hereby promulgated by the Secretary of the Arkansas Department of Health as the List of Controlled Substances for the State of Arkansas.

Each controlled substance or basic class thereof has been assigned an "Administration Controlled Substance Code Number" for purposes of identification. These numbers are for internal management and are used as a means to identify substances with complex and cumbersome chemical names.

Next to the code number is the date the substance was placed in schedule by the Secretary of the Arkansas Department of Health. A "*" denotes the substance was scheduled prior to April, 1979.

I, Shane David, Pharm.D., Section Chief of Pharmacy Services for the Arkansas Department of Health, do hereby certify that the documents attached hereto are true and correct copies of the current List of Controlled Substances adopted by the Arkansas State Board of Health in accordance with Arkansas state law.

Shane David, Pharm.D., Branch Chief
Pharmacy Services Section

STATE OF ARKANSAS)
)
COUNTY OF SALINE)

I, Marci Middleton, do hereby certify that Shane David, Pharm.D., well known to me, appeared before me and signed the above referenced document.

Sworn and subscribed to before me this day of, _____.

Notary Public

My commission expires

ARKANSAS DEPARTMENT OF HEALTH

LIST OF CONTROLLED SUBSTANCES

SECTION I AUTHORITY

The following scheduling of these controlled substances has been hereby promulgated pursuant to Arkansas Code Annotated §5-64-201 and §5-64-216.

SECTION II PURPOSE

Due consideration has been given applicable Federal regulations, current scientific knowledge regarding the listed substances, the evidence of actual or relative potential for abuse, the history and current patterns of abuse, the risk to the public health, and potential to produce psychic or psychological dependence liability.

SECTION III GENERAL REQUIREMENTS

(Attached copy of the listing of scheduling of controlled substances)

SECTION IV REPEAL

All lists of schedules of controlled substances in conflict herewith are hereby repealed.

CERTIFICATION

This will certify the following list of scheduling of controlled substances was adopted by the Arkansas State Board of Health at a session of the Board held in Little Rock, Arkansas on the _____ day of _____, _____, and after a Public Hearing on the _____ day of _____, _____, held in Little Rock, Arkansas, at the State Department of Health Building.

Secretary of Health, Arkansas Department of Health

ARTICLE II

SCHEDULE I

(a) Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.

(b) **Opiates: (Narcotic Drugs)** Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, salts is possible within the specific chemical designation (for purposes of 3-methylthiofentanyl only, the term isomer includes the optical and geometric isomers):

(1) Acetylmethadol -----	9601*
(2) Allylprodine -----	9602*
(3) Alphacetylmethadol (except Levo-alphacetylmethadol (LAAM)) -----	9603*
(4) Alphameprodine -----	9604*
(5) Alphamethadol -----	9605*
(6) Benzethidine -----	9606*
(7) Betacetylmethadol -----	9607*
(8) Betameprodine -----	9608*
(9) Betamethadol -----	9609*
(10) Betaprodine -----	9611*
(11) Dextromoramide -----	9613*
(12) Diampromide -----	9615*
(13) Diethylthiambutene -----	9616*
(14) Difenoxin -----	9168*
(15) Dimenoxadol -----	9617*
(16) Dimepheptanol -----	9618*
(17) Dimethylthiambutene -----	9619*
(18) Dioxaphetyl butyrate -----	9621*
(19) Dipipanone -----	9622*
(20) Ethylmethylthiambutene -----	9623*
(21) Etoxeridine -----	9625*
(22) Furethidine -----	9626*
(23) Hydroxypethidine -----	9627*

- (24) Ketobemidone ----- 9628*
- (25) Levomoramide ----- 9629*
- (26) Levophenacymorphan ----- 9631*
- (27) Morpheridine ----- 9632*
- (28) MPPP [other name(s): (1-methyl-4-phenyl-4-propionoxypiperidine)] ----- 9661-(10-1985)
- (29) Noracymethadol ----- 9633*
- (30) Norlevorphanol ----- 9634*
- (31) Normethadone ----- 9635*
- (32) Norpipanone ----- 9636*
- (33) PEPAP [other name(s): 1-(2-phenylethyl)-4-phenyl-4 acetyloxypiper-idine] - 9663-(10-1985)
- (34) Phenadoxone ----- 9637*
- (35) Phenampromide ----- 9638*
- (36) Phenomorphan ----- 9647*
- (37) Phenoperidine ----- 9641*
- (38) Piritramide ----- 9642*
- (39) Proheptazine ----- 9643*
- (40) Properidine ----- 9644*
- (41) Propiram ----- 9649*
- (42) Racemoramide ----- 9645*
- (43) Tilidine ----- 9750-(9-1981)
- (44) Trimeperidine ----- 9646*
- (45) Acetyl norfentanyl [other name(s): N-phenyl-N-4-piperidiny-acetamide]----- (4-2017)
- (46) AH-7921 [other name(s): 3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide]-----9551-(4-2017)
- (47) W-18 [other name(s): 1-(4-nitrophenylethyl)piperidylidene-2-(4-chlorophenyl)sulfonamide]----- (4-2017)
- (48) W-15 [other name(s): 1-phenylethylpiperidylidene-2-(4-chlorophenyl)Sulfonamide] ----- (4-2017)
- (49) MT-45 [other name(s): 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine] ----- 9560-(4-2017)
- (50) U-47700 [other name(s): trans-3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide] ----- 9547-(4-2017)
- (51) Fentanyl-related substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. Fentanyl-related substance means any substance not otherwise listed, and for which no exemption or approval is in effect under section

505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that is structurally related to fentanyl by one or more of the following modifications: -----(4-2021)

- (i) Replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle;
- (ii) Substitution in or on the phenethyl group with alkyl, alkenyl, alkoxy, hydroxyl, halo, haloalkyl, amino or nitro groups;
- (iii) Substitution in or on the piperidine ring with alkyl, alkenyl, alkoxy, ester, ether, hydroxyl, halo, haloalkyl, amino or nitro groups;
- (iv) Replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle; or
- (v) Replacement of the N-propionyl group by another acyl group.
- (vi) Fentanyl-related substances shall include, but are not limited to:
 - (A) Acetyl-alpha-methylfentanyl [other name(s): (N-[1-[1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide)] -----9815-(2-1986)
 - (B) Alpha-methylfentanyl [other name(s): (N-[1-(alpha-methyl-beta-phenethyl)-4-piperidyl] propronanilide; 1-(1-methyl-2-phenylethyl)-4(N-propanilido)piperidine)] ----- 9814-(6-1982)
 - (C) Alpha-methylthiofentanyl(N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide) ----- 9832-(2-1986)
 - (D) Beta-hydroxyfentanyl [other name(s): (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide)] ----- 9830-(2-1986)
 - (E) Beta-hydroxy-3-methylfentanyl [other name(s): N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropamide] ----- 9831-(2-1986)
 - (F) 3-Methylfentanyl [other name(s): (N-[3-Methyl-1-(2-phenylethyl)-4-piperidyl]-N-Phenylpropanamide)] ----- 9813-(10-1985)
 - (G) 3-methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide) ----- 9833-(2-1986)
 - (H) Para-fluorofentanyl [other name(s): (N-[4-fluorophenyl]-N-[1-(2-phenethyl)-4-piperidinyl]propanamide)] ----- 9812-(11-1986)
 - (I) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide -----9835-(2-1986)
 - (J) Acetyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide] -----9821-(4-2017)
 - (K) Butyryl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide]-----9822-(4-2017)
 - (L) Beta-hydroxythiofentanyl [other name(s): N-{1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl}-N-phenylpropionamide]-----9836-(4-2017)

- (M) Acetyl fentanyl 4-methylphenethyl analog [other name(s): N-{1-[2-(4-methylphenyl)ethyl]-4-piperidinyl}-N-phenyl-acetamide] ----- (4-2017)
- (N) Valeryl fentanyl [other name(s): N-phenyl-N[1-(2-phenylethyl)-4-piperidinyl]-pentanamide]-----9840-(4-2017)
- (O) Furanyl fentanyl [other name(s): N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylfuran-2-carboxamide]-----9834-(4-2017)
- (P) Isobutyryl fentanyl [other name(s): 2-methyl-N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide]-----9827-(4-2017)
- (Q) Ocfentanil [other name(s): N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide] -----9838-(4-2017)
- (R) 4-methoxy butyryl fentanyl [other name(s): N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide] ----- (4-2017)
- (S) Para-fluorobutyryl fentanyl [other name(s): N-(4-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide] -----9823-(4-2017)
- (T) Acryl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide] ----- 9811-(6-2020)
- (U) 4-Fluoroisobutyryl fentanyl [other name(s): N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide]----- 9824-(6-2020)
- (V) Tetrahydrofuranyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide] ----- 9843-(6-2020)
- (W) Cyclopropyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide] ----- 9845-(4-2021)
- (X) Methoxyacetyl fentanyl [other name(s): 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide] ----- 9825-(4-2021)
- (Y) Ortho-fluorofentanyl [other name(s): N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide] ----- 9816-(4-2021)
- (Z) Crotonyl fentanyl [other name(s): (E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide] ----- 9844-(5-2022)
- (AA) Cyclopentyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide] ----- 9847-(5-2022)
- (BB) Para-chloroisobutyryl fentanyl [other name(s): N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide] ----- 9826-(5-2022)
- (CC) Para-methoxybutyryl fentanyl [other name(s): N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide] ----- 9837-(5-2022)
- (DD) Beta-methyl fentanyl [other name(s): N-phenyl-N-(1-(2-phenylpropyl) piperidin-4-yl)propionamide] ----- 9856-(5-2022)
- (EE) Beta'-phenyl fentanyl [other name: N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide] ----- 9842-(5-2022)

- (FF) 2'-Fluoro ortho-fluorofentanyl [other name(s): N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide] ----- 9855-(5-2022)
- (GG) 4'-Methyl acetyl fentanyl [other name(s): N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide] ----- 9819-(5-2022)
- (HH) Ortho-fluorobutyryl fentanyl [other name(s): N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide] ----- 9846-(5-2022)
- (II) Ortho-methyl acetylfentanyl [other name(s): N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide] ----- 9848-(5-2022)
- (JJ) Ortho-methyl methoxyacetyl fentanyl [other name(s): 2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide] ----- 9820-(5-2022)
- (KK) Para-methylfentanyl [other name(s): N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide] ----- 9817-(5-2022)
- (LL) Phenyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide] ----- 9841-(5-2022)
- (MM) Thiofuranyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide] ----- 9839-(5-2022)
- (NN) Fentanyl carbamate [other name(s): ethyl(1-phenethylpiperidin-4-yl)(phenyl)carbamate] ----- 9851-(5-2022)
- (OO) Ortho-fluoroacryl fentanyl [other name(s): N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)acrylamide] ----- 9852-(5-2022)
- (PP) Ortho-fluoroisobutyryl fentanyl [other name(s): N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide] ----- 9853-(5-2022)
- (QQ) Para-fluoro furanyl fentanyl [other name(s): N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide] ----- 9854-(5-2022)
- (52) Zipeprol ----- 9873
- (53) Brorphine ----- 9098
- (54) Benzimidazole-opioid substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. Benzimidazole-opioid substances includes any substance, not otherwise listed or excepted, and for which no exemption or approval is in effect under Section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that structurally has benzimidazole ring with an ethylamine at its 1-position and benzyl group at its 2-position:
- (i) With or without substitution on the benzimidazole;
 - (ii) With or without substitution at the ethylamine;
 - (iii) With or without inclusion of the ethylamine in a cyclic structure;
 - (iv) With or without substitution on the benzyl ring; or
 - (v) With or without replacement of the benzyl ring with an aromatic ring.
 - (vi) Benzimidazole-opioid substances shall include but are not limited to:

(A) 4'-Hydroxy Nitazene;	
(B) 5-Aminoisotonitazene;	
(C) Butonitazene;	
(D) Clonitazene ;	9612 *
(E) Etodesnitazene, [other name(s): Etazene];	
(F) Etonitazene ;	9624*
(G) Flunitazene;	
(H) Isotonitazene;	9614
(I) Isotodesnitazene ;	
(J) Metodesnitazene;	
(K) Metonitazene;	9757
(L) N-Desethyl Etonitazene ;	
(M) N-Desethyl Isotonitazene ;	
(N) N-Piperidinyl Etonitazene [other name(s): Etonitazepipne];	
(O) N-Pyrrolidino Etonitazene [other name(s): Etonitazepyne];	
(P) N-Pyrrolidino Protonitazene; and	
(Q) Protonitazene.	

(c) **Opium derivatives: (Narcotic Drugs)** Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Acetorphine	9319*
(2) Acetyldihydrocodeine	9051*
(3) Benzylmorphine	9052*
(4) Codeine methylbromide	9070*
(5) Codeine-N-Oxide	9053*
(6) Cyprenorphine	9054*
(7) Desomorphine	9055*
(8) Dihydromorphine	9145*
(9) Drotebanol	9335*
(10) Etorphine (except hydrochloride salt)	9056*
(11) Heroin	9200*
(12) Hydromorphanol	9301*

(13) Methyldesorphine -----	9302*
(14) Methyldihydromorphine -----	9304*
(15) Morphine methylbromide -----	9305*
(16) Morphine methylsulfonate -----	9306*
(17) Morphine-N-Oxide -----	9307*
(18) Myrophine -----	9308*
(19) Nicocodeine -----	9309*
(20) Nicomorphine -----	9312*
(21) Normorphine -----	9313*
(22) Pholcodine -----	9314*
(23) Thebacon -----	9315*
(24) Mitragynine -----	(11-2015)
(25) 7-Hydroxymitragynine-----	(11-2015)

(d) **Hallucinogenic substances:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of the following hallucinogenic substance, or which contains any of its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation (for purposes of this paragraph only, the term "isomer" includes the optical, position and geometric isomers):

(1) alpha-ethyltryptamine -----	7249-(12-1993)
Some trade or other names: etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl)indole; alpha-ET; and AET.	
(2) 4-bromo-2,5-dimethoxy-amphetamine -----	7391*
Some trade or other names: 4-bromo-2,5-dimethoxy-alpha-methylphenethylamine; 4-bromo-2,5-DMA.	
(3) 4-bromo-2,5-dimethoxyphenethylamine -----	7392-(8-1995)
Some trade or other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1 aminoethane; alpha-desmethyl DOB; 2C-B, Nexus.	
(4) 2,5-dimethoxyamphetamine -----	7396*
Some trade or other names: 2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA.	
(5) 2,5-dimethoxy-4-ethylamphetamine -----	7399-(3-1988)
Some trade or other names: DOET.	
(6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine -----	7348-(1-2005)
Some trade or other names: 2C-T-7.	

- (7) 4-methoxyamphetamine ----- 7411*
Some trade or other names: 4-methoxy-alpha- methylphenethylamine;
paramethoxyamphetamine; PMA.
- (8) 5-methoxy-3,4-methylenedioxy-amphetamine ----- 7401*
- (9) 4-methyl-2,5-dimethoxyamphetamine ----- 7395*
Some trade and other names: 4-methyl-2,5-dimethoxy-
alphamethylphenethylamine; "DOM"; and "STP".
- (10) 3,4-methylenedioxy amphetamine ----- 7400*
- (11) 3,4-methylenedioxymethamphetamine ----- 7405-(10-1985)
Some trade or other names: MDMA)
- (12) 3,4-methylenedioxy-N-ethylamphetamine ----- 7404-(6-1990)
Some trade or other names: N- ethy-alpha-methyl-3,4 (methylenedioxy)
phenethylamine, N-ethyl MDA; MDE; MDEA.
- (13) N-hydroxy-3,4-methylenedioxyamphetamine ----- 7402-(6-1990)
Some trade or other names: N-hydroxy-alpha-methyl-3,4(methylenedioxy)
phenethylamine; N-hydroxy MDA
- (14) 3,4,5-trimethoxy amphetamine ----- 7390*
- (15) 5-methoxy-n,n-dimethyltryptamine 5-MeO-DMT ----- 7431*(1-2011)
- (16) alpha-methyltryptamine ----- 7432-(7-2005)
Some trade or other names: AMT
- (17) Bufotenine ----- 7433*
Some trade and other names: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole;
3-(2-dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-
dimethyltryptamine; mappine.
- (18) Diethyltryptamine ----- 7434*
Some trade or other names: N,N-Diethyltryptamine;DET.
- (19) Dimethyltryptamine ----- 7435*
Some trade or other names: DMT
- (20) 5-methoxy-N,N-diisopropyltryptamine ----- 7439-(7-2005)
Some trade or other names: 5-MeO-DIPT.
- (21) Ibogaine ----- 7260*
Some trade and other names: 7-Ethyl-6,6 beta; 7,8,9,10,12,13-octahydro-2-
methoxy-6,9-methano-5H-pyrido [1',2': 1,2] azepino [5,4-b] indole;
Tabernanthe iboga.
- (22) Lysergic acid diethylamide ----- 7315*

- (23) Mescaline ----- 7381*
- (24) Parahexyl ----- 7374-(7-1983)
Some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo [b,d] pyran; Synhexyl.
- (25) Peyote ----- 7415*
Meaning all parts of the plant presently classified botanically as *Lophophora williamsii* Lemaire, whether growing or not; the seeds thereof; any extract from any part of such plant; and every compound, manufacture, salts, derivative, mixture or preparation of such plant, its seeds or extracts. (Interprets 21 USC 812 (c), Schedule I (c) (12)).
- (26) N-ethyl-3-piperidyl benzilate ----- 7482*
- (27) N-methyl-3-piperidyl benzilate ----- 7484*
- (28) Psilocybin ----- 7437*
- (29) Psilocyn ----- 7438*
- (30) Ethylamine Analog of phencyclidine ----- 7455*
Some trade or other names: N-ethyl-1-phenylcyclohexylamine, (phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine; cyclohexamine; PCE.
- (31) Pyrrolidine Analog of phencyclidine ----- 7458*
Some trade or other names: 1-(1-phenylcyclohexyl)-pyrrolidine; PCPy; PHP
- (32) Thiophene Analog of phencyclidine ----- 7470*
Some trade or other names: 1-[1-(2-thienyl) cyclohexyl] Piperidine; 2-Thienyl analog of phencyclidine; TPCP; TCP.
- (33) 1-[1-(2-Thienyl)cylcohexyl]pyrrolidine ----- 7473-(9-1989)
Some other trade or other names: TCPy.
- (34) N,N-Diallyl-5-Methoxytryptamine; ----- (6-2012)
Some trade or other names: 5-MeO DALT; 5-Methoxy-DALT
- (35) 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine;
25C-NBOMe ----- (5-2013)
- (36) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl) methyl]ethanamine;
25I-NBOMe ----- (8-2013)
- (37) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine; 2C-E ----- 7509-(11-2013)
- (38) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine; 2C-D ----- 7508-(11-2013)
- (39) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine; 2C-C ----- 7519-(11-2013)
- (40) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine; 2C-I ----- 7518-(11-2013)
- (41) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine; 2C-T-2 ----- 7385-(11-2013)

- (42) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine; 2C-T-4 ----- 7532-(11-2013)
- (43) 2-(2,5-Dimethoxyphenyl)ethanamine; 2C-H ----- 7517-(11-2013)
- (44) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine; 2C-N ----- 7521-(11-2013)
- (45) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine; 2C-P ----- 7524-(11-2013)
- (46) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine; 25B-NBOMe ----- (9-2018)
- (47) 2-[[[2-(4-bromo-2,5-dimethoxyphenyl)ethyl]amino]methyl]-phenol; 25B-NBOH ----- (11-2018)
- (48) 2-[[[2-(4-iodo-2,5-dimethoxyphenyl)ethyl]amino]methyl]-phenol; 25I-NBOH ----- (11-2018)
- (49) 2-(4-ethyl-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl) methyl]ethanamine; 25E-NBOMe ----- (7-2019)
- (50) 2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl) methyl]ethanamine; 25H-NBOMe ----- (7-2019)
- (51) 2-[[[2-(4-chloro-2,5-dimethoxyphenyl)ethyl]amino]methyl]- phenol; 25C-NBOH ----- (7-2019)
- (52) 2-[[[2-(2,5-dimethoxyphenyl)ethyl]amino]methyl]-phenol; 25H-NBOH ----- (7-2019)
- (53) 1-(4-methoxyphenyl)-N-methylpropan-2-amine ----- 1245-(5-2022)
Some trade or other names: Para-methoxymethamphetamine; PMMA
- (54) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one ----- 7286
Some trade or other names: Methoxetamine; MXE

(e) **Depressants:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

- (1) gamma-hydroxybutyric acid [other name(s): GHB; gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxydutanolic acid; sodium oxybate; sodium oxybutyrate], and its known precursors and analogs. Precursors include but are not limited to: gamma-butyrolactone ----- 2010-(2-2001)
- (2) Mecloqualone ----- 2572*
- (3) Methaqualone ----- 2565*
- (4) Benzodiazepine substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. Benzodiazepine substances includes any substance, not otherwise listed or excepted, and for which no exemption or approval is in effect under section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that structurally has a fused 1,4-diazepine and benzene ring structure with a phenyl connected to the diazepine ring, with any substitution(s) or replacement(s)

on the 1,4-diazepine or benzene ring, any substitution(s) on the phenyl ring, or any combination thereof. Benzodiazepine substances shall include but are not limited to:

- (i) Bromazolam;
- (ii) Clonazolam; -----(4-2021)
- (iii) Flualprazolam;----- (4-2021)
- (iv) Flubromazepam; -----(4-2021)
- (v) Flubromazolam;----- (4-2021)
- (vi) Phenazepam;----- (6-2012)
- (vii) Phenazolam [other name(s): Clobromazolam].

(5) Thienodiazepine substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. Thienodiazepine substances includes any substance, not otherwise listed or excepted, and for which no exemption or approval is in effect under section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that structurally has a fused 1,4-diazepine and thiophene ring structure with a phenyl connected to the 1,4-diazepine ring, with any substitution(s) or replacement(s) on the 1,4-diazepine or thiophene ring, any substitution(s) on the phenyl ring, or any combination thereof. Thienodiazepine substances shall include but are not limited to:

- (i) Etizolam ----- (12-2014)

(f) Stimulants:

(1) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:

- (i) Cathinone ----- 1235-(3-1988)
- (ii) (±) CIS-4-Methylaminorex [(±)CIS-4,5-dihydro-4- methyl-5-phenyl-2-oxazolamine] ----- 1590-(6-1990)
- (iii) Fenethylamine ----- 1503-(9-1981)
- (iv) N-Benzylpiperazine----- 7493-(1-2005)
Some trade or other names: BZP, 1-Benzylpiperazine
- (v) N-ethylamphetamine ----- 1475-(6-1982)
- (vi) N-[1-(1-benzyl-4-piperidyl)-N-phenylpropanamide (benzylfentanyl), its optical isomers, salts and salts of isomers ----- 9818-(2-1986)
- (vii) N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropan-mide (thenylfentanyl), its optical isomers, salts and salts of isomers ----- 9834-(2-1986)

- (viii) N,N-Dimethylamphetamine [other name(s): N,N,Alpha-trimethylbenzeneethanamine; N,N,Alpha-trimethylphenethylamine], its salts, optical isomers, and salts of optical isomers ----- 1480-(2-1989)
- (ix) Methcathinone (some other names: 2-Methylamine-Propiophenone, alpha (methylamino)- Propiophenone, 2 (methylamino)-1-phenylpropan-1-one, alpha-N-Methylaminopropiophenone, monomethylpropion, ephedrone, N-methylcathinone, methycathinone, AL-464, AL-422, AL-463 and UR-1431), its salts, optical isomers and salts of optical isomers ----- 1237-(12-1993)
- (x) Aminorex [other name(s): aminoraphen, 2-amino-5 phenyl-2-oxazoline, or 4,5 dihydo-5-phenyl-2-oxazolamine], its salts, optical isomers, and salts of optical isomers ----- 1585-(12-1993)
- (xi) 4,4'-Dimethylaminorex some other names: 4,4'-DMAR, 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine, or 4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine ----- 1595-(5-2022)
- (xii) Amineptine ----- 1219
- (xiii) Mesocarb ----- 1227
- (xiv) Methyl-N-ethylcathinone (MEC)----- (6-2014)
- (xv) Methiopropamine. [other name(s): N-methyl-1-(thiophen-2-yl)propan-2-amine] ----- 1478
- (2) Any material, compound, mixture, or preparation, whether produced directly or indirectly from a substance of vegetable origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis, that contains any quantity of the following substances, or that contains any of the following substances' analogs, salts, isomers, and salts of isomers when the existence of the analogs, salts, isomers, and salts of isomers is possible within the specific chemical designation, with the following chemical structure is included in Schedule I:
- (i) 4-Methylmethcathinone (Mephedrone) ----- 1248-(3-2011)
- (ii) Methylenedioxypropylvalerone (MDPV) ----- (3-2011)
- (iii) 3,4-Methylenedioxy-N-methylcathinone (Methylone) ----- 7540-(3-2011)
- (iv) 4-Methoxymethcathinone ----- (3-2011)
- (v) 3-Fluoromethcathinone ----- (3-2011)
- (vi) 4-Fluoromethcathinone----- (3-2011)
- (vii) 1-(1,3-benzodioxol-5-yl)-2-methylamino)butan-1-one-(Butylone) ----- 7541-(11-2014)
- (viii) Alpha-Pyrrolidinopentiophenone (Alpha-PVP) ----- 7545-(11-2015)
- (ix) 4-methyl-N-ethylcathinone (4-MEC) ----- 1249-(9-2018)
- (x) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP) ----- 7498-(9-2018)
- (xi) 2-(methylamino)-1-phenylpentan-1-one (Pentedrone) ----- 1246-(9-2018)

- (xii) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (Pentylone; bk-MBDP) -----7542-(9-2018)
- (xiii) 4-fluoro-N-methylcathinone (4-FMC, Flephedrone) -----1238-(9-2018)
- (xiv) 3-fluoro-N-methylcathinone (3-FMC)-----1233-(9-2018)
- (xv) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (Naphyrone) -----1258-(9-2018)
- (xvi) Alpha-pyrrolidinobutiophenone ([Alpha]-PBP) -----7546-(9-2018)
- (xvii) A compound, unless listed in another schedule or a legend drug, that is structurally derived from 2-Amino-phenyl-1-propanone by modification or by substitution: -----(3-2012)
- (A) In the phenyl ring to any extent with alkyl, alkoxy, alkylendioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one (1) or more other univalent substituents;
- (B) At the 3-position with an alkyl substituent; or
- (C) At the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.
- (xviii) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)pentan-1-one (N-Ethylpentylone) 7543-(7-2019)
- (xix) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)propan-1-one (Ethylone)-----7547-(4-2021)
- (xx) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-1-butanone (Eutylone) -----7549-(4-2021)
- (xxi) 2-(ethylamino)-1-phenylhexan-1-one [other name(s): (N-Ethylhexedrone ; Alpha-Ethylaminohexanophenone)] ----- 7246
- (xxii) 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one [other name(s): (Alpha-Pyrrolidinohexanophenone ; Alpha-PHP)]----- 7544
- (xxiii) 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one [other name(s): (4-Methyl-alpha-ethylaminopentiophenone ; 4-MEAP)]----- 7245
- (xxiv) 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one [other name(s): (4'-Methyl-alpha-pyrrolidinohexiophenone ; MPHP)] ----- 7446
- (xxv) 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one [other name(s): (Alpha-Pyrrolidinoheptaphenone ; PV8)] ----- 7548
- (xxvi) 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one [other name(s): (4'-Chloro-alpha-pyrrolidinovalerophenone ; 4-chloro-alpha-PVP)] ----- 7443

SCHEDULE II

- (a) Schedule II shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the Controlled Substances Code Number set forth opposite it.
- (b) **Narcotic Drugs:** Substances, vegetable origin or chemical synthesis. Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or

indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis:

- (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, naldemedine, nalmefene, naloxegol, naloxone, 6 β -naltrexol, naltrexone and samidorphan, and their respective salts, but including the following:
- | | |
|-----------------------------------|---------------|
| (i) Raw opium ----- | 9600* |
| (ii) Opium extracts ----- | 9610* |
| (iii) Opium fluid extracts ----- | 9620* |
| (iv) Powdered opium ----- | 9639* |
| (v) Granulated opium ----- | 9640* |
| (vi) Tincture of opium ----- | 9630* |
| (vii) Codeine ----- | 9050* |
| (viii) Dihydroetorphine ----- | 9334* |
| (ix) Ethylmorphine ----- | 9190* |
| (x) Etorphine hydrochloride ----- | 9059* |
| (xi) Hydrocodone ----- | 9193* |
| (xii) Hydromorphone ----- | 9150* |
| (xiii) Metopon ----- | 9260* |
| (xiv) Morphine ----- | 9300* |
| (xv) Oripavine ----- | 9330*(9-2007) |
| (xvi) Oxycodone ----- | 9143* |
| (xvii) Oxymorphone ----- | 9652* |
| (xviii) Thebaine ----- | 9333* |
| (xix) Tapentadol ----- | 9780-(5-2009) |
| (xx) Noroxymorphone ----- | 9668-(4-2021) |
- (2) Any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (b) (1) of this section, except that these substances shall not include the isoquinoline alkaloids of opium.*
- (3) Opium poppy and poppy straw.*
- (4) Coca leaves (9040) and any salt, compound, derivative, or preparation of coca leaves, (including cocaine (9041) and ecgonine (9180) and their salts, isomers, derivatives and salts of isomers and derivatives), and any salt, compound,

derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, except that the substances shall not include: ----- *

(i) Decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine ; ----- *

(ii) [¹²³I]ioflupane; or

(iii) [¹⁸F]FP-CIT.

(5) Concentrate or poppy straw (the crude extract of poppy straw in either liquid, solid or powder form which contains the phenanthrene alkaloids of the opium poppy), ----- 9670.*

(c) **Opiates: (Narcotic Drugs)** Unless specifically excepted or unless in another schedule, any of the following opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designations:

(1) Alfentanil ----- 9737-(2-1987)

(2) Alphaprodine ----- 9010*

(3) Anileridine ----- 9020*

(4) Bezitramide ----- 9800*

(5) Bulk Dextropropoxyphene (non-dosage forms) ----- 9273-(9-1981)

(6) Carfentanil ----- 9743-(9-1988)

(7) Dihydrocodeine ----- 9120*

(8) Diphenoxylate ----- 9170*

(9) Fentanyl ----- 9801*

(10) Isomethadone ----- 9226*

(11) Levo-alphaacetylmethadol (LAAM) ----- 9648-(12-1993)

(12) Levomethorphan ----- 9210*

(13) Levorphanol ----- 9220*

(14) Metazocine ----- 9240*

(15) Methadone ----- 9250*

(16) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane ----- 9254*

(17) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid ----- 9802*

(18) Pethidine (Meperidine) ----- 9230*

(19) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine ----- 9232*

(20) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate ----- 9233*

(21)	Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid -----	9234*
(22)	Phenazocine -----	9715*
(23)	Piminodine -----	9730*
(24)	Racemethorphan -----	9732*
(25)	Racemorphan -----	9733*
(26)	Remifentanil -----	9739-(11-1996)
(27)	Sufentanil -----	9740-(9-1981)
(28)	Thiafentanil -----	9729-(4-2021)
(29)	Oliceridine -----	9245-(5-2022)
(30)	Tianeptine -----	(5-2022)

(d) **Stimulants:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system:

(1)	Amphetamine, its salts, optical isomers, and salts of its optical isomers -----	1100*
(2)	Methamphetamine, its salts, isomers, and salts of its isomers -----	1105*
(3)	Lisdexamfetamine -----	1205*(7-2007)
(4)	Phenmetrazine and its salts -----	1631*
(5)	Methylphenidate -----	1724*

(e) **Depressants:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1)	Amobarbital -----	2125*
(2)	Glutethimide -----	2550-(2-1991)
(3)	Pentobarbital -----	2270*
(4)	Phencyclidine -----	7471*
(5)	Secobarbital -----	2315*

(f) **Hallucinogenic Substances:**

(1)	Nabilone -----	7379-(11-1987)
-----	----------------	----------------

[Other name(s) for nabilone: (\pm)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one].

(2) Dronabinol in an oral solution in a drug product approved for marketing by the U.S. Food and Drug Administration; [(-)-delta-9-trans-tetrahydrocannabinol(delta-9-THC)].-----7365-(7-2019)

(g) **Immediate Precursor:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances:

(1) Immediate precursor to Amphetamine and Methamphetamine:

(i) Phenylacetone ----- 8501-(3-1980)
Some trade or other names: phenyl-2-propanone; P2P; benzyl methyl Ketone; methyl benzyl Ketone.

(2) Immediate precursor to Phencyclidine (PCP):

(i) 1-phenylcyclohexylamine ----- 7460*
(ii) 1-piperidinocyclohexanecarbonitrile (PCC) ----- 8603*

(3) Immediate precursor to Fentanyl:

(i) 4-anilino-N-phenethylpiperidine (ANPP) ----- 8333*(8-2010)
(ii) N-phenyl-N-(piperidin-4-yl)propionamide (norfentanyl) ----- 8366-(4-2021)

SCHEDULE III

(a) Schedule III shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.

(b) **Stimulants:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under Section 308.32, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances ----- 1405*

(2) Benzphetamine ----- 1228*

(3) Chlorphentermine ----- 1645*

(4) Clortermine ----- 1647*

(5) Phendimetrazine ----- 1615*

(c) **Depressants:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:

(1) Any compound, mixture, or preparation containing:

- | | | |
|-------|---------------------|---------------|
| (i) | Amobarbital ----- | 2126* |
| (ii) | Secobarbital ----- | 2316* |
| (iii) | Pentobarbital ----- | 2271* |
| (iv) | Embutramide ----- | 2020*(9-2006) |

or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule.

(2) Any suppository dosage form containing:

- | | | |
|-------|---------------------|-------|
| (i) | Amobarbital ----- | 2126* |
| (ii) | Secobarbital ----- | 2316* |
| (iii) | Pentobarbital ----- | 2271* |

or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository.

(3) Any substance which contains any quantity of a derivative of barbituric acid or any salt thereof ----- 2100*

(4) Chlorhexadol ----- 2510*

(5) Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the Federal Food, Drug, and Cosmetic Act----- 2012-(2-2001)

(6) Ketamine, its salts, isomers, and salts of isomers ----- 7285-(7-1999)

Some other names for Ketamine: (+)-2-(2-Chlorophenyl)-2-(Methylamino)-Cyclohexanone.

(7) Lysergic acid ----- 7300*

(8) Lysergic acid amide ----- 7310*

(9) Methyprylon ----- 2575*

(10) Sulfondiethylmethane -----2600*

(11) Sulfonethylmethane ----- 2605*

(12) Sulfonmethane ----- 2610*

(13) Tiletamine and zolazepam or any salt thereof ----- 7295-(3-1988)

Some trade or other name for a tiletamine- zolazepam combination product: Telazol.

Some trade or other names for tiletamine: -2(ethylamino)-2-(2-thienyl)-cyclohexanone.

Some trade or other names for zolazepam: -4(2-fluorophenyl)-6,8-dihydro-1,3,8,-trimethylpyrazolo-[3,4-e] [1,4,-]diazepin-7(1-H)-one. flupyrzapon.

(14) Perampanel ----- 2261-(11-2013)

(d) Nalorphine ----- 9400*

(e) **Narcotic drugs:** Unless specifically excepted or unless listed in another schedule:

(1) Any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

(i) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium ----- 9803*

(ii) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts ----- 9804*

(iii) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts ----- 9807*

(iv) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts ----- 9808*

(v) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts ----- 9809*

(vi) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts ----- 9810*

(2) Any material, compound, mixture, or preparation containing any of the following narcotic drugs or their salts, as set forth below:

(i) Buprenorphine ----- 9064-(6-1985)
(10-02 Transfer)

(ii) Reserved

(f) **Anabolic Steroids:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts of isomers is possible within the specific chemical designation: ----- 4000

- (1) Boldenone; -----(9-1991)
- (2) Boldione; -----(1-2010)
- (3) Chlorotestosterone (4-chlortestosterone); -----(9-1991)
- (4) Clostebol; -----(9-1991)
- (5) Dehydrochlormethyltestosterone; -----(9-1991)
- (6) Desoxymethyltestosterone----- (1-2010)
- (7) Dihydrotestosterone (4-dihydrotestosterone); -----(9-1991)
- (8) Drostanolone; -----(9-1991)
- (9) Ethylestrenol; -----(9-1991)
- (10) Fluoxymesterone; -----(9-1991)
- (11) Formebolone (formebolone); -----(9-1991)
- (12) Mesterolone; -----(9-1991)
- (13) Methandienone, also known as Methandrostenolone; -----(9-1991)
- (14) Methandranone; -----(9-1991)
- (15) Methandriol; -----(9-1991)
- (16) Methenolone; -----(9-1991)
- (17) Methyltestosterone; -----(9-1991)
- (18) Mibolerone; -----(9-1991)
- (19) Nandrolone; -----(9-1991)
- (20) 19-Nor-4,9(10)-Androstadienedione ----- (1-2010)
- (21) Norethandrolone; -----(9-1991)
- (22) Oxandrolone; -----(9-1991)
- (23) Oxymesterone; -----(9-1991)
- (24) Oxymetholone; -----(9-1991)
- (25) Stanolone; -----(9-1991)
- (26) Stanozolol; -----(9-1991)
- (27) Testolactone; -----(9-1991)
- (28) Testosterone; -----(9-1991)
- (29) Trenbolone -----(9-1991)
- (30) Prostanazol -----(8-2012)
- (31) Methasterone -----(8-2012);

and

(32) Any salt, ester, or isomer of a drug or substance described or list in this paragraph, if that salt, ester, or isomer promotes muscle growth. -----(9-1991)

(g) Exempt anabolic steroid products: Compounds, mixtures, or preparations that contain an anabolic steroid that have been exempted by the Secretary:

NDC Number	
(1) Andro-Estro 90-4 -----	0536-1605
(2) Androgyn L.A -----	0456-1005
(3) Component E-H in Process Pellets -----	Ivy Labs Inc.
(4) Component E-H in Process Granulation -----	Ivy Labs Inc
(5) Component TE-S in process Granulation -----	Ivy Labs Inc
(6) Component TE-S in process Pellets -----	Ivy Labs Inc
(7) depANDROGYN -----	0456-1020
(8) Depo-Testadiol -----	0009-0253
(9) DEPO-T.E -----	52765-257
(10) depTESTROGEN -----	51698-257
(11) Duomone -----	52047-360
(12) DUO-SPAN II -----	0684-0102
(13) DURATESTTRIN -----	43797-016
(14) Essian -----	Pharmaceutics
(15) Essian H.S -----	Pharmaceutics
(16) Esterified Estrogens & Methyltestosterone, USP (0.625 mg/1.25mg) -----	Interpharm
(17) Esterified Estrogens & Methyltestosterone, USP (1.25mg/2.5mg) -----	Interpharm
(18) Esterified Estrogens & Methyltestosterone (0.625mg/1.25mg) Tablet -----	ANDAPharm
(19) Esterified Estrogens & Methyltestosterone (1.25mg/2.5mg) Tablet -----	ANDAPharm
(20) Estratest -----	0032-1026
(21) Estratest HS -----	0032-1023
(22) Menogen -----	59243-570
(23) Menogen HS -----	59243-560
(24) Methyltestosterone & Esterified Estrogens (2.5mg/1.25Mg) -----	Lannett Co
(25) Methyltestosterone & Esterified Estrogens (Half Strength) (1.25mg/0.625mg) -----	Lannett Co
(26) PAN ESTRA TEST -----	0525-0175
(27) Premarin with Methyltestosterone -----	0046-0879
(28) Premarin with Methyltestosterone -----	0046-0878

(29)	Syntest D.S -----	66576-231
(30)	Stntest H.S-----	66576-230
(31)	Synovex H in process bulk pellets -----	Syntex Animal
(32)	Synovex H in process granulation -----	Syntex Animal
(33)	Synovex Plus in process granulation -----	Fort Dodge
(34)	Synovex Plus in process bulk pellets -----	Fort Dodge
(35)	TEST-ESTRO Cypionates -----	0536-9470
(36)	Testoderm with Adhesive 4mg/d-----	Alza Corp
(37)	Testoderm 4mg/d-----	17314-4608
(38)	Testoderm 6mg/d-----	17314-4609
(39)	Testoderm with Adhesive 6mg/d-----	17314-2836
(40)	Testoderm in process film-----	Alza Corp
(41)	Testoderm with Adhesive in process film -----	Alza Corp
(42)	Testosterone Cypionate/Estradiol Cypionate injection -----	54274-530
(43)	Testosterone Cypionate/Estradiol Cypionate injection -----	0182-3069
(44)	Testosterone Cyp 50 Estradiol Cyp 2 -----	0814-7737
(45)	Testosterone Cypionate/Estradiol Cypionate injection -----	0364-6611
(46)	Testosterone Cypionate/Estradiol Cypionate injection -----	0402-0257
(47)	Testosterone Enanthate/Estradiol Valerate injection -----	0182-3073
(48)	Testosterone Enanthate/Estradiol Valerate injection -----	0364-6618
(49)	Testosterone Enanthate/Estradiol Valerate injection -----	0402-0360
(50)	Testosterone Ophthalmic Solution-----	Allergan
(51)	Tilapia Sex Reversal Feed (investigational -----	Ranger, Inc

(h) Veterinary Anabolic Steroid Implant Products: Anabolic steroid products expressly intended for administration through implants in cattle or other nonhuman species exempted by the Secretary.

NDC/DIN

(1)	Component E-H -----	021641-002
(2)	Component E-H -----	01968327
(3)	Component TE-S -----	021641-004
(4)	Component T-H -----	0211641-006
(5)	Component T-S -----	0211641-005
(6)	F-TO -----	00093351

(7) Finaplix-H -----	12799-807-10
(8) Finaplix-S -----	12799-807-07
(9) Heifer-old -----	Boehringer
(10) Heifer-old -----	Ingelheim
(11) Heifer-old -----	Ivy Lab.
(12) Implus-H -----	0009-0434-01
(13) Implus-H -----	06-0434-01
01968327	
(14) Masculinizing Feed for Fish (Investigational) -----	Rangen, Inc.
(15) Revalor-G -----	12799-811
(16) Revalor-H -----	12799-810
(17) Revalor-S -----	12799-809
(18) Synovex H -----	0856-3901
(19) Synovex H -----	Syntex
(20) Synovex Plus -----	0856-3904
(21) Tilapia Sex Reversal Feed (investigational) -----	Zeigler Bros.

If veterinary products that are granted exempted status are subsequently distributed with the intent that they be used in humans, the distribution would be subject to the criminal sanctions of the CSA despite the drugs' exempted status.

(i) **Hallucinogenic substances:**

- (1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration approved drug product ----- 7369-(11-1987)
- [Some other names for dronabinol: (6a R-trans)-6a,7,8, 10a-tetrahydro-6, 6, 9-trimethyl-3-pentyl-6H-dibenzo [b,d] pyran-1-ol, or (-)-delta 9-(trans)-tetrahydrocannabinol]

SCHEDULE IV

- (a) Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.
- (b) **Narcotic drugs:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

- (1) Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit----- 9167*
- (2) Dextro propoxyphene (alpha-(+)-4-dimethylamino- 1,2-diphenyl-3-methyl-2-propionoxybutane) ----- 9278-(11-1987)

(c) **Depressants:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

- (1) Alprazolam ----- 2882-(6-1982)
- (2) Barbital ----- 2145*
- (3) Bromazepam ----- 2748-(1-1985)
- (4) Camazepam ----- 2749-(1-1985)
- (5) Chloral betaine ----- 2460*
- (6) Chloral hydrate ----- 2465*
- (7) Chlordiazepoxide ----- 2744*
- (8) Clobazam ----- 2751-(1-1985)
- (9) Clonazepam ----- 2737*
- (10) Clorazepate ----- 2768*
- (11) Clotiazepam ----- 2752-(1-1985)
- (12) Cloxazolam ----- 2753-(1-1985)
- (13) Delorazepam ----- 2754-(1-1985)
- (14) Diazepam ----- 2765*
- (15) Dichloralphenazone ----- 2467-(10-2002)
- (16) Estazolam ----- 2756-(1-1985)
- (17) Ethchlorvynol ----- 2540*
- (18) Ethinamate ----- 2545*
- (19) Ethyl loflazepate ----- 2758-(1-1985)
- (20) Fludiazepam ----- 2759-(1-1985)
- (21) Flunitrazepam ----- 2763-(1-1985)
- (22) Flurazepam ----- 2767*
- (23) Fospropofol----- 2138-(11-2009)
- (24) Halazepam ----- 2762-(6-1982)
- (25) Haloxazolam ----- 2771-(1-1985)

(26)	Ketazolam	2772-(1-1985)
(27)	Loprazolam	2773-(1-1985)
(28)	Lorazepam	2885*
(29)	Lormetazepam	2774-(1-1985)
(30)	Mebutamate	2800*
(31)	Medazepam	2836-(1-1985)
(32)	Meprobamate	2820*
(33)	Methohexital	2264*
(34)	Methylphenobarbital (mephobarbital)	2250*
(35)	Midazolam	2884-(1-1985)
(36)	Nimetazepam	2837-(1-1985)
(37)	Nitrazepam	2834-(1-1985)
(38)	Nordiazepam	2838-(1-1985)
(39)	Oxazepam	2835*
(40)	Oxazolam	2839*
(41)	Paraldehyde	2585*
(42)	Petrichloral	2591*
(43)	Phenobarbital	2285*
(44)	Pinazepam	2883-(1-1985)
(45)	Prazepam	2764*
(46)	Quazepam	2881-(11-1986)
(47)	Temazepam	2925-(9-1981)
(48)	Tetrazepam	2886-(1-1985)
(49)	Triazolam	2887-(7-1983)
(50)	Zaleplon	2781-(9-1999)
(51)	Zolpidem	2783-(12-1993)
(52)	Zopiclone	2784-(1-2006)
(53)	Alfaxalone	2731-(2-2014)
(54)	Carisoprodol	8192-(4-1997)
(55)	Tramadol	9752-(8-2007)
(56)	Suvorexant	2223-(8-2014)
(57)	Brexanolone	2400-(4-2021)
(58)	Lemborexant	2245-(4-2021)

- (59) Remimazolam ----- 2846-(5-2022)
 (60) Daridorexant ----- 2410

(d) **Stimulants:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

- (1) Cathine ((+)-Norpseudoephedrine----- 1230-(3-1988)
 (2) Diethylpropion ----- 1610*
 (3) Fencamfamin ----- 1760-(3-1988)
 (4) Fenproporex ----- 1575-(3-1988)
 (5) Lorcaserin ----- 1625-(6-2013)
 (6) Mazindol ----- 1605-(6-1982)
 (7) Mefenorex ----- 1580-(3-1988)
 (8) Modafinil----- 1680-(1-1999)
 (9) Pemoline (including organometallic complexes and chelates thereof) ----- 1530*
 (10) Phentermine ----- 1640*
 (11) Pipradrol ----- 1750-(9-1981)
 (12) Serdexmethylphenidate ----- 1729
 (13) Sibutramine ----- 1675-(2-1998)
 (14) Solriamfetol ----- 1650-(4-2021)
 (15) SPA ((-)-1-dimethylamino-1,2-diphenylethane) ----- 1635-(9-1981)

(e) **Other substances:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts; isomers whether optical, position, or geometric), and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:

- (1) Pentazocine ----- 9709-(4-1979)
 (2) Butorphanol ----- 9720-(4-1997)
 (3) Nalbuphine ----- (4-1997)
 (4) Eluxadoline ----- 9725-(4-2017)

SCHEDULE V

(a) Schedule V shall consist of the drugs and other substances by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section.

- (b) **Narcotic Drugs:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs and their salts, as set forth below.

Reserved

- (c) **Narcotic drugs containing nonnarcotic active medicinal ingredients.** Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs or salts thereof, which shall include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:
- (1) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams. ----- *
 - (2) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams. ----- *
 - (3) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams. ----- *
 - (4) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit. ----- *
 - (5) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams. ----- *
 - (6) Not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit. ----- *
- (d) **Stimulants:** unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having stimulant effect on the central nervous system, including its salts, isomers and salts of isomers:
- (1) Pyrovalerone ----- 1485-(3-1988)
 - (2) Ephedrine: a -{-(Methylamino)ethyl}benzene-methanol; ----- (10-1995)
a-{-(methylamino) ethyl}benzyl alcohol; 2-methylamino-1-phenyl-1-propanol;
1-phenyl-1-hydroxy-2-methylaminopropane; 1-phenyl-2-methylaminopropanol; a - hydroxy-b-methylaminopropylbenzene; a product which occurs in the Chinese herb Ma Huang (*Ephedra vulgaris*, *Ephedra sinica* Stapf., *Ephedra equisetina* Bunge, Gnetaceae) in several other *Ephedra* spp.
 - (3) Phenylpropanolamine ----- (7-2005)
 - (4) Pseudoephedrine ----- (7-2005)

Pursuant to Ark. Code Ann. § 5-64-212 as amended in 2005, this Schedule V classification shall NOT apply to any ephedrine, phenylpropanolamine, or pseudoephedrine in liquid, liquid capsule, or liquid gel capsule form. However, sales limits mandated by statute shall apply to all products with ephedrine, phenylpropanolamine, or pseudoephedrine as a listed ingredient regardless of the dosage form.

(e) **Depressants:** Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers:

- (1) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid ----- 2782-(1-2006)
- (2) Lacosamide ----- 2746-(5-2009)
- (3) Brivaracetam ----- 2710-(4-2017)
- (4) Lasmiditan ----- 2790-(4-2021)
- (5) Cenobamate ----- 2720-(4-2021)
- (6) Ganaxolone ----- 2401

(f) **Other substances:**

- (1) None.

SCHEDULE VI ****

(a) In addition to any substance placed in Schedule VI by the Secretary of the Department of Health under § 5-64-214, any material, compound, mixture, or preparation, whether produced directly or indirectly from a substance of vegetable origin or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, that contains any quantity of the following substances, or that contains any of their salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation, is included in Schedule VI:

- (1) Marijuana ----- **
- (2) Tetrahydrocannabinols, unless the tetrahydrocannabinol is: ----- **
 - (i) Contained in hemp-derived cannabidiol; ----- (6-2020)
 - (ii) Not more than three-tenths of one percent (0.3%) of delta-9 tetrahydrocannabinol in the hemp-derived cannabidiol on a dry weight basis as verified by a nationally accredited laboratory for quality, purity and accuracy standards; and----- (6-2020) ***
 - (iii) Not approved by the United States Food and Drug Administration for marketing as a medication; ----- (6-2020)
- (3) A synthetic equivalent of:
 - (i) The substance contained in the Cannabis plant; or----- **
 - (ii) The substance contained in the resinous extractives of the genus Cannabis; ----- **
- (4) Salvia divinorum or Salvinorin A, which includes all parts of the plant presently classified botanically as Salvia divinorum, whether growing or not, the seeds of the plant, any extract from any part of the plant, and every compound, manufacture, derivative, mixture, or preparation of the plant, its seeds, or its

extracts, including salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation; ----- **

- (5) Synthetic substances, derivatives, or their isomers in the chemical structural classes described below in subdivisions (a)(5)(i)-(a)(5)(x) of this section and also specific unclassified substances in subdivision (a)(5)(xi) of this section. Compounds of the structures described in this subdivision (a)(5), regardless of numerical designation of atomic positions, are included in this subdivision (a)(5). The synthetic substances, derivatives, or their isomers included in this subdivision (a)(5) are:

(i) Tetrahydrocannabinols:

(A) Tetrahydrocannabinols, including without limitation the following: ----- **

- a) Delta-1 cis or trans tetrahydrocannabinol [other name(s): Delta-9 cis or trans tetrahydrocannabinol], and its optical isomers; ----- **
- b) Delta-6 cis or trans tetrahydrocannabinol [other name(s): Delta-8 cis or trans tetrahydrocannabinol], and its optical isomers; ----- **
- c) Delta- 3,4 cis or trans tetrahydrocannabinol [other name(s): Delta-6a,10a cis or trans tetrahydrocannabinol], and its optical isomers ; ----- **
- d) Delta-10 cis or trans tetrahydrocannabinol, and its optical isomers ;----- ***
- e) Delta-8 tetrahydrocannabinol acetate ester; ----- ***
- f) Delta-9 tetrahydrocannabinol acetate ester; ----- ***
- g) Delta-6a,10a, tetrahydrocannabinol acetate ester;----- ***
- h) Delta-10 tetrahydrocannabinol acetate ester; and,----- ***
- i) A product derived from industrial hemp that was produced as a result of a synthetic chemical process that converted the industrial hemp or a substance contained in industrial hemp into Delta-8, Delta-9, Delta 6a,10a, or Delta-10 tetrahydrocannabinol including their respective acetate esters. ----- ***

(B) Dronabinol in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the United States Food and Drug Administration is not a tetrahydrocannabinol under this subdivision (a)(5)(i); ----- **

- (ii) Naphthoylindoles, or any compound structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation the following: ----- **

(A) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole; ----- **

- (B) JWH-015, or 1-Propyl-2-methyl-3-(1-naphthoyl)indole; ----- **
- (C) JWH-018, or 1-Propyl-3-(1-naphthoyl)indole; -----
- (D) JWH-019, or 1-Hexyl-3-(1-naphthoyl)indole; ----- **
- (E) JWH-073, or 1-Butyl-3-(1-naphthoyl)indole; ----- **
- (F) JWH-081, or 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole; ----- **
- (G) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole; ----- **
- (H) JWH-122, or 1-Pentyl-3-(4-methyl-1-naphthoyl)indole; ----- **
- (I) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole; ----- **
- (J) JWH-200, or 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl) indole; ----- **
- (K) JWH-210, or 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole; ----- **
- (L) JWH-398, or 1-Pentyl-3-(4-chloro-1-naphthoyl)indole; ----- **
- (M) AM-2201, or 1-(5-fluoropentyl)-3-(1-naphthoyl)indole; ----- **
- (N) MAM2201, or (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone; ----- **
- (O) EAM2201, or (1-(5-fluoropentyl)-1H-indol-3-yl)(4-ethyl-1-naphthalenyl)-methanone; and ----- **
- (P) THJ-2201, or [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone; ----- 7024-(7-2019)
- (iii) Naphthylmethylindoles, or any compound structurally derived from an H-indol-3-yl-(1-naphthyl) methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation the following: ----- **
- (A) JWH-175, or 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane; and----- **
- (B) JWH-184, or 1-Pentyl-1H-3-yl-(4-methyl-1-naphthyl)methane; ----- **
- (iv) Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; ----- **
- (v) Naphthylmethylindenes, or any compound structurally derived from 1-(1-naphthylmethyl)indene with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-

- methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-176, or E-1-[1-(1-Naphthalenylmethylene)-1H-inden-3-yl]pentane; ----- **
- (vi) Phenylacetylindoles, or any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including without limitation the following: ----- **
- (A) JWH-201, or 2-(4-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone; ----- **
- (B) JWH-203, or 1-Pentyl-3-(2-chlorophenylacetyl)indole; ----- **
- (C) JWH-250, or 1-Pentyl-3-(2-methoxyphenylacetyl)indole; ----- **
- (D) JWH-251, or 1-Pentyl-3-(2-methylphenylacetyl)indole; and ----- **
- (E) RCS-8, or 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole; ----- **
- (vii) Cyclohexylphenols, or any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent, including without limitation the following: ----- **
- (A) CP 47,497 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol; ----- **
- (B) Cannabicyclohexanol or CP 47,497 C8 homologue, or 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol; and ----- **
- (C) CP 55,940, or 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol; ----- **
- (viii) Benzoylindoles, or any compound structurally derived from a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including without limitation the following: ----- **
- (A) AM-694, or 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole; ----- **
- (B) RCS-4, or 1-Pentyl-3-(4-methoxybenzoyl)indole; ----- **
- (C) WIN-48,098 or Pravadoline, or (4-Methoxyphenyl)-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone; ----- **

- (D) AM-2233, or 1-[(N-methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole; and ----- **
- (E) RCS-4 (C4 homologue) or (4-methoxyphenyl)(1-butyl-1H-indol-3-yl)-methanone; ----- **
- (ix) Adamantoylindoles, or Adamantoylindazoles, including Adamantyl Carboxamide Indoles and Adamantyl Carboxamide Indazoles, or any compound structurally derived from 3-(1-adamantoyl) indole, 3-(1-adamantoyl) indazole, or 3-(2-adamantoyl)indole by substitution at a nitrogen atom of the indole or indazole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole or indazole ring to any extent and whether or not substituted in the adamantyl ring to any extent, including without limitation the following: ----- **
- (A) AM-1248, or 1-adamantyl-[1-[(1-methylpiperidin-2-yl)methyl]indol-3-yl]methanone; ----- **
- (B) AB-001, or 1-adamantyl-(1-pentylindol-3-yl)methanone; ----- **
- (C) JWH-018 adamantyl carboxamide, or 1-pentyl-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1H-indole-3-carboxamide [other name(s): 2NE1, moved in Schedule VI in 2020] ----- **
- (D) AKB-48, or N-(1-adamantyl)-pentyl-1H-indazole-3-carboxamide; ----- **
- (E) 5F-AKB-48, or N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide ----- 7049**
- (F) STS-135, or N-(1-adamantyl)-1-(5-fluoropentyl)indole-3-carboxamide; ----- **
- (x) Tetramethylcyclopropylcarbonylindoles or any compound structurally derived from 3-(2,2,3,3-tetramethylcyclopropylcarbonyl) indole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent, including without limitation the following: ----- **
- (A) UR-144, or (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone; ----- **
- (B) XLR-11, or [1-(5-fluoropentyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone; ----- **
- (C) A-796,260, or [1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone; ----- **
- (D) 5-Chloro-UR-144, or [-(5-chloropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone; ----- **

- (E) 5-Bromo-UR-144, or [1-(5-bromopentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone; and ----- **
- (F) A-834,735, or 1-(tetrahydropyran-4-ylmethyl)-1H-indol-3-yl-(2,2,3,3-tetramethylcyclopropyl)methanone; ----- **
- (xi) Unclassified Synthetic Cannabinoids, including without limitation the following: ----- **
- (A) CP 50556-1 hydrochloride, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] Acetate; ----- **
- (B) HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; ----- **
- (C) HU-211, or Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; ----- **
- (D) Dimethylheptylpyran or DMHP; ----- **
- (E) WIN55,212-2, or 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl-1-naphthalenylmethanone; ----- **
- (F) URB597, or [3-(3-carbamoylphenyl)phenyl] N-Cyclohexylcarbamate; ----- **
- (G) URB754, or 6-methyl-2-[(4-methylphenyl)amino]-1-benzoxazin-4-one; ----- **
- (H) CB-13, or 1-naphthalenyl[4-(pentyloxy)-1 naphthalenyl]-methanone; ----- **
- a) URB602, or cyclohexyl N-(3-phenylphenyl)carbamate; ----- **
- (I) PB-22, or quinolin-8-yl 1-(5-pentyl)-1H-indole-3-carboxylate; ----- **
- (J) 5F-PB-22, or quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate; ----- **
- (K) BB-22, or quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate; ----- **
- (L) NNEI (MN-24), or N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide; ----- **
- (M) 5F-NNEI, or 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-carboxamide; ----- **
- (N) 5-Fluoro-AMB, or n-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine methyl ester ----- 7033-(9-2018)
- (O) MMB-CHMICA, or methyl-(1-cyclohexylmethyl)-1H-indole-3-carbonyl)-L-valinate ----- 7044-(9-2018)
- (P) 5-Fluoro-ADB, or methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate; ----- 7034-(11-2018)
- (Q) 5-Fluoro-MDMB-PICA, or methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate ----- 7041-(11-2018)

- (R) MDMB-CHMICA, or methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate; ----- 7042-(11-2018)
- (S) FUB-AMB, or methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate; ----- 7021-(11-2018)
- (T) MDMB-FUBINACA, or methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate; ----- 7020-(11-2018)
- (U) AB-PINACA, or N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide; -----7023-(7-2019)
- (V) AB-CHMINACA, or N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide; -----7031-(7-2019)
- (W) MAB-CHMINACA, or N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide;- ----- (11-2014)
- (X) AB-FUBINACA, or N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide;- -----(9-2018)
- (Y) ADB-PINACA, or N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide;----- (9-2018)
- (Z) 5F-CUMYL-PINACA, or 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide -----7083-(6-2020)
- (AA) ADB-FUBINACA, or N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide ----- 7010-(4-2021)
- (BB) 4-Fluoro-MDMB-BUTINACA, or methyl(S)-2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate; ----- 7043-(4-2021)
- (CC) 5F-AB-PINACA, or N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide----- 7025-(5-2022)
- (DD) 4-CN-CUMYL-BUTINACA, or 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide ----- 7089 -(5-2022)
- (EE) 5F-CUMYL-P7AICA, or 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide ----- 7085-(5-2022)
- (FF) NM2201, or Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate----- 7221-(5-2022)
- (GG) 5F-EDMB-PINACA, or Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate ----- 7036
- (HH) FUB-144, or (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl) methanone; ----- 7014
- (II) FUB-AKB48, or N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide; ----- 7047
- (JJ)MDMB-4en-PINACA, or Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate;

(KK) CH-PIATA, or N-cyclohexyl-2-(1-pentylindol-3-yl)acetamide.

(6) A synthetic substance, derivative, or its isomers with:

- (i) Similar chemical structure to any substance described in subdivisions (a)(1)-(a)(5) of this section; or ----- **
- (ii) Similar pharmacological effects to any substance described in subdivisions (a)(1)-(a)(5) of this section. ----- **

(b) However, except as provided under subsection (c) of this section, the Secretary shall not delete a controlled substance listed in this section from Schedule VI.

(c) A prescription drug approved by the United States Food and Drug Administration under 21 U.S.C. § 355 is excluded from Schedule VI unless the secretary objects under § 5-64-201.

*-Scheduled before April, 1979.

** -Schedule VI is revised to conform to Act 329 of 2013.

*** - Schedule VI is revised further to conform to Act 629 of 2023. Each substance added to the Controlled Substances List pursuant to Act 629 of 2023 shall have the following effective dates:

(a) For persons who are under twenty-one (21) years of age, the effective date shall be the effective date of Act 629 of 2023; and,

(b) For persons who are twenty-one (21) years of age or older, the effective date shall be August 1, 2023.

**** Pursuant to ongoing litigation, and a preliminary injunction against enforcing Act 629 of 2023, the changes made to the List of Controlled Substances pursuant to Act 629 of 2023 are not enforceable until a final order issued in the matter, Bio Gen, LLC, et al. v. Sarah Huckabee Sanders, et al., Case No. 4:23-CV-00718-BRW, Central Division, Eastern District of Arkansas, United States District Court.



Arkansas Department of Health

4815 West Markham Street • Little Rock, Arkansas 72205-3867 • Telephone (501) 661-2000

Governor Sarah Huckabee Sanders

Renee Mallory, RN, BSN, Secretary of Health

Jennifer Dillaha, MD, Director

PUBLIC COMMENT REPORT

Proposed Rules Pertaining to the List of Controlled Substances in Arkansas

PUBLIC COMMENTS:

Public comment period expired January 29, 2024. A public hearing was held at the Department of Health, 4815 W. Markham St., Little Rock, Arkansas on January 22, 2024. A notice of the public comment period and the public hearing was posted in newspaper on December 22, 2023, December 23, 2023, and December 24, 2023. In addition, a second notice was also posted in the newspaper on December 30, 2023, December 31, 2023, and January 1, 2024, extending the public comment period to January 29, 2024.

The Department received approximately fourteen comments, written and verbal, during the public comment period. All of the noted comments received indicated concerns and conveyed information regarding the scheduling of xylazine, specifically concerns recommending an exemption for veterinary use. (Comments received are attached.)

AGENCY RESPONSE:

Upon review and consideration of the concerns raised by members of the public and industry professionals the Department is withdrawing its proposed scheduling of xylazine and will proceed with the remaining proposed amendments to the List of Controlled Substances.

The Department will further review the potential scheduling of xylazine, to include any input or recommendations from the Drug Enforcement Administration or other experts, as well as potential exemption for legitimate veterinary use before the next proposed amendments to the List are presented.

Shane David

From: Shane David
Sent: Wednesday, January 10, 2024 1:15 PM
To: Kate Williams
Cc: Laura Shue (ADH); S.Craig Smith; Charles Thompson (ADH)
Subject: RE: Xylazine

Good afternoon Dr. Williams,

I have received your public comment. It will be included in our public comment report that will be available on our website after conclusion of the public comment period, along with the Department's response.

Thanks,

Shane

From: Kate Williams <katewilliamsdvm@gmail.com>
Sent: Tuesday, January 9, 2024 5:19 PM
To: Shane David <Shane.david@arkansas.gov>
Subject: Re: Xylazine

You don't often get email from katewilliamsdvm@gmail.com. [Learn why this is important](#)

Shane,

Please see attached background information pertaining to xylazine.

I recommend that the Arkansas Dept of Health Pharmacy shadow the language in the Support Act to keep xylazine in the hands of veterinarians as federal law allows and to not schedule on the state level this very important veterinary use drug as a CS Schedule III.

Veterinarians are not the source of the illegal use of xylazine, illegal raw ingredients (powdered raw xylazine) in the hands of drug cartels when mixed with fentanyl, etc are the source of the illegal drug. Why make it more difficult for veterinarians to procure, store or use a "veterinary use only" FDA approved drug within their daily practices. Additionally, since xylazine is a veterinary use drug, the CS scheduling could entice legitimate manufacture of xylazine for sale to veterinarians to stop due to overwhelming government oversight. There is no other drug to replace xylazine in the veterinary market. Since surrounding states (OK) have currently exempt xylazine from scheduling for veterinarians, (I think LA and TN are working on legislation as well), I recommend the state of AR mirror the Support Act language to keep xylazine off the CS list and within the hands of the veterinarians.

Once again, I appreciate your attention in this matter and I am available as needed to answer questions regarding the Xylazine scheduling and concerns within the veterinary community.

Kate Williams, DVM
(479) 633-1317

On Tue, Jan 9, 2024 at 1:10 PM Kate Williams <katewilliamsdvm@gmail.com> wrote:

Shane,

I am reaching out to you regarding the Arkansas Department of Health, Pharmacy Services issuance of a meeting notice on 1/23/2024 regarding xylazine. Xylazine is a very important drug for use in veterinary medicine used for sedation, anesthesia and analgesia in animals such as horses, cattle and other animals. Can you assist me with understanding of the Ar Department of Health's proposed plan to schedule Xylazine as CS III in the state of Arkansas? I am a member of the Arkansas Veterinary Medical Association and serve on the American Veterinary Medical Association, House of Delegates representing Arkansas. After participating in proposed legislation of xylazine on the federal level, I would like to understand the proposal for the upcoming meeting since any action/recommendation will impact the veterinarians in the state of Arkansas.

Please feel free to call me at (479) 633-1317 or via email, katewilliamsdvm@gmail.com. I appreciate your time and look forward to hearing from you.

Kate Williams, DVM, MS

Medical Director/Veterinarian
St Francis Animal Hospital
121 Virginia St
Springdale, AR 72764
cell: 479-633-1317
katewilliamsdvm@gmail.com
sfahdvm@gmail.com

Xylazine: an essential animal sedative used across veterinary medicine



Veterinary access to legitimate xylazine must be preserved while combating the emerging public health threat of illicit xylazine

KEY POINTS:

- Xylazine is an essential drug for the safe handling of many species, particularly cattle, given there is no practical alternative for sedation in cattle.
- Any legislative or regulatory interventions to combat illicit xylazine need to safeguard the availability of veterinary prescription xylazine and its responsible use by veterinarians and our clients.
- Scheduling of xylazine without a provision for its unique uses in veterinary medicine will severely disrupt or eliminate the legitimate supply and prohibit critical uses of the drug.
- The AVMA supports public health efforts and policy intended to combat illicit xylazine.

What is the issue?

- Illicit xylazine is being mixed with illicit fentanyl. This potent drug combination poses grave health and safety risks for humans.
- As policy is crafted to help stop the illicit supply, we are concerned that new enforcement tools could severely impact the legal and responsible access and use of xylazine by veterinarians and our clients.
- Limiting veterinary access to xylazine will jeopardize animal welfare and human safety.

Why is xylazine so important in veterinary medicine?

- Xylazine is a prescription animal sedative used to facilitate safe medical evaluation, treatment, and surgical care of many species and is critical when working with livestock, zoo, laboratory, and wildlife species.
- In cattle, xylazine is the only safe and effective sedative drug.
- Xylazine can be reversed in veterinary patients, which prevents secondary injuries and allows them to quickly and safely re-enter the herd or the wild.

How is xylazine currently regulated for veterinary use?

- Xylazine is an FDA-approved prescription animal drug that can only be used by or under the order of a licensed veterinarian and can only be dispensed in the course of the veterinarian's professional practice.
- Federal and state laws require all prescription drugs (for people and animals) to be distributed only to those who are legally entitled to obtain and possess them, and veterinarians are required to keep extensive records.
- Manufacturers and distributors have established internal compliance systems to ensure they are only providing products to those legally entitled to them.

Why is the AVMA concerned about scheduling of xylazine without addressing the unique veterinary uses?

- Without legislation from Congress, the AVMA is concerned the DEA will move to schedule xylazine without a veterinary exemption which would limit how veterinarians are able to use the drug.
- Additionally, without federal legislative and regulatory uniformity, some states will individually regulate xylazine creating a patchwork of rules and regulations for manufacturers and distributors to navigate, increasing the likelihood for supply disruption.
- Xylazine is a low-volume, low-margin generic animal drug. If the regulatory burden or facility investments are too high, these manufacturers will likely choose to discontinue production.
- It is our understanding that there is not significant diversion of xylazine from U.S. veterinary supply channels. In discussions with the Administration, federal agencies, and state law enforcement, illicit manufacturing and importation of xylazine from overseas is commonly raised as a concerning source.

Xylazine: an essential animal sedative used across veterinary medicine



What type of legislation would the AVMA support?

- The AVMA would support legislation that exempts the legitimate veterinary uses from any policy interventions, such as scheduling. This has been done before for an animal drug and will strike the right balance of protecting communities from illicit xylazine while maintaining critical veterinary access.
- The AVMA supports continued FDA-oversight of xylazine in non-human species as a prescription animal drug.
- The AVMA supports requiring manufacturers and distributors of legitimate xylazine to report sales to the DEA through an existing tracking system (ARCOS) that identifies unusual activity or changes in ordering patterns.

Status of current xylazine legislation:

- Xylazine language was included in H.R. 4531, the Support for Patients and Communities Reauthorization Act, which recently passed the House with overwhelming bipartisan support on a vote of 386-37. The included provision schedules xylazine as a Schedule III drug and exempts the FDA-approved veterinary product and its use from scheduling. The Senate will now consider the House version of the bill.
- Additionally, H.R. 1839/S. 993 Combating Illicit Xylazine Act is a bipartisan, bicameral bill that would help combat illicit xylazine trafficking while maintaining veterinarians' access under its current prescription status.

FOR MORE INFORMATION

Colin MacCarthy

Phone: 202-641-2533**Cell:** 202-641-2533

FOR IMMEDIATE RELEASE: 07/19/2023

(WASHINGTON, DC) July 19, 2023 — The House Energy and Commerce Committee passed the SUPPORT Act - a legislative package aimed to address the growing threat of the opioid crisis, which includes key components of the AVMA-endorsed Combating Illicit Xylazine Act. After sustained advocacy efforts from the AVMA, **the language within the SUPPORT Act would schedule xylazine as a Schedule III drug while exempting from scheduling the FDA-approved animal drug, which means that veterinarians will be able to use it as they always have under federal law.**

Illicit xylazine has now been found across the country mixed with fentanyl and other narcotics. This potent drug combination poses grave health and safety risks to human users. In veterinary medicine, xylazine is an important prescription sedative used to facilitate the safe handling and treatment of many species and is particularly important for use in cattle, horses, wildlife, and research species.

In both the House and Senate, the AVMA helped develop, introduce, and build support for the bipartisan Combating Illicit Xylazine Act. In this bill, anyone involved with the manufacturing, distribution, dispensing, or possession of xylazine with the intent to traffic for human use would be subject to Schedule III penalties under the federal Controlled Substances Act. At the same time, the legitimate veterinary uses would remain under their current prescription status.

The AVMA remains supportive of the approach taken in both the SUPPORT Act and the Combating Illicit Xylazine Act as they both equip the DEA with resources to address illicit xylazine while maintaining veterinary access to the animal drug at its current prescription status under the Food and Drug Administration (FDA).

"The House Energy and Commerce Committee advancing key components of the Combating Illicit Xylazine Act represents months of collaborative work between the AVMA, congressional offices, federal agencies, and other stakeholders," said Dr. Rena Carlson, AVMA President. "The AVMA appreciates the dedication lawmakers have demonstrated to address the public health crisis of illicit xylazine while at the same time understanding how essential the animal sedative is to veterinary medicine. On behalf of the veterinary community, we are incredibly appreciative of the strong leadership demonstrated by Reps. August Pfluger, Jimmy Panetta, Gus Bilirakis, and Ken Buck, and Senators Catherine Cortez Masto, and Chuck Grassley - the steadfast congressional champions of this legislation that protects public health and animal welfare. Thank you to Chairwoman Cathy McMorris Rodgers and Ranking Member Frank Pallone for their bipartisan support in recognizing the need to advance this legislation as part of the Committee's public health initiatives. This policy strikes a well-balanced approach and the AVMA will continue its efforts in both chambers to ensure this policy is signed into law."

Reps. Pfluger, Panetta, Bilirakis, and Buck issued the following statements:

"The drug crisis in our country is becoming more tragic by the day, with drug traffickers turning to an important veterinary tranquilizer to make drugs more addictive—and more deadly," said Rep. Plufger. "I am proud that the SUPPORT Act builds upon my legislation with Rep. Panetta to address illicit xylazine use while protecting access to the critical drug for veterinary use."

"The rise of xylazine-adulterated fentanyl threatens public health and public safety in communities throughout our country," said Rep. Panetta. "After seeing the threat start to grow, I authored the bipartisan Combating Illicit Xylazine Act to take a proactive and targeted approach to regulating xylazine's use in veterinary medicine while ensuring that our law enforcement has the tools they need to prevent its abuse. We just took another important step forward in this fight, and I'll continue to work alongside my partners both in and out of Congress to deliver the urgent action needed to confront this crisis head-on."

"Our goal is to save lives and to make sure law enforcement has the tools it needs to respond appropriately to those who are making these deadly concoctions that are killing so many of our neighbors," said Rep. Bilirakis. "At the same time, we must ensure that those veterinarians who are using xylazine for legitimate purposes have the ability to continue doing so. Our legislation strikes that right balance."

"The opioid epidemic has taken far too many lives across our country, including in my own home state of Colorado. Adding the deadly fentanyl adulterant xylazine to the Controlled Substances Act would save lives and prevent needless opioid overdoses," said Rep. Buck. "The Combating Illicit Xylazine Act would give law enforcement the tools necessary to stop this drug from wreaking havoc in our most vulnerable communities while also protecting the rights of veterinarians and cattlemen to use xylazine legally."

About the AVMA

Serving more than 100,000 member veterinarians, the AVMA is the nation's leading representative of the veterinary profession, dedicated to improving the health and wellbeing of animals, humans and the environment. Founded in 1863 and with members in every U.S. state and territory and more than 60 countries, the AVMA is one of the largest veterinary medical organizations in the world. Informed by our members' unique scientific training and clinical knowledge, the AVMA supports the crucial work of veterinarians and advocates for policies that advance the practice of veterinary medicine and improve animal and human health.

Shane David

From: Shane David
Sent: Wednesday, January 10, 2024 5:05 PM
To: Everett Rogers
Cc: S.Craig Smith; Charles Thompson (ADH); Laura Shue (ADH)
Subject: RE: Xylazine Pharmacy Board Regulation

Good afternoon Dr. Rogers,

I have received your public comment. It will be included in our public comment report that will be available on our website after conclusion of the public comment period, along with the Department's response.

Thanks,

Shane

From: Everett Rogers <everettrogers@hotmail.com>
Sent: Wednesday, January 10, 2024 4:30 PM
To: Shane David <shane.david@arkansas.gov>
Cc: Arkansas VMA <arkansasvma@comcast.net>; Everett Rogers <everettrogers@hotmail.com>
Subject: Xylazine Pharmacy Board Regulation

You don't often get email from everettrogers@hotmail.com. [Learn why this is important](#)

Mr. David,

Attached please find a PDF letter for public comment regarding proposed changes in the Controlled Substance List for Xylazine hearing on January 23, 2024.

Sincerely,
Everett Rogers, DVM, President
Arkansas Veterinary Medical Association
1404 Clover Circle
Paragould, AR 72450-4868
(870) 236-0778
everettrogers@hotmail.com

January 10, 2024

Arkansas Department of Health
Center for Health Protection, Pharmacy Services Section

Ref: Proposed changes in the Controlled Substance List Summary (Final) 002:
"10. Xylazine. Xylazine is utilized in veterinarian medicine and would be included into Schedule III. Schedule III,(c), (15)."

The Arkansas Veterinary Medical Association would urge that the commercially available xylazine, for veterinary use, be exempted from being listed as a Schedule III drug when being "dispensed or prescribed for, or administration to, a nonhuman species of a drug containing xylazine that has been approved by the Secretary of Health and Human Services under section 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.A. 360b)".

The Veterinary Medical Profession is well aware of and concerned about the illicit use of xylazine. The drug cartels intercept powdered bulk supplies of the product in transit to legitimate production facilities. This powdered product is then mixed with other illicit drugs which are sold on the streets. However, the commercially available xylazine used by veterinary practitioners is a liquid injectable product, which cannot be used to mix with illicit street drugs and is not the source of the illicit use of xylazine. Our profession supports efforts to end the illicit use of all drugs, including xylazine. We would urge and support the criminalization of the illicit use of xylazine punishable as a felony offense.

Xylazine is an essential tool used by veterinary practitioners for the sedation of many species, especially large animals, in order to humanely and safely perform diagnostic and surgical procedures. There are no practical alternatives for sedation in food animals. This drug is a low volume, low margin generic animal drug. If the regulatory burden is too high, the few manufacturers of this product will likely choose to stop production. This would prove disastrous to livestock producers and to food animal veterinary practitioners.

Currently, there are two pieces of federal legislation being considered: HR1839/S993 "Combating Illicit Xylazine Act" and HR4531 "Support for Patients and Communities Reauthorization Act" both of which exempt the FDA approved veterinary product and its use from scheduling and maintain its prescription status. The American Veterinary Medical Association supports both of these pieces of legislation.

Everett Rogers, DVM, President
Arkansas Veterinary Medical Association
1404 Clover Circle
Paragould, AR 72450-4868

Shane David

From: Shane David
Sent: Tuesday, January 16, 2024 10:39 AM
To: Lindy O'Neal
Cc: Laura Shue (ADH); Charles Thompson (ADH); S.Craig Smith
Subject: RE: Veterinary Xylazine Use

Good morning Dr. O'Neal,

I have received your public comment. It will be included in our public comment report that will be available on our website after conclusion of the public comment period, along with the Department's response.

Thanks,

Shane

From: Lindy O'Neal <lindyoneal.dvm@gmail.com>
Sent: Tuesday, January 16, 2024 10:33 AM
To: Shane David <shane.david@arkansas.gov>
Subject: Veterinary Xylazine Use

You don't often get email from lindyoneal.dvm@gmail.com. [Learn why this is important](#)

Hello Mr. David,

My name is Lindy O'Neal, and I am a small animal practitioner in Northwest Arkansas. I own two animal hospitals in Rogers, AR.

I am writing today to offer a perspective regarding the xylazine scheduling and offer support for a veterinary exemption. Right now two neighboring states, Louisiana & Tennessee, have passed a waiver to keep veterinary use of xylazine not-scheduled. The ideal situation would be for Arkansas to also waive xylazine scheduling for veterinary use.

The xylazine problem stems from the powdered form that is coming from Mexico in large quantities (20 pound packages). The veterinary form is a liquid, sold in small quantities of 10, 20 or 50mL bottles. There is no way that the liquid veterinary drug could play a significant part in today's xylazine use problem because it would take SO much of the liquid to convert to powder.

While human medicine does not use this medication, veterinarians count on this medication on a daily basis. Thankfully, small animal medicine has developed newer medications so I don't personally rely on this medication on a daily basis. But there is NO other approved drug equal to xylazine for use in bovine. If this becomes more highly regulated, the manufacturers within the US may discontinue production of the xylazine due to costs and regulatory burdens. Our cattle industry is struggling enough as it is, please help us by preventing a new barrier for them.

Please let me know if you'd like to talk, I can make myself available. I have attached a document that is more eloquent with wording than I am. Please take time to review it and ask questions if you have any.

Sincerely,

Lindy O'Neal, DVM
1203 S. 43rd Street
Rogers, AR 72758

w. 479.335.1400

c. 501.580.5420

<https://www.amcrogers.com/>

Xylazine: an essential animal sedative used across veterinary medicine



Veterinary access to legitimate xylazine must be preserved while combating the emerging public health threat of illicit xylazine

KEY POINTS:

- Xylazine is an essential drug for the safe handling of many species, particularly cattle, given there is no practical alternative for sedation in cattle.
- Any legislative or regulatory interventions to combat illicit xylazine need to safeguard the availability of veterinary prescription xylazine and its responsible use by veterinarians and our clients.
- Scheduling of xylazine without a provision for its unique uses in veterinary medicine will severely disrupt or eliminate the legitimate supply and prohibit critical uses of the drug.
- The AVMA supports public health efforts and policy intended to combat illicit xylazine.

What is the issue?

- Illicit xylazine is being mixed with illicit fentanyl. This potent drug combination poses grave health and safety risks for humans.
- As policy is crafted to help stop the illicit supply, we are concerned that new enforcement tools could severely impact the legal and responsible access and use of xylazine by veterinarians and our clients.
- **Limiting veterinary access to xylazine will jeopardize animal welfare and human safety.**

Why is xylazine so important in veterinary medicine?

- Xylazine is a prescription animal sedative used to facilitate safe medical evaluation, treatment, and surgical care of many species and is critical when working with livestock, zoo, laboratory, and wildlife species.
- In cattle, xylazine is the only safe and effective sedative drug.
- Xylazine can be reversed in veterinary patients, which prevents secondary injuries and allows them to quickly and safely re-enter the herd or the wild.

How is xylazine currently regulated for veterinary use?

- Xylazine is an FDA-approved prescription animal drug that can only be used by or under the order of a licensed veterinarian and can only be dispensed in the course of the veterinarian's professional practice.
- Federal and state laws require all prescription drugs (for people and animals) to be distributed only to those who are legally entitled to obtain and possess them, and veterinarians are required to keep extensive records.
- Manufacturers and distributors have established internal compliance systems to ensure they are only providing products to those legally entitled to them.

Why is the AVMA concerned about scheduling of xylazine without addressing the unique veterinary uses?

- Without legislation from Congress, the AVMA is concerned the DEA will move to schedule xylazine without a veterinary exemption which would limit how veterinarians are able to use the drug.
- Additionally, without federal legislative and regulatory uniformity, some states will individually regulate xylazine creating a patchwork of rules and regulations for manufacturers and distributors to navigate, increasing the likelihood for supply disruption.
- Xylazine is a low-volume, low-margin generic animal drug. If the regulatory burden or facility investments are too high, these manufacturers will likely choose to discontinue production.
- It is our understanding that there is not significant diversion of xylazine from U.S. veterinary supply channels. In discussions with the Administration, federal agencies, and state law enforcement, illicit manufacturing and importation of xylazine from overseas is commonly raised as a concerning source.

Xylazine: an essential animal sedative used across veterinary medicine



What type of legislation would the AVMA support?

- The AVMA would support legislation that exempts the legitimate veterinary uses from any policy interventions, such as scheduling. This has been done before for an animal drug and will strike the right balance of protecting communities from illicit xylazine while maintaining critical veterinary access.
- The AVMA supports continued FDA-oversight of xylazine in non-human species as a prescription animal drug.
- The AVMA supports requiring manufacturers and distributors of legitimate xylazine to report sales to the DEA through an existing tracking system (ARCOS) that identifies unusual activity or changes in ordering patterns.

Status of current xylazine legislation:

- Xylazine language was included in H.R. 4531, the Support for Patients and Communities Reauthorization Act, which recently passed the House with overwhelming bipartisan support on a vote of 386-37. The included provision schedules xylazine as a Schedule III drug and exempts the FDA-approved veterinary product and its use from scheduling. The Senate will now consider the House version of the bill.
- Additionally, H.R. 1839/S. 993 Combating Illicit Xylazine Act is a bipartisan, bicameral bill that would help combat illicit xylazine trafficking while maintaining veterinarians' access under its current prescription status.

Shane David

From: Shane David
Sent: Tuesday, January 16, 2024 4:45 PM
To: Rene' LaVergne
Cc: Laura Shue (ADH); S.Craig Smith; Charles Thompson (ADH)
Subject: RE: Xylazine for veterinary use

Good afternoon Dr. LaVergne,

I have received your public comment. It will be included in our public comment report that will be available on our website after conclusion of the public comment period, along with the Department's response.

Thanks,

Shane

From: Rene' LaVergne <cajundvm@gmail.com>
Sent: Tuesday, January 16, 2024 4:24 PM
To: Shane David <shane.david@arkansas.gov>
Subject: Xylazine for veterinary use

You don't often get email from cajundvm@gmail.com. [Learn why this is important](#)

To whom it may concern:

I stand with my veterinary colleagues in asking that Xylazine for prescriptive purposes be preserved and under the direction of a licensed veterinarian with an established doctor, client patient relationship. This drug is the only sedative for safe handling of cattle, and in my small animal hospital, is valuable for the sedation of an injured animal, where general anesthesia is not a viable option.

We are in favor of scheduling the elicited use, diversion of the powder form, mixed with other elicited drugs and sold on the streets. All elicited drug trade poses a threat to our human youth. Our concern is that this valuable drug in the hands of a licensed veterinarian is vital. If the schedule is applied, manufacturers will discontinue production, which will critically affect the safety of cattle producers, veterinarians and the animals themselves.

Please consider following the proposed federal statute that classifies the drug (from elicited channels), while preserving the legitimate veterinary prescriptive use.

Thank you for fighting the good fight,

Rene' LaVergne, DVM
Pinnacle Valley Westrock Animal Hospital
501-878-7375

Shane David

From: Shane David
Sent: Thursday, January 18, 2024 11:55 AM
To: Yahoo Mail
Cc: S.Craig Smith; Charles Thompson (ADH); Laura Shue (ADH)
Subject: RE: Xylazine

Good morning Dr. Helms,

I have received your public comment. It will be included in our public comment report that will be available on our website after conclusion of the public comment period, along with the Department's response.

Thanks,

Shane

From: Yahoo Mail <gatewayanimals@sbcglobal.net>
Sent: Wednesday, January 17, 2024 7:32 PM
To: Shane David <shane.david@arkansas.gov>
Subject: Xylazine

You don't often get email from gatewayanimals@sbcglobal.net. [Learn why this is important](#)

January 17, 2024

Arkansas Department of Health
Center for Health Protection, Pharmacy Services Section

Ref: Proposed changes in the Controlled Substance List concerning Xylazine

Dear Mr. David and whoever else that may be concerned:

I have been a mixed animal practice owner and a predominately large animal veterinarian in the Great State of Arkansas for over 28 years. My practice utilizes Xylazine on a daily basis, whether it be to sedate a small companion animal, a horse, a cow or any other farm animal species. Xylazine is an economical and safe drug for use as a chemical restraint agent.

I believe most veterinary practitioners are fully aware of the abuse of Xylazine within the illicit drug trade. Most of what I read states that the Xylazine creating the abusive drug problem is not coming from veterinary channels; therefore, how is restricting Xylazine in veterinary medicine going to decrease the illicit human abuse of this product? Restricting Xylazine, will in fact, create more work for veterinarians by requiring stricter documentation of when and where it is administered. Without easy access to Xylazine many animals may be made to suffer if an economical alternative can not be secured.

If extra restrictions are placed on Xylazine, it will most likely drive the cost of this product up placing greater financial burdens on both pet and farm animal owners.

Again I ask the question; if the illicit product that is being abused is not believed to be coming from veterinary channels, then how is restricting Xylazine going to decrease the number of human overdoses?

Classifying Xylazine as a controlled substance simply does not make any sense because it will not stop nor will it decrease the human abuse problem.

Sincerely,

Roger Helms, DVM
Gateway Animal Clinic
3219 Hwy 67B North
Walnut Ridge, AR 72466
[870-759-1031](tel:870-759-1031)

[870-886-6704](tel:870-886-6704)
GatewayAnimals@sbcglobal.net

Shane David

From: Shane David
Sent: Thursday, January 18, 2024 12:12 PM
To: Darren McVay
Subject: RE: Xylazine

Good afternoon Dr. McVay,

I have received your public comment. It will be included in our public comment report that will be available on our website after conclusion of the public comment period, along with the Department's response.

Thanks,

Shane

From: Darren McVay <dmcvay865@gmail.com>
Sent: Wednesday, January 17, 2024 9:06 PM
To: Shane David <shane.david@arkansas.gov>
Subject: Xylazine

You don't often get email from dmcvay865@gmail.com. [Learn why this is important](#)

To whom it may concern,

Veterinarians have long been entrusted as an integral part of ensuring the safety of this nation's (and the world's) food supply. As a practicing food animal veterinarian, I do not take this responsibility lightly. We work hard to continually improve our quality of medicine, and thus positively affect the welfare of all animals entrusted to our care. Veterinarians have non-regulatory, self-imposed bans on medications which we honor and abide by: the voluntary ban on aminoglycosides in food animals. I believe these clearly prove veterinarians have the safety of the public as an utmost priority. The fact that obtaining xylazine for illicit use is outside the veterinary channels indicates no veterinary wrongdoing and should negate any and all efforts to impose needless, burdensome regulations on law abiding veterinarians. Furthermore, increased regulation would likely lead to decreased use by veterinarians, leading to decreased demand, which may very well lead manufacturers to either cease production or increase price incrementally. Ceasing production would remove the ONLY licensed product for chemical restraint of cattle, which is a serious welfare issue. Price increases must be passed on to clients, which places an undue financial burden on the public. These unintended consequences and collateral fallout alone far outweigh any rational attempt to proceed with or even logically consider increased regulation on veterinary xylazine use and would be an egregious leap backward for animal welfare, not forward progress. Any effort in regulating xylazine should specifically exempt veterinary use. The fact that Arkansas is experiencing a shortage of large animal veterinarians is a widely known problem. Xylazine regulation in an individual state will be a repulsion to attracting potential veterinarians interested in practicing in Arkansas, not a draw to our state. This will further compound our large animal shortage. This is yet another negative unintended consequence. When we step back and look at the big picture of illicit xylazine use, the veterinarian is absolutely nowhere in the picture. As a governing body, I

would hope your interest would be to stand with and support the veterinarian, not to oppose the veterinarian and impose burdensome regulations that will have no effect on its intended purpose,

Sincerely,
Darren McVay DVM

Shane David

From: Shane David
Sent: Monday, January 22, 2024 4:21 PM
To: Michelle Bufkin Horton
Cc: Laura Shue (ADH); S.Craig Smith; Charles Thompson (ADH); Connie Melton
Subject: RE: Comment Letter for the Proposed Rule Change - Controlled Substance List

Good afternoon Mr. Bufkin,

I have received your public comment. It will be included in our public comment report that will be available on our website after conclusion of the public comment period, along with the Department's response.

Thanks,

Shane

From: Michelle Bufkin Horton <michelle@arbeef.org>
Sent: Monday, January 22, 2024 3:52 PM
To: Shane David <shane.david@arkansas.gov>
Subject: Comment Letter for the Proposed Rule Change - Controlled Substance List

You don't often get email from michelle@arbeef.org. [Learn why this is important](#)

David,

Attached you will find the comment letter from the Arkansas Cattlemen's Association addressing SUMMARY OF PROPOSED AMENDMENTS TO RULES PERTAINING TO THE LIST OF CONTROLLED SUBSTANCES FOR THE STATE OF ARKANSAS.

Thank you for the opportunity to submit comments. Please let me know if I can provide any more information to you.

Kindly,

Michelle Bufkin Horton
Executive Vice President
Arkansas Cattlemen's Association
Office: 501-224-2114 | Cell: 334-313-2315
www.arbeef.org





Arkansas Cattlemen's Association

www.arbeef.org • 310 Executive Court • Little Rock, Arkansas 72205 • (501) 224-2114

January 22, 2024

Arkansas Department of Health
Center for Health Protection, Pharmacy Services Section

Re: Proposed changes in the Controlled Substance List Summary 002: "10 Xylazine.
Xylazine is utilized in veterinarian medicine and would be included into Schedule III.

The Arkansas Cattlemen's Association (ACA) urges the Arkansas Department of Health to exempt the commercially available xylazine, for veterinary use, from being listed as a Schedule III drug when being "dispensed or prescribed for, or administration, to a nonhuman species of a drug containing xylazine that has been approved by the Secretary of Health and Human Services under section 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.A 260b)."

Xylazine is an essential tool for cattle producers to humanely sedate cattle for treatment or to examine the animal. Moving this drug to a Schedule III classification, without exemption, would cause substantial harm to the cattle in our members' care and to the industry. Furthermore, increasing the regulatory burden for manufacturers could create a supply issue, as there are limited manufacturers of xylazine. The end effect would be disastrous to livestock producers and their veterinarians, as there are no practical alternatives for sedation in livestock used for food production.

There are currently two pieces of federal legislation in committee that exempt the FDA-approved veterinary product and its use from scheduling and maintaining its prescription status: HR18369/S993 and HR4531.

While the ACA is aware of the illicit use of xylazine and the dangers it can pose to the public; it is important to note that the commercially available xylazine used by veterinary practitioners and livestock producers is a liquid injectable product, which cannot be used to mix with illicit street drugs.

We appreciate the opportunity to provide these comments and can be reached for any clarification and discussion needed.

Sincerely,

Michelle Bufkin Horton
Executive Vice President
Arkansas Cattlemen's Association

Shane David

From: Shane David
Sent: Tuesday, January 23, 2024 8:29 AM
To: Helen Wick
Cc: S.Craig Smith; Laura Shue (ADH); Charles Thompson (ADH)
Subject: RE: Keeping xylazine exempt from Class III schedule for veterinarians

Good morning Dr. Hoerler,

I have received your public comment. It will be included in our public comment report that will be available on our website after conclusion of the public comment period, along with the Department's response.

Thanks,

Shane

From: Helen Wick <helenwick@gmail.com>
Sent: Monday, January 22, 2024 8:29 PM
To: Shane David <shane.david@arkansas.gov>
Subject: Keeping xylazine exempt from Class III schedule for veterinarians

You don't often get email from helenwick@gmail.com. [Learn why this is important](#)

To the Arkansas Department of Health Center for Health Protection, Pharmacy Services Section ,

Ref: Proposed changes in the Controlled Substance List Summary (Final) 002: "10. Xylazine. Xylazine is utilized in veterinarian medicine and would be included into Schedule III. Schedule III,(c), (15)."

I am a mixed practice veterinarian and regularly use xylazine, especially for large animal sedation. On my food animal farm calls, I often hear from rural farmers and ranchers how difficult it is to even find a veterinarian to come out on a call, much less have it be economical. I can reach for xylazine to sedate a dangerous, injured, or very painful animal, making this much less stressful for both the animal and all the people involved. I always worry about a farmer or farmhand getting injured by an unpredictable animal. With economical and relatively safe sedation provided by xylazine, we can accomplish good veterinary care with fewer people. If this drug becomes controlled, I will have to get my own DEA license, spend extra time with logs, and pay a much higher price for this drug. As a result, I will have to pass on most of this cost to the producer, which fills me with dread knowing that I somehow have to make veterinary care economical for food animals. I don't want to hesitate using a sedative because of its cost or lack of availability, only to put more people in harm's way of a dangerous animal. I don't want to hesitate giving an animal pain relief and preventing further injury.

I am very concerned about keeping our medications out of the wrong hands, and agree that something must be done, but I do not think increasing xylazine to a Schedule III drug will achieve that. I have made it a point to lock up all sedatives to prevent any access, whether accidental or malicious, and I think a lot of other veterinarians are also becoming more cautious. We all need to work together and be creative in finding ways to curb illicit drug use, and many ways do not have to be legislative. In this case, increased regulatory pressure for veterinarians is very unlikely to make a positive difference, and will certainly make a very negative one for the animals under our care.

Sincerely,

Helen Hoerler, DVM
17960 Syble Road
Lincoln, AR 72744
phone 918-575-1514

Shane David

From: Shane David
Sent: Tuesday, January 23, 2024 1:53 PM
To: Sarah Shedenhelm
Cc: S.Craig Smith; Charles Thompson (ADH); Laura Shue (ADH)
Subject: RE: Xylazine

Good afternoon Dr. Shedenhelm,

I have received your public comment. It will be included in our public comment report that will be available on our website after conclusion of the public comment period, along with the Department's response.

Thanks,

Shane

From: Sarah Shedenhelm <sarah.shed@gmail.com>
Sent: Tuesday, January 23, 2024 9:34 AM
To: Shane David <shane.david@arkansas.gov>
Subject: Xylazine

You don't often get email from sarah.shed@gmail.com. [Learn why this is important](#)

Mr. David,

I'm sure you have received many emails from veterinarians regarding our concern over xylazine becoming a schedule III drug. I will keep this concise. I fully support the request to grant AR veterinarians a waiver to continue to use the veterinary formulation of xylazine without registering as a controlled drug. If this waiver is not granted, the manufactures of our vet formulations will most certainly discontinue manufacturing leaving a devastating impact on cattle medicine. Thank you for considering our request and please reach out if you have any questions.

Sarah Shedenhelm, DVM
870-421-6927

Shane David

From: Shane David
Sent: Tuesday, January 23, 2024 11:30 AM
To: Fuchs, David - FSIS
Cc: S.Craig Smith; Charles Thompson (ADH); Laura Shue (ADH)
Subject: RE: [External Email]Re: Regarding xylazine usage in Veterinary Medicine

Good morning Dr. Fuchs,

I have received your public comment. It will be included in our public comment report that will be available on our website after conclusion of the public comment period, along with the Department's response.

Thanks,

Shane

From: Fuchs, David - FSIS <david.fuchs@usda.gov>
Sent: Tuesday, January 23, 2024 9:31 AM
To: Sarah Shedenhelm <sarah.shed@gmail.com>
Cc: Shane David <shane.david@arkansas.gov>; David Fuchs <david.fuchsdvm@yahoo.com>
Subject: RE: [External Email]Re: Regarding xylazine usage in Veterinary Medicine

You don't often get email from david.fuchs@usda.gov. [Learn why this is important](#)

Understood

Thank you very much.

Dr. David C. Fuchs VMO/SPHV
Office of Field Operations Circuit 3502
(P/M112)(P/M112A)(P/M7211)
Food Safety and Inspection Service, USDA
601 Tyson Drive Building 1
Green Forest, AR 72638
Phone: (870) 438-7114
Fax (870)438-5247
Cell (870)577-5543
David.Fuchs@usda.gov

From: Sarah Shedenhelm <sarah.shed@gmail.com>
Sent: Tuesday, January 23, 2024 9:29 AM
To: Fuchs, David - FSIS <david.fuchs@usda.gov>
Cc: shane.david@arkansas.gov; David Fuchs <david.fuchsdvm@yahoo.com>
Subject: [External Email]Re: Regarding xylazine usage in Veterinary Medicine

You don't often get email from sarah.shed@gmail.com. [Learn why this is important](#)

[External Email]

If this message comes from an **unexpected sender** or references a **vague/unexpected topic**;

Shane David

From: Fuchs, David - FSIS <david.fuchs@usda.gov>
Sent: Tuesday, January 23, 2024 9:22 AM
To: sarah.shed@gmail.com
Cc: Shane David; David Fuchs
Subject: Regarding xylazine usage in Veterinary Medicine

You don't often get email from david.fuchs@usda.gov. [Learn why this is important](#)

Dr. Shedenhelm,

If petitions are needed to be signed, I can support this concern.

Thank you for all your works!

Regards

Dr. David C. Fuchs VMO/SPHV

Office of Field Operations Circuit 3502
(P/M112)(P/M112A)(P/M7211)
Food Safety and Inspection Service, USDA
601 Tyson Drive Building 1
Green Forest, AR 72638
Phone: (870) 438-7114
Fax (870)438-5247
Cell (870)577-5543
David.Fuchs@usda.gov

This electronic message contains information generated by the USDA solely for the intended recipients. Any unauthorized interception of this message or the use or disclosure of the information it contains may violate the law and subject the violator to civil or criminal penalties. If you believe you have received this message in error, please notify the sender and delete the email immediately.

Use caution before clicking links or opening attachments.

Please send any concerns or suspicious messages to: Spam.Abuse@usda.gov

There is no petition that I am aware of. The best thing that you can do is write an email to Shane David expressing your concerns. Tennessee and Louisiana have granted waivers for vet use and so we are simply asking for the same waiver.

Sarah Shedenhelm, DVM

On Tue, Jan 23, 2024 at 9:22 AM Fuchs, David - FSIS <david.fuchs@usda.gov> wrote:

Dr. Shedenhelm,

If petitions are needed to be signed, I can support this concern.

Thank you for all your works!

Regards

Dr. David C. Fuchs VMO/SPHV

Office of Field Operations Circuit 3502

(P/M112)(P/M112A)(P/M7211)

Food Safety and Inspection Service, USDA

601 Tyson Drive Building 1

Green Forest, AR 72638

Phone: (870) 438-7114

Fax (870)438-5247

Cell (870)577-5543

David.Fuchs@usda.gov

Shane David

From: Laura Shue (ADH)
Sent: Thursday, January 25, 2024 7:30 AM
To: lilesanimalclinic@att.net
Subject: Re: Xylazine

Thank you for your comment. It will be included in the public comment report with the agency response.

Laura Shue

From: lilesanimalclinic@att.net <lilesanimalclinic@att.net>
Sent: Thursday, January 25, 2024 2:36 AM
To: Laura Shue (ADH) <Laura.Shue@arkansas.gov>
Subject: Xylazine

[You don't often get email from lilesanimalclinic@att.net. Learn why this is important at <https://aka.ms/LearnAboutSenderIdentification>]

Ms Shue:

Thank you for working on the xylazine dilemma . It is very important to practitioners in small and especially large animal practice. Encumbering its use could very well cause injury or fatalities among veterinarians , clients, and/or patients.

Does this constitute a written comment, or is it an egregious breach of protocol again ?

Sincerely,

Michael Liles , DVM

501-279-7553.

Sent from my iPhone

Shane David

From: Shane David
Sent: Monday, January 29, 2024 3:53 PM
To: Mark Lambert
Cc: Laura Shue (ADH); Charles Thompson (ADH); S.Craig Smith
Subject: RE: Comments regarding Controlled Substances

Good afternoon Mr. Lambert,

I have received your public comment. It will be included in our public comment report that will be available on our website after conclusion of the public comment period, along with the Department's response.

Thanks,

Shane

From: Mark Lambert <mark.lambert@arfb.com>
Sent: Monday, January 29, 2024 2:20 PM
To: Shane David <shane.david@arkansas.gov>
Subject: Comments regarding Controlled Substances

You don't often get email from mark.lambert@arfb.com. [Learn why this is important](#)

Mr. David,

Please see the attached comments in regard to Xylazine being listed on the Controlled Substance List. Please don't hesitate to reach out if you have any questions.

Thank you for your time,

Mark Lambert



January 29, 2024

Arkansas Department of Health
Center for Health Protection, Pharmacy Services Section
4815 W. Markham St.
Little Rock, AR 72205

RE: Re: Proposed changes in the Controlled Substance List Summary 002: "10 Xylazine. Xylazine is utilized in veterinarian medicine and would be included into Schedule III."

The Arkansas Farm Bureau Federation urges the Arkansas Department of Health to exempt commercially available xylazine, for veterinary use, from being listed as a Schedule III drug when being "dispensed or prescribed for, or administration to, a nonhuman species of a drug containing xylazine that has been approved by the Secretary of Health and Human Services under section 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.A 260b)."


Xylazine is an essential tool for large animal veterinarians to humanely sedate animals for examination, diagnosis and treatment. Moving this drug to a Schedule III classification, without a veterinary exemption, would cause substantial harm to ranchers and negatively impact the safe and affordable care of their animals. Ranchers must utilize veterinarians to care for and diagnose livestock to ensure herd health and provide a safe and vibrant food system. The addition of xylazine as a schedule III drug, without a veterinary exemption, will burden veterinarians with unnecessary regulations and jeopardize ranchers' access to expert care of their animals. Currently, there are no other cost effective and practical alternatives to sedate large animals. Additionally, loss of access to xylazine will jeopardize the safety of veterinarians who rely on this drug to safely examine livestock, potentially causing a negative impact to animal and herd health within our state. The only acceptable alternatives would financially impact ranchers, who must now pay for far more expensive sedatives during veterinary examination, if those alternative medications are even available.

There are currently two pieces of federal legislation in committee that exempt the FDA-approved veterinary product and its use from scheduling and maintaining its prescription status: HR18369/S993 and HR4531.

While Arkansas Farm Bureau is aware of the illicit use of xylazine and the dangers it can pose to the public; it is important to note that the commercially available xylazine used by veterinary practitioners and livestock producers is a liquid injectable product, which cannot be used to mix with illicit street drugs.

We appreciate the opportunity to provide these comments and can be reached for any clarification and discussion needed.

Regards,


Mark Lambert
Director of State Affairs

Proposed Amendments to the List of Controlled Substances for the State of Arkansas
Arkansas Code Annotated § 5-64-201 through 5-64-216
Public Hearing held on January 23, 2024
Public comments made during the hearing.

Rule and Specific Information:	Individual/Group	Comments
<p>Proposed Amendment(s) to the Controlled Substance List. All comments listed are in opposition to the addition of xylazine into Schedule III without an exemption for veterinarian use.</p>	<p>*Dr. Kate Williams, Companion Animal Veterinarian in Northwest Arkansas, Serves on Arkansas Veterinary Medical Association (AVMA) Board as American Veterinary Medical Association alternate delegate</p>	<p>Xylazine is “an important prescription veterinary sedative used to facilitate safe handling and treatment of large animals, primarily equine and cattle. Any changes to scheduling of xylazine in the state of Arkansas could potentially negatively impact veterinary access to the drug and limit what veterinarians can do for safe handling of cattle. The cattle and horse business in the state of Arkansas is a very large economic benefit to the state of Arkansas. Xylazine is used as a sedative for fractious and large animals and used for safe handling. Because it is not an opioid, it can be reversed, and the animals can be right back into the herd during post operative care.”</p> <p>“We as veterinarians understand the pose to public health, but limiting veterinary access to this drug is critical and jeopardizes animal and human safety. On the legislative side and on the big picture side, there are two acts that are currently being proposed at the federal government side. One is the Combating Illicit Xylazine Act which is primarily targeted to create illicit xylazine as a Schedule III drug exempting veterinary use so it can continue</p>

(*) An asterisk denotes the individual had provided a written public comment and made a verbal public comment at the public hearing held on January 23, 2024. This will reflect one comment received.

Proposed Amendments to the List of Controlled Substances for the State of Arkansas
 Arkansas Code Annotated § 5-64-201 through 5-64-216
 Public Hearing held on January 23, 2024
 Public comments made during the hearing.

		<p>as we are currently using it. Then there is the Support Act language which does the same thing, it schedules Xylazine as a Schedule III federally while exempting the use of the medication as legitimate use in veterinary medicine. Without congressional legislation, the AVMA is concerned that the DEA removes xylazine to schedule III without the veterinary exemption which will limit the access of this important drug to veterinary medicine. Without federal legislation, this results in a regulatory uniformity mismatch. Basically, states are trying to patchwork their listing of xylazine as a schedule III drug and acting before the federal government has an opportunity to schedule xylazine as a schedule III. The intent of these two legislative actions is to exempt veterinary use.”</p> <p>“Xylazine is a liquid, comes directly through legitimate veterinary channels. It is an FDA approved veterinary use only bottle of liquid xylazine. What we use in veterinary medicine on the farms, in clinics, in zoos, in laboratory animals, in wildlife is the injectable version which comes in 50 ml bottles. That is not the source of the problem. The source of illicit xylazine is diversion of xylazine from the</p>
--	--	--

(*) An asterisk denotes the individual had provided a written public comment and made a verbal public comment at the public hearing held on January 23, 2024. This will reflect one comment received.

Proposed Amendments to the List of Controlled Substances for the State of Arkansas
 Arkansas Code Annotated § 5-64-201 through 5-64-216
 Public Hearing held on January 23, 2024
 Public comments made during the hearing.

		<p>manufacturers. So, it's coming into Mexico, basically from overseas. So, the raw product is being manufactured illicitly or legally but is being diverted into the drug market and then that raw product, which is a powder form, is then being split into fentanyl and entering the illicit drug trade. So, I urge and encourage the ADH to consider the information that our team is about to present and consider exempting xylazine from a schedule III drug in the state of Arkansas while we wait for the federal government to actually schedule it as a Schedule III with the exemption for the states."</p>
	<p>*Dr. Everett Rogers, President of the Arkansas Veterinary Medical Association, practicing veterinarian for 49 years, has small animal practice in Jonesboro</p>	<p>Xylazine is "an indispensable tool particularly in the large animal section, for the use of cattle and horses for sure. These large animals can be very health threatening to their handlers, injuries can occur. On the other side of it, when we do minor surgical procedures on large animals, from a humane standpoint the xylazine does provide a mechanism to provide some pain relief during these minor surgical procedures."</p> <p>"The problem with Schedule III is it would require more paperwork, more bureaucracy involved with that. If a veterinarian had a particular client that was a large producer and had a large number of</p>

(*) An asterisk denotes the individual had provided a written public comment and made a verbal public comment at the public hearing held on January 23, 2024. This will reflect one comment received.

Proposed Amendments to the List of Controlled Substances for the State of Arkansas
Arkansas Code Annotated § 5-64-201 through 5-64-216
Public Hearing held on January 23, 2024
Public comments made during the hearing.

		<p>horses or cattle, was well trained and responsible, if that veterinarian wanted to dispense a small quantity, maybe 5 cc, for them to use in their management procedures in their farms, having it Schedule III would eliminate this.”</p> <p>“Where the problem is coming from is not from the veterinary practitioner out in the field, the problem is coming from the diversion of the powdered product before it is manufactured. Also, there is no compounding situation with this drug, all of our sources are coming directly from end stage manufacturers. There are probably only a couple of manufacturers producing xylazine now, there are some fears that is kind of a low volume drug for them and if this is scheduled, they might stop producing it. We are concerned about the lack of availability for the legitimate use of it in veterinary practice.”</p>
	<p>Dr. Rob Conner, veterinarian of 34 years from Mountain Home with a mixed animal practice</p>	<p>“Xylazine is a product we use routinely on the farm for our horse clients as well as our food animal clients. We also use it historically occasionally in small animal practice when there is a lack of availability of analogous products. The risk for us as large animal practitioners, and speaking on behalf of the farmers and others, in those</p>

(*) An asterisk denotes the individual had provided a written public comment and made a verbal public comment at the public hearing held on January 23, 2024. This will reflect one comment received.

Proposed Amendments to the List of Controlled Substances for the State of Arkansas
Arkansas Code Annotated § 5-64-201 through 5-64-216
Public Hearing held on January 23, 2024
Public comments made during the hearing.

		<p>applications, I have no other alternative. So, if you take that away as the product that I can use to sedate animals, to assist in their capture, control, or anesthesia, I have no analogous products to use. As a matter of safety, which is paramount on the farm, when dealing with large animals that tend to be fractious, it is certainly something that could put the public at higher risk.”</p> <p>“Products that we use are small bottles of liquid and I’m told the nefarious use of xylazine is actually powder coming from other sources. So, I do think we are not putting the public at risk. We are very careful with those drugs. I do hold a DEA license, so I am very careful to not risk my license. Veterinarians can be trusted to protect the public from this drug. I do feel quite confident that this is something that should continue to be available as a prescription item. We do not sell bottles of this over the counter, this is something that we do totally control.”</p>
	<p>Rodney Baker, lobbyist for the Arkansas Veterinarian Medical Association</p>	<p>“I’ve been asked by my friends at the Cattlemen’s Association to share that they have filed a letter on this issue reflecting their concerns about losing xylazine as a prescription drug. They asked me to share that</p>

(*) An asterisk denotes the individual had provided a written public comment and made a verbal public comment at the public hearing held on January 23, 2024. This will reflect one comment received.

Proposed Amendments to the List of Controlled Substances for the State of Arkansas
Arkansas Code Annotated § 5-64-201 through 5-64-216
Public Hearing held on January 23, 2024
Public comments made during the hearing.

		with you. They couldn't be here today and send their apologies."
	*Mark Lambert, State Affairs Director with Farm Bureau	"We represent 180,000 farmers, ranchers, and rural Arkansans across Arkansas. The number one thing that everyone is concerned with is the safe and effective use of veterinary care. If veterinarians can't do their job and treat these animals in a safe and effective manner then that puts our farmers, our ranchers, our veterinarians, and everybody at risk with the loss of this product. Farm Bureau plans to submit comments on the rescheduling of xylazine to exempt our veterinarians so they can have safe and effective veterinary care for animals."

(*) An asterisk denotes the individual had provided a written public comment and made a verbal public comment at the public hearing held on January 23, 2024. This will reflect one comment received.